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ABSTRACT 
FROM SUGAR TO ACETATE – THE ORIGINS OF ACETYL-COA DICTATE ITS USE 
IN CELLS AND IN MICE.  
Steven Zhao 
Dr. Kathryn Wellen 
Changes in environmental factors, diet, and genetics all influence metabolism, 
which is frequently dysregulated at the cellular and organismal levels in diseases such 
as metabolic syndrome, cancer, and inborn errors of metabolism. These maladies are 
often intertwined; for example, metabolic diseases such as obesity and inborn errors of 
metabolism such as fumarate hydratase deficiency can both increase the risk for 
developing certain cancers. One metabolic pathway frequently altered in disease is de 
novo lipogenesis (DNL). Aberrant DNL is believed to play a critical role in pathogenesis 
of cancer and non-alcoholic fatty liver disease (NAFLD), a manifestation of metabolic 
syndrome in the liver. DNL requires the metabolite, acetyl-CoA, which is predominantly 
synthesized in the cytosol and nucleus from the cleavage of citrate through the action of 
ATP-citrate lyase (ACLY). Consistent with its role in DNL, elevated levels or activity of 
ACLY is frequently observed in cancer and NAFLD. Therefore, I utilized a genetic loss-
of-function approach coupled with metabolomic methods to investigate how abrogating 
ACLY impacts metabolism in proliferating cells and the liver. Unexpectedly, impairment 
of ACLY leads to metabolic compensation through ACSS2-dependent acetate usage at 
the cellular and tissue levels. Moreover, by depleting ACLY, we identify a link between 
dietary carbohydrate and microbiome-derived acetate in supporting hepatic DNL. These 
findings have revised our understanding of acetyl-CoA metabolism in cells, and how 
nutritional sources feed into this pathway in disease context
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CHAPTER 1: ACETYL-CoA METABOLISM IN DISEASE 
 
Acetyl-CoA production links catabolic and anabolic metabolism in cells.  
 
Acetyl-coenzyme A (Acetyl-CoA) is a metabolite that links nutrient breakdown for energy 
and the synthesis of more complex metabolites. Due to this positioning within cellular 
metabolism, acetyl-CoA production and abundance is tightly regulated in response to 
nutritional availability and other signals such as oncogenic activation1. However, the 
mechanisms that govern this regulation are still not entirely understood. Adding to the 
complexity, acetyl-CoA can be synthesized in various cellular compartments and from 
different substrates. Discussed below are the sources and locations of acetyl-CoA 
production at the time of this work.  
Pyruvate: 
Glucose is taken into cells via the SLC2/GLUT family of transporters, which are 
expressed in a tissue-specific manner2. Following uptake, glucose is phosphorylated by 
hexokinase to glucose-6-phosphate and trapped within the cell. Glucose-6-phosphate is 
shunted into glycolysis, resulting in the production of pyruvate in the cytosol. Pyruvate is 
imported into the mitochondria by the mitochondrial pyruvate carrier (MPC), which is 
converted into acetyl-CoA within the mitochondria by the pyruvate dehydrogenase 
complex (PDC). Mitochondrial acetyl-CoA is condensed with oxaloacetate to form 
citrate, which can enter the citric acid cycle to fuel the generation of ATP, NADH, and 
FADH2 or be exported from the mitochondria to the cytosol in exchange for malate via 
the transporter SLC25A13 (Figure 1.1). In addition to the mitochondria, the PDC has 
been reported to also function within the nucleus to generate nuclear acetyl-CoA4. 
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Citrate: 
In addition to glucose, catabolism of other nutrients such as fatty acids and amino acids 
within the mitochondria can also yield citrate (Figure 1.1). Once exported out of the 
mitochondria, nuclear-cytosolic citrate is cleaved into acetyl-CoA by the enzyme ATP-
citrate lyase (ACLY) in an ATP-dependent manner, regenerating oxaloacetate as a by-
product. Given the high concentrations of circulating glucose (~5 mM) and abundance of 
other nutritional sources, this is believed to be the major route of nuclear-cytosolic 
acetyl-CoA production in vivo. Consistent with this, congenital deletion of Acly in mice 
fails to produce viable offspring, displaying early embryonic lethality around E8.55. Like 
the PDC, ACLY has also been found to localize to the nucleus6, although its nuclear 
regulation and functions remains largely unknown.  
Acetate: 
In addition to citrate, another major route of acetyl-CoA synthesis is utilizing the short-
chain fatty acid (SCFA) acetate. In vivo, levels of circulating acetate are relatively low 
(~100 M), as compared to glucose (~5 mM), but can reach much higher levels in 
certain parts of circulation such as the portal vein that connects the intestine to the liver7. 
This is because the majority of acetate is produced in the large intestine by the gut 
microbiome, which ferment undigestible nutrients into SCFAs such as butyrate, 
propionate, and acetate. However, despite its lower circulating levels, turnover of acetate 
in vivo is very high8, suggesting that it is avidly used by cells within the body. Acetate is 
taken up by mammalian cells through the proton-coupled monocarboxylate transporters 
such as MCT1 and MCT47, and directly ligated to free CoA in an ATP-dependent 
manner by the Acyl-CoA Synthetase Short Chain family of enzymes (ACSS1, ACSS2, 
ACSS3)9. Of these, ACSS1/3 are found in the mitochondria, whereas ACSS2 is found in 
the cytosol and nucleus like ACLY.  
 3 
 
 
Figure 1.1 | Acetyl-CoA metabolism in mammalian cells.  
Acetyl-CoA is synthesized using multiple substrates and in various cellular compartments. 
Mitochondrial acetyl-CoA is synthesized from pyruvate via glucose by the PDC, or acetate by 
ACSS1/3. Cytosolic acetyl-CoA is synthesized from citrate and acetate, by ACLY and ACSS2 
respectively. Acetyl-CoA can diffuse from the cytosol to the nucleus, yet the PDC, ACLY and 
ACSS2 all localize to the nucleus. Acetyl-CoA is used for histone acetylation to regulate the 
epigenome, as well as for synthesis of lipids such as cholesterol and fatty acids.  
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Acetyl-CoA metabolism in cancer 
 
In order for a cell to divide, it must effectively double its cellular contents, including 
nucleic acids, proteins, and lipids. As a disease of unrestrained proliferation, cancer cells 
must overcome this metabolic barrier and either acquire or generate enough molecular 
building blocks to divide frequently. To accomplish this, cancer cells rewire their 
metabolism to favor uptake of nutrients such as glucose and perform glycolysis even in 
the presence of oxygen, also known as the Warburg effect10. In addition, cancer cells will 
increase usage of anapleurotic metabolites such as glutamine11, and even scavenge for 
macromolecules to break down into metabolic building blocks12. Discussed below are 
two prominent ways that acetyl-CoA metabolism promotes cancer growth: epigenetic 
regulation and lipid metabolism (Figure 1.1).   
Metabolic Control of Epigenetics in Cancer13 
 
Abstract 
Alterations in the epigenome and metabolism both affect molecular rewiring in cancer 
cells and facilitate cancer development and progression. However, recent evidence 
suggests the existence of important bidirectional regulatory mechanisms between 
metabolic remodeling and the epigenome (specifically methylation and acetylation of 
histones) in cancer. Most chromatin-modifying enzymes require substrates or cofactors 
that are intermediates of cell metabolism. Such metabolites, and often the enzymes that 
produce them, can transfer into the nucleus, directly linking metabolism to nuclear 
transcription. We discuss how metabolic remodeling can contribute to tumour epigenetic 
alterations, thereby affecting cancer cell differentiation, proliferation and/or apoptosis, as 
well as therapeutic responses. 
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Introduction 
Epigenetic plasticity in cancer facilitates the acquisition of its hallmark characteristics14,15. 
The metabolic traits of tumour cells are also crucial for adjusting to changes in the 
availability of oxygen and nutrients (carbohydrates, lipids and amino acids) in the tumour 
microenvironment, to sustain proliferation and resist mitochondria-dependent 
apoptosis10,16,17. Cellular metabolism and the epigenome interact with one another and 
with the genetic and molecular drivers of cancer, in a bidirectional manner. An 
integrative understanding of the interplay between the molecular, metabolic and 
epigenetic rewiring in cancer is far from complete, but conceptual themes are beginning 
to emerge. Further elucidation of these links is likely to lead to more effective cancer 
therapies. 
Most post-translational modifications (PTMs), such as phosphorylation, acetylation and 
other acyl modifications, methylation and O-linked N-acetylglucosamine modification (O-
GlcNAcylation), require metabolites as substrates (FIG. 1.2). In the nucleus, these 
metabolites are used for chromatin modifications, including acetyl-CoA for histone 
acetylation and S-adenosylmethionine (SAM) for histone and DNA methylation. The 
histone code hypothesis is based on writers, erasers and readers of chromatin marks6. 
This assumes that the ‘ink’ in this process is never limiting; however, based on a growing 
body of evidence that the availability of metabolites to the writers has an impact on 
chromatin modifications, we believe that it may be time to add a fourth parameter in this 
code: the metabolite-producing enzymes, which provide the ink for histone modification 
(FIG. 1.2). In this Review, we discuss how metabolic control of the epigenome is 
emerging as a crucial mechanism by which cancer cells can adapt to a changing 
environment. 
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Basic biochemistry of acetylation 
More than 8,000 unique acetylation sites in proteins have been detected in mammalian 
cells18–20. Within the nucleus, histones comprise the bulk of acetylation loci. The 
chromatin of mammalian cells contains at least 10 billion potential acetylation sites, 
meaning that a global change in histone acetylation may lead to a substantial reduction 
in cellular or nuclear acetyl-CoA levels. Given the high amounts of energy stored in a 
molecule of acetyl-CoA, this may represent a potential energy sink21. 
Each histone octamer subunit (as well as the linker histone, H1) contains multiple lysine 
residues, which are positively charged in the nucleoplasmic environment, leading to 
attraction of the negatively charged DNA. More than 60 of these lysine residues are 
known to be acetylated in mammals (H1 has 16 sites, H2A has 10 sites, H2B has 16 
sites, H3 has 13 sites and H4 has 9 sites)22,23. Acetylation neutralizes the positive charge 
of lysine, loosening the interaction between the histone and the negatively charged DNA 
and leading to a more open chromatin configuration (euchromatin) that is permissive for 
transcription. Histone deacetylation is usually associated with condensed, compacted 
chromatin (heterochromatin) and transcriptional repression. 
Protein acetylation occurs both cotranslationally onto the N-terminal residue of a protein, 
catalysed by Nα acetyl­ transferases, and post-translationally onto the Nε amino group of 
lysine residues. Lysine acetylation is catalysed by multiple families of lysine 
acetyltransferases (KATs) and reversed by lysine deacetylases (KDACs). Nα affects 
approximately 85% of human proteins and is important for their stability, localization and 
function24,25. Nε acetylation can alter protein function by altering its catalytic activity, 
interactions with other factors, subcellular localization and stability26. These effects can 
originate directly from changes in charge, from binding of proteins that contain acetyl-
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lysine recognition bromodomains27,28 or from prevention of other post-translational lysine 
modifications (including ubiquitylation, methylation and formylation)26. Nε acetylation can 
also occur through a non-enzymatic mechanism throughout the cell, and this is 
promoted in alkaline environments such as the mitochondrial matrix29,30. Thus, pH 
gradients, such as the one that occurs across the inner mitochondrial membrane (that is, 
mitochondrial membrane potential, which is increased in most tumours31,32), may directly 
influence acetylation reactions33. Conversely, acetylation of histones in the nucleus may 
influence intracellular pH (pHi) because acetate export from the cell is proton coupled34. 
Hence, in low-pHi conditions global deacetylation of histones generates acetate to be 
exported as a mechanism to extrude protons to neutralize pHi34.  
Owing to the very large amounts of acetate stored on his- tones, histone acetylation has 
been proposed to function as a pHi buffer34. Histone acetylation is variable within 
tumours, probably reflecting differences in the tumour microenvironment and cellular 
diversity. Attempts have been made to correlate clinical outcomes with histone 
acetylation levels in tumour specimens that, perhaps not surprisingly, have led to 
conflicting results35–40. As discussed, there are also many non-histone acetylation 
targets, a complexity that is very difficult to address in clinical specimens. Acetyl-CoA is 
the sole donor of acetyl groups for acetylation in eukaryotic cells26. This central 
metabolite comprises an acetyl moiety (CH3CO) bound through a high-energy thioester 
bond to CoA, which is a derivative of vitamin B5, ATP and cysteine21. Hydrolysis of the 
energy-rich thioester bond results in the release of 31.4 kJ mol–1 of energy. To put this in 
perspective, the energy released by the hydrolysis of ATP to ADP + Pi is 30.5 kJ mol–1 
41,42. This makes acetyl-CoA a very unstable molecule, suggesting that acetylation must 
occur very close to the site where acetyl-CoA is produced. Along with the fact that 
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acetyl-CoA cannot easily cross cellular membranes, this underlies the importance of 
acetyl-CoA compartmentalization in the regulation of acetylation reactions. 
Basic biochemistry of methylation 
Methylation is different from acetylation and other PTMs in that both proteins and DNA 
can be methylated. In human DNA, cytosines are typically methylated in the context of 
CpG dinucleotides. Overall, methylation of CpG islands in promoter regions typically 
inhibits transcription. Cancers frequently display global DNA hypomethylation compared 
with their healthy tissue counterparts, although at the same time, exhibiting 
hypermethylation of CpG islands in genomic regions responsible for the expression of 
tumour suppressor genes such as von Hippel–Lindau tumour suppressor (VHL), BRCA1 
or retinoblastoma 1 (RB1)43–46. 
Histone methylation can occur on lysine or arginine 
residues, ranging from mono- to trimethylation. These histone methyl marks can either 
activate or repress gene expression depending on which residue is modified and the 
number of methyl groups incorporated. DNA methylation tends to be a more stable 
modification than histone methylation, but much of tumour suppressor gene silencing is 
driven by histone modification, before DNA methylation occurs47. Nearly half of the 
known histone methyltransferases (HMTs) have been associated with cancer48. The first 
histone demethylase (HDM), that is, lysine-specific histone demethylase 1 (LSD1; also 
known as KDM1A), was discovered only in 200449, but since then several classes of 
demethylase, which we discuss below, have shown remarkable links to metabolism and 
cancer, including the Jumonji-C (JMJC) domain-containing HDMs (JHDMs), which can 
remove mono-, di- and trimethylation groups, and the TET enzymes, which are 
responsible for initiating the demethylation of DNA by hydroxylating 5-methylcytosine. 
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Similar to acetylation, methylation uses the energy stored in a sulfur bond to facilitate the 
reaction. SAM is the primary methyl group donor and is generated    in the methionine 
cycle from methionine and ATP. The methionine cycle begins with the conversion of 
methionine into SAM, which is catalysed by a methionine adenosyltransferase. After 
donating its methyl group, SAM becomes S-adenosylhomocysteine (SAH). S-
Adenosylhomocysteine hydrolase (SAHH) deadenylates SAH to make homocysteine. 
The cycle is completed when homocysteine accepts a methyl group from the folate cycle 
to regenerate methionine50,51. 
Metabolic control of epigenetics 
The relationship between epigenetic regulation and metabolism is complex, with 
overarching themes but also context-specific mechanisms. We first discuss the role of 
metabolites as regulators of enzymatic activity, followed by the choreography of 
subcellular compart- mentalization of metabolic pathways as they relate to epigenetic 
modifications, focusing on acetyl-CoA producers as an example. We then describe the 
impact of oncogenic metabolic rewiring on acetyl-CoA production and histone acetylation 
in cancer cells. 
Metabolites promote and inhibit enzyme activity.  
In phosphorylation (which is the most thoroughly studied mechanism in signalling), 
kinases use an important intracellular metabolite, ATP, as a substrate. However, kinases 
typically have high affinity for ATP, and thus are regulated by other types of signalling 
cue but generally not by ATP availability. A notable exception is AMP-activated protein 
kinase (AMPK), which evolved to sense energy changes and becomes activated when 
the AMP/ATP ratio rises in the cell52. In contrast, many chromatin-modifying enzymes 
not only use metabolic intermediates as cofactors or substrates but are also regulated by 
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their availability. Thus the levels of these metabolites can influence the capacity of the 
cell to write or erase chromatin marks, pointing to an intimate relationship between 
metabolic and epigenetic regulation. 
As described above, DNA and HMTs use SAM as a methyl donor, while the product 
SAH inhibits methyl- transferase activity50 (FIG. 1.2). Similarly, the Krebs cycle (also 
known as the tricarboxylic acid (TCA) cycle) inter- mediate α-ketoglutarate (α-KG) is a 
required co-substrate for JHDMs and TET methylcytosine dioxygenases, which 
participate in a multi-step DNA demethylation process; whereas structurally related 
metabolites such as succinate, fumarate and 2-hydroxyglutarate (2-HG) are competitive 
inhibitors of these α-KG-dependent dioxygenase enzymes53–56. 
Acetylation is similarly promoted by the acetyl group donor acetyl-CoA and inhibited by 
its product, CoA1,57,58 (FIG. 1.2). Adding complexity, recent evidence suggests that other 
acyl-CoAs, notably palmitoyl-CoA59, can also act as inhibitors of KAT reactions. 
Crotonyl-CoA, conversely, is used as an alternative substrate by the acetyltransferase 
p300 (crotonylation)60. Deacetylation reactions are also metabolically responsive. Sirtuin 
deacetylases, in both mitochondria and nuclei, use NAD+ as a cofactor, and energy-
depleted conditions that promote AMPK activation increase NAD+ levels and promote 
sirtuin-mediated deacetylation61 (FIG. 1.2). Whereas deacetylation reactions are 
energetically favourable, sirtuins are intriguing as they catalyse the reaction in a 
seemingly wasteful way: one NAD+ molecule is hydrolysed to produce NADH and O-
acetyl-ADP-ribose. In order to understand the importance of these reactions, factors 
beyond deacetylation need to be considered; for example, the anabolic fate of O-acetyl-
ADP-ribose in cancer cells or interactions with ‘nearby’ acetyl-CoA producers that also 
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regulate and are regulated by the NAD+/NADH ratio, like the pyruvate dehydrogenase 
complex (PDC; which we discuss below). In addition to metabolic regulation of sirtuin 
deacetylases, metabolic products, including the glycolytic product lactate and the ketone 
body β-hydroxybutyrate, have been identified as endogenous inhibitors of KDACs62,63. 
With numerous metabolites potentially affecting each histone modification, 
understanding the true influences of metabolism on chromatin might seem hopelessly 
com- plex. Towards reducing this complexity, a recent metabolomics study in cancer 
cells analysed the relationship of global histone acetylation with levels of various 
metabolites, including acetyl-CoA, CoA, NAD+ and β-hydroxy- butyrate, upon dose-
dependent glycolytic inhibition, and found that the level of acetyl-CoA was the best 
predictor of histone acetylation levels in this context64. 
The spatial choreography of metabolism in subcellular compartments.  
Acetyl-CoA is present in the mammalian cell in multiple, distinct pools: mitochondrial, 
cytosolic, nuclear, peroxisomal and in the endoplasmic reticulum (ER). Acetyl-CoA 
cannot readily cross organelle membranes and thus these pools are physically 
separated. In addition, owing to its inherent instability, it is likely that acetyl-CoA is 
synthesized locally according to its intended use in the cell. Thus, localized sub-pools of 
acetyl-CoA may be locally produced and used in specific functions. 
The largest and best understood pools of acetyl-CoA in the cell are the mitochondrial, 
cytosolic and nuclear pools. Mitochondrial acetyl-CoA has key roles in the Krebs cycle 
and mitochondrial ATP production, whereas the cytosolic pool supplies fatty acid, 
cholesterol and hexosamine biosynthesis pathways. Mitochondria are the major site of 
acetyl-CoA production from nutrient catabolism. Acetyl-CoA is produced in mitochondria 
from glycolysis-derived pyruvate through the glucose oxidation gate-keeping enzyme 
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PDC; catabolism of branched chain amino acids and β-oxidation of fatty acids also 
contribute to the mitochondrial acetyl-CoA pool depending on cell type and 
conditions21,65. Acetyl- CoA condenses with oxaloacetate inside mitochondria to 
generate citrate, which is oxidized within the Krebs cycle to produce the electron donors 
NADH and FADH2 or citrate is exported to the cytoplasm. After export from the 
mitochondria, citrate is cleaved into oxaloacetate and acetyl-CoA by the enzyme ATP-
citrate lyase (ACLY) in an ATP-dependent manner. This pathway is a major route for 
extramitochondrial acetyl-CoA production in mammalian systems under nutrient-replete 
conditions66. However, under stressed conditions, such as low nutrient availability or 
hypoxia, citrate can be generated through reductive carboxylation of glutamine in the 
cytoplasm through isocitrate dehydrogenase 1 (IDH1), in addition to the mitochondrial 
pathway, which involves IDH267–69. Acetate can also be activated upon ligation to CoA to 
produce acetyl-CoA in an ATP-dependent reaction by acyl-CoA synthetase short-chain 
family member 2 (ACSS2). Although not normally a fuel in most mammalian cells, 
acetate uptake and use increases in tumours70,71, particularly under hypoxic conditions in 
which acetate has been shown to contribute a significant fraction of the lipogenic acetyl-
CoA pool72,73. Under hypoxic conditions, acetate also promotes histone acetylation 
globally and at the promoters of lipogenic genes, promoting their expression74 (FIG. 1). 
Global levels of nuclear histone acetylation are sensitive to overall acetyl-CoA levels; 
however, it is attractive to speculate that localized production of acetyl-CoA by spatial 
regulation of acetyl-CoA producers could confer specificity to metabolic regulation of 
acetylation. Presently, it is known that several acetyl-CoA-producing enzymes are 
localized to the nucleus, in addition to other cellular compartments. ACLY and ACSS2 
have been known for several years to be present in the nucleus in addition to the 
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cytoplasm, and to participate in the regulation of overall histone acetylation levels66,75. 
ACSS2 has recently been described as predominantly nuclear in some tumours76, and 
exposure to exogenous acetate promotes its nuclear localization76. Additionally, the PDC 
was recently shown to dynamically translocate from mitochondria to nuclei following 
serum stimulation, epidermal growth factor (EGF) signalling or mitochondrial stress, 
where it produces acetyl-CoA to promote histone acetylation4. These data, as well as 
other evidence of acetyl-CoA producers localizing to the nucleus in disease states such 
as cancer73,76,77, suggest that acetyl-CoA production may be spatially controlled, 
potentially conferring specificity to the effects of metabolism on acetylation (FIG. 1.3). 
It is unclear whether nuclear ACLY, ACSS2 and PDC are redundant or fulfil distinct roles 
in the nucleus. Studies have pinpointed a metabolic role for nuclear ACSS2 in stress 
responses, whereby acetylation of hypoxia-inducible factor 2α (HIF2α) by the 
acetyltransferase CREB-binding protein (CBP; also known as CREBBP) is dependent on 
nuclear translocation of ACSS2 to supply acetyl-CoA76,77. Similarly, as discussed, 
mitochondrial stress was shown to promote PDC translocation to the nucleus to increase 
histone acetylation involved in cell cycle progression4. Additionally, the presence of a 
functional Krebs cycle was shown to be important for maintaining overall levels of 
histone acetylation, regardless of the availability of exogenous acetate68. Parsing out 
the relative contributions and mechanisms of compensation between each of these 
enzymes in different contexts will be important for both understanding the physiological 
control mechanisms for acetylation and identifying opportunities for targeting these 
pathways. Moreover, the mechanisms governing their nuclear localization remain 
elusive, as none has a reported nuclear localization sequence. It is likely that the 
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mechanism by which each of the acetyl-CoA-producing enzymes are brought into the 
nucleus has a substantial impact on their function within the organelle. 
Oncogene rewiring of acetyl-CoA metabolism.  
The importance of acetyl-CoA in several pathways and multiple cellular compartments 
implicates it as a chief target of the metabolic remodelling and molecular rewiring in 
cancer. Indeed, evidence that frequent primary molecular changes or driver mutations in 
cancer can directly affect acetyl-CoA homeostasis suggests an intimate link between 
molecular and metabolic signalling. MYC and AKT both fulfil prominent roles in 
stimulating nutrient uptake and rewiring cellular metabolism in cancer cells78–80. Among 
their metabolic roles, both have been shown to promote acetyl-CoA production through 
ACLY. MYC regulates acetyl-CoA production for use in lipid synthesis and histone 
acetylation81, and MYC- deficient cells maintain lower acetyl-CoA levels, despite 
evidence of compensatory mechanisms82,83. AKT directly phosphorylates and activates 
ACLY84,85, thus enabling cells to maintain histone acetylation even when glucose 
availability is limited1. Conversely, AKT inhibition decreases cellular acetyl-CoA and 
histone acetylation levels. Notably, overall histone acetylation levels in human prostate 
tumours and gliomas correlate significantly with phosphorylated Ser473 on AKT1. Thus, 
AKT activation in cancer cells may enable them to sustain a high nuclear level of acetyl-
CoA, preventing histone acetylation from fluctuating with microenvironmental nutrient 
availability. Such a mechanism could conceivably enable cells to maintain pro-
proliferative gene expression programmes in a harsh microenvironment, enabling them 
to respond more rapidly when adequate nutrients for growth become available. 
Tyrosine kinases can phosphorylate pyruvate dehydrogenase kinase (PDK) and activate 
it, thus indirectly inhibiting PDC86; they can also directly phosphorylate and inhibit 
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PDC87,88. The net result is a decrease in PDC activity and thus a net decrease in 
mitochondrial acetyl-CoA pro- duction and Krebs cycle activity, with all its downstream 
effects, including reduced α-KG, citrate and NADH levels. EGF can promote PDC 
translocation in the nucleus, where it can remain constitutively active, producing acetyl-
CoA, because PDK, which tonically inhibits PDC in mitochondria, is absent from the 
nucleus, at least in some cancers4. Although it is becoming increasingly clear that 
oncogenic alterations in acetyl-CoA homeostasis facilitate tumorigenesis and 
progression, delineating the effects on metabolism and molecular signalling has 
remained elusive. Below, we propose three models of how metabolic rewiring can lead 
to remodelling of the epigenome landscape in tumours as part of a greater bidirectional 
feedback mechanism between molecular signalling and metabolism in cancer. 
Potential models of coordination 
As the body of literature on metabolic control of the epigenome has grown, it has 
become clear that a single mode of regulation does not apply universally to all scenarios 
in which metabolism influences chromatin marks. Therefore, in delineating the 
relationship between cellular metabolism and epigenetic modification, we propose three 
models that we believe encapsulate the types of regulation that have been observed 
thus far (FIG. 1.4). These models provide a framework within which to understand the 
diverse roles for metabolism in epigenetic control in cancer biology and how the 
molecular and metabolic rewiring may influence these processes, although raising 
questions that remain to be addressed. 
Model 1: inhibitor metabolite production and chromatin regulation. Some chromatin-
modifying enzymes use metabolites as substrates, but these metabolites are not 
normally regulatory for the function of the enzyme, except in the presence of inhibitor 
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metabolites. For example, α-KG is a co-substrate required for the activity of some 
histone and DNA demethylases, as discussed above (FIG. 1.2). Metabolites that 
interfere with the use of α-KG by these enzymes, including 2-HG, succinate and 
fumarate, which are structurally similar to α-KG, can inhibit some demethylases when 
their levels are elevated. The discovery of mutations in IDH1 and IDH2, through genomic 
studies of gliomas and other cancers, led to the identification of the first oncometabolite, 
(R)-2-hydroxyglutarate (R-2HG), produced by the mutant IDH enzymes89–93. Tumours 
harbouring IDH1 or IDH2 mutations exhibit increased histone and DNA methylation and 
more poorly differentiated gene expression profiles93–96 (FIG. 1.4). For in-depth 
discussion on the biology of IDH mutations and R-2HG, see recent review articles56,97. 
Interestingly, the other enantiomer, S-2HG, is produced by lactate dehydrogenase (LDH) 
under hypoxic conditions, in which it also affects histone methylation and hypoxic 
transcriptional responses98,99. Accumulation of succinate or fumarate, which occurs in 
tumours deficient for succinate dehydrogenase (SDH) or fumarate hydratase (FH), 
similarly inhibit α-KG- dependent enzymes, resulting in hypermethylation54,55,100. 
Conversely, embryonic stem cells (ESCs) maintain an elevated α-KG/succinate ratio that 
is crucial for maintaining histone and DNA demethylation and pluripotency101. Thus, 
production of inhibitor metabolites in both physiological and pathological conditions can 
alter the activity of chromatin-modifying enzymes. 
Model 2: nutrient sensing and regulation of chromatin. Chromatin modifications can also 
occur in direct response to physiological changes in nutrient availability. Such 
mechanisms may enable cells to optimize crucial short- and long-term adaptation 
mechanisms in conditions of limited fuel supply, such as those commonly found in many 
tumours. A canonical example of metabolite sensing is that of AMPK, which responds to 
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AMP and/or ADP availability52. As cells conduct work, ATP is consumed and ADP 
produced. The adenylate kinase reaction buffers cellular ATP concentrations, converting 
two ADP molecules into ATP and AMP. Hence, rising AMP levels convey energetic 
stress to the cell, doing so by binding to the γ-subunit of the AMPK heterotrimer, 
facilitating a conformational change that promotes phosphorylation of AMPKα-Thr172 by 
liver kinase B1 (LKB1; also known as STK11). AMPK has been described as regulating 
numerous activities in the cell52,102, generally serving to restore energy balance by 
inhibiting energy consuming pathways and activating mechanisms that promote ATP 
production. Recent evidence implicates AMPK in stress-induced histone 
phosphorylation103, suggesting that insults to the energy status of the cell can be 
translated into functional outputs in part through histone modification and gene 
regulation (FIG. 1.4). 
Another example of how the overall supply of nutrients can be sensed and can affect 
epigenetic mechanisms comes from the dependence of methylation reactions on diet-
derived essential amino acids (BOX 1). Owing to dependence on the essential amino 
acid methionine (up to 50% of the daily intake of methionine is converted into SAM104) 
and folate to propagate the methionine cycle, the serum levels of SAM and SAH in 
patients, as well as the degree of methylation in tumours, change with diet105,106. For 
example, dietary folate supplementation increases global DNA methylation of rectal 
mucosa107 and colonic polyps108. Furthermore, tumour samples from patients with colon 
cancer who consumed more than 400 μg folate per day seem to have more global DNA 
methylation than tumour samples from patients consuming less than 200μg folate per 
day109. This may have direct effects on tumorigenesis, as consuming a methyl donor-
deficient diet has been shown to reduce spontaneous tumour formation in animals 
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predisposed to intestinal tumours110. Moreover, methylation of specific histone residues 
(H4K3-trimethyl (me3)) is directly related to the availability of dietary methionine and 
intracellular production of SAM, further linking metabolism to epigenetic regulation111. 
Finally, nuclear and cytosolic acetyl-CoA levels may be sensed by the cell, enabling it to 
gauge its metabolic health. Acetyl-CoA levels are dynamic and parallel growth and 
proliferation, as well as histone acetylation, in both yeast and mammalian cells. This 
suggests that cells may sense acetyl-CoA to optimize the metabolic needs of 
proliferation with nutrient supply1,112–114. The evidence for acetyl-CoA availability affecting 
acetylation levels first emerged from an elegant study conducted in yeast75. Unlike 
mammalian cells, Saccharomyces cerevisiae relies on a single enzyme outside 
mitochondria to produce acetyl-CoA, Acs2p, the orthologue of mammalian ACSS2. 
Deletion of ACS2 resulted in a rapid drop in overall histone acetylation levels, and 
reconstitution with either a nucleus- or cytosol-confined enzyme, but not with a 
mitochondria-confined enzyme, restored histone acetylation. This study demonstrated 
the need for continuous production of acetyl-CoA in the nucleus or cytoplasm to sustain 
histone acetylation levels, and additionally provided experimental evidence for the 
separation of the mitochondrial and nuclear–cytosolic acetyl-CoA pools. Importantly, 
acetyl-CoA availability is also crucial for sustaining histone acetylation levels in 
mammalian cells, mediated largely through ACLY1,66. 
If acetyl-CoA levels are indeed ‘sensed’, this implies that one or more acetyltransferases 
are potential sensors, mediating acetylation reactions in a nutrient-responsive manner. 
According to a nutrient-sensing model, bulk cellular acetyl-CoA levels fluctuate with 
nutrient availability or metabolic state to influence histone acetylation. Acetyl-CoA 
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concentrations in yeast oscillate during metabolic cycles, over a range of approximately 
3–30 μM, corresponding to periods of growth112; increased acetyl- CoA coincides with 
rising levels of histone acetylation both globally and locally at the promoters of growth-
associated genes112. This regulation occurs in a manner dependent on the SAGA 
acetyltransferase complex112, as yeast Gcn5 has a high KD for acetyl-CoA 
(approximately 8.5 μM) and can therefore be affected by acetyl-CoA oscillations. In 
addition to requiring acetyl-CoA for their activity, KATs are also subject to inhibition by 
their product, that is, CoA. Thus, it has been hypothesized that it may be the acetyl-
CoA/CoA ratio that regulates KAT activity and histone acetylation in mammalian 
cells57,58. Moreover, the acetyl-CoA/CoA ratio not only influences the enzymatic activity 
of KATs, but also alters their specificity115,116. Glucose restriction or inhibition of signal 
transduction through the PI3K–AKT pathway results in a decline in both total acetyl-CoA 
levels and the acetyl-CoA/CoA ratio, corresponding to reduction in histone acetylation1. 
Experiments in isolated nuclei further showed that bulk histone acetylation can indeed 
be regulated by the acetyl-CoA/CoA ratio1. The acetyl-CoA/CoA ratio is also affected in 
liver by fasting and refeeding, suggesting its relevance to nutritional responses in whole 
organisms117. Conversely, glycolysis inhibition with 2-deoxy-D-glucose (2-DG) caused 
acetyl-CoA levels to fall, but acetyl-CoA/CoA ratio to rise, suggesting that these effects 
may be driven by alternative mechanisms in addition to feedback inhibition64. Such 
apparent differences may also be reflective of measuring whole-cell instead of nuclear 
levels of these metabolites, as necessitated by current mass spectrometry methods. 
Collectively, these findings suggest that acetyl-CoA levels and/or the acetyl-CoA/CoA 
ratio is a major indicator of the metabolic status of a cell, and that this should perhaps 
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now be added to the AMP/ATP and NAD+/NADH ratios, which have already been 
established as crucial rheostats in metabolic sensing (FIG. 1.5). 
Model 3: localized metabolite production and chromatin regulation. We discussed how 
nuclear acetyl-CoA- producing enzymes (ACLY, ACSS2 and PDC) provide the ink in an 
expanded definition of the histone code and can regulate global histone acetylation and 
global acetyl-CoA homeostasis. There is now emerging evidence that direct recruitment 
of metabolic enzymes to specific sites on chromatin can facilitate site-specific cofactor or 
substrate production and histone modification (FIGS 1.3,1.4). Such regulation could 
participate in altered gene regulation in cancer and contribute to diverse cancer 
phenotypes. 
One of the first examples of local production of a metabolite through recruitment of a 
metabolic enzyme into a transcription factor complex was described for S-
adenosylmethionine synthase isoform type 2 (MAT2A), which is recruited through a 
direct protein–protein interaction to the DNA binding sites of the transcription factor 
MAFK118. There, MAT2A locally synthesizes SAM118, which can then be used for 
localized histone methylation through interactions with HMTs such as SETDB1119 (FIG. 
1.4). 
Very recently, two additional complexes containing acetyl-CoA-producing enzymes were 
described. The aryl hydrocarbon receptor (AHR), a transcription factor associated with 
xenobiotic metabolism, forms a complex on chromatin with pyruvate kinase M2 (PKM2), 
PDC and the acetyltransferase p300120. This complex results in acetylation of H3K9 at 
the enhancer of CYP1A1, an AHR target gene, enhancing its transcription120. In this 
complex, PKM2 uses phosphoenolpyruvate to produce pyruvate and ATP, as it does in 
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the cytoplasm. The pyruvate is then used by PDC to produce acetyl-CoA, which is 
provided to p300 for histone acetylation. The PDC, which despite its very large size is 
translocated as an intact complex and remains functional in the nucleus4, can efficiently 
use this locally produced metabolite to produce acetyl-CoA and acetylate the target 
histone lysine through p300, as all the enzymes and the transcription factor form a 
complex (FIG. 1.3). This beautiful example of a targeted local acetylation system in the 
nucleus raises the intriguing possibility that such mechanisms may be commonly used to 
regulate transcription. 
Additionally, recent evidence in yeast has shown that the yeast PKM2 orthologue, Pyk1, 
forms a large complex with serine biosynthesis and methionine cycle enzymes, as well 
as Acs2p. The existence of this complex, coined serine-responsive SAM-containing 
metabolic enzyme (SESAME), is another example of metabolic enzymes acting in 
concert to regulate epigenetic marks. The SESAME complex interacts with the Set1 
methyltransferase complex, providing the necessary SAM for H3K4 methylation at target 
genes121. Moreover, serine produced by members of the SESAME complex is proposed 
to activate Pyk1 kinase activity, increasing H3T11 phosphorylation at sites where the 
SESAME complex is recruited by Set1121. It remains to be determined whether an 
analogous SESAME complex exists in mammalian cells. 
Local metabolite production may also influence chromatin-dependent processes beyond 
transcription, such as the repair of DNA damage. Consistent with this possibility, a 
recent study implicated nuclear FH in non-homologous end-joining DNA double-strand 
break repair122. Recruitment of FH facilitates localized production of fumarate, which 
inhibits the activity of the α-KG-dependent lysine-specific demethylase 2B (KDM2B), 
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resulting in elevated histone H3K36 methylation and DNA repair protein recruitment to 
double-strand DNA break sites. 
By considering these three models, it is clear that metabolic influences on the cancer 
epigenome can occur through multiple mechanisms. These mechanisms are not 
mutually exclusive and tumours probably engage all three modes of regulation. The first 
model (inhibitor metabolite production), is probably the best understood mechanism of 
regulation in the context of cancer biology at present, owing to intense investigation of 
the mechanisms through which IDH1 and IDH2 mutations contribute to tumorigenesis. 
The second model (nutrient sensing-mediated regulation of chromatin) clearly occurs 
and is altered in tumours, although a mechanistic understanding of how it regulates 
specific biological processes is lacking. Much more work is needed in this area to 
elucidate both the sensing mechanisms and how they mediate specific responses. The 
third model (localized metabolite production) is just beginning to gain attention, as 
demonstrated by several very recent studies and it seems likely that additional examples 
of this type of regulation will emerge. As new examples of metabolic regulation of 
chromatin are studied, considering them in the framework of these three models may 
help in elucidating the logic and biological functions of such regulation. 
Impact on major cell decisions 
Despite the evidence that the overall availability of acetyl-CoA levels (or the acetyl-
CoA/CoA ratio) can regulate histone acetylation, at this point it may be premature to 
conclude that this can also directly regulate major cell decisions in a coordinated 
manner, affecting all cellular compartments. For example, does an increase in this 
rheostat of metabolism promote cell proliferation, cell death or differentiation? If so, this 
would imply that drugs that would ultimately increase or decrease acetyl-CoA levels may 
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regulate such cell decisions that form the foundation of many diseases such as cancer 
or degenerative diseases. Evidence has emerged that an increase in nuclear acetylation 
is associated with cell cycle progression and proliferation (FIG. 1.6). As discussed, 
increased acetyl-CoA levels are associated with increased histone acetylation, 
proliferation and growth, and a large proportion of acetyl-CoA-responsive genes are 
involved in cell growth and cell cycle progression1,112. Indeed, nuclear acetylation may 
promote the expression of proliferation genes at the expense of differentiation, at least in 
certain contexts4,123. For example, mouse ESCs have very high levels of acetyl-CoA, 
which, upon induction of the differentiation process, decrease significantly124. A similar 
fluctuation of acetyl-CoA during differentiation has also been observed recently in human 
ESCs, which produce acetyl-CoA through glucose metabolism but rapidly suppress this 
function during differentiation. Loss of pluripotency is associated with decreased 
glycolytic activity, lowered acetyl-CoA levels and histone deacetylation123. In contrast, 
when acetyl-CoA levels are preserved through exogenous supply of acetate, preserved 
histone acetylation delays stem cell differentiation123. 
Cell survival and death decisions are also affected by acetyl-CoA availability. Autophagy, 
a catabolic process that is crucial for organelle quality control and cell survival during 
metabolic stress, is suppressed by high acetyl-CoA availability. In the nucleus, acetyl-
CoA induces histone acetylation and repression of pro- autophagic genes125. 
Additionally, high cytoplasmic levels of acetyl-CoA suppress autophagy in a p300-
dependent manner126 (FIG. 1.6). Furthermore, organelle-specific depletion of acetyl-CoA 
owing to loss of function of the transporter responsible for the import of acetyl-CoA into 
the ER, which is crucial for lysine acetylation of proteins in the ER, induces 
autophagy127. Interestingly, low levels of acetyl-CoA are also associated with protection 
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against pro-apoptotic stimuli. The anti-apoptotic protein BCL-XL (also known as 
BCL2L1) suppresses acetyl-CoA levels and N-terminal acetylation of caspase 2, 
promoting cell survival21,128. Alterations in metabolite availability for chromatin 
modification during ageing may also have a role in modulating the survival of whole 
organisms. At mid-life, flies (Drosophila melanogaster) were found to exhibit increased 
ATP-citrate lyase (termed ATPCL in flies) activity, acetyl-CoA levels and levels of 
acetylation on several histone lysines compared with young flies. Interfering with ATPCL 
or the acetyltransferase Chameau extended lifespan129. The evidence is mounting that 
acetyl-CoA levels are important regulators of major cellular decisions, spanning the fate 
of individual stem cells to the life expectancy of an entire organism. 
The global effects of methylation are more difficult to interpret given the interplay 
between histone and DNA methylation, that is, overall hypomethylation in cancer, but 
increased methylation of CpG islands. In ESCs, maintaining an elevated α-KG/succinate 
ratio decreases suppressive methylation marks on DNA and histones, which promotes 
pluripotency101. Methionine metabolism and the availability of SAM also regulate stem 
cell differentiation and the transition from naive to primed ESCs130–132. Tumours 
exhibiting hypermethylation, including those with IDH and SDH mutations, are 
associated with poorly differentiated gene expression profiles93,94,96,100,133,134 (FIG. 1.6). 
Moreover, interfering with either 2-HG production or DNA methylation promotes 
differentiation in the context of IDH mutation134–138. It has recently emerged that 
disruption of demethylation also promotes carcinogenesis at least in part through 
regulation of chromatin structure. In IDH-mutant glioma, hypermethylation of CCCTC 
binding factor (CTCF) binding sites was shown to result in the loss of CTCF binding and 
interaction between previously insulated topologically associating domains (TADs). This 
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enabled a constitutive enhancer to aberrantly interact with and upregulate the oncogene 
platelet-derived growth factor receptor-α (PDGFRA)139. Consistent with recent evidence 
that conserved CTCF binding sites are frequently mutated in cancer and can affect 
differentiation and tumorigenesis140–142, mutations of IDH genes may promote tumour 
growth by disrupting chromatin structure in addition to methylation patterns in genes and 
regulatory elements. Thus, metabolic control of demethylation through α-KG participates 
in maintaining chromatin organization and regulating differentiation processes, both of 
which are disrupted by the production of inhibitory metabolites such as 2-HG. 
Acetylation promotes metabolic rewiring 
In addition to histones, acetylation can directly regulate the function or intracellular 
localization of many proteins that are crucial to carcinogenesis (FIG. 1.7). For example, 
acetylation seems to directly promote mitochondrial suppression and glycolysis 
upregulation. Hyperacetylation of mitochondrial enzymes owing to loss of sirtuin 3 
(SIRT3) has been shown to predispose rodents to cancer as well as other proliferative 
diseases in animals and humans, such as pulmonary arterial hypertension143–145. 
Acetylation can suppress mitochondrial function by several mechanisms: inhibition of the 
production of acetyl-CoA-producing pathways such as PDC87 and β-oxidation146,147; 
inhibition of the activity of Krebs cycle enzymes like IDH2148 and SDH149,150; suppression 
of complex I of the electron transport chain151 and dismutation of superoxide by 
mitochondrial super-oxide dismutase (MnSOD; also known as SOD2)152; and increase in 
the nuclear transcriptional activity of the HIF1α–aryl hydrocarbon receptor nuclear 
translocator (ARNT) complex153, which subsequently suppresses mitochondria by 
several mechanisms including upregulation of PDK154. As acetylation inhibits PDC by 
promoting the recruitment of PDK, and PDK is not found in the nuclear fraction of PDC, 
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this may be an escape mechanism by which PDC is able to produce acetyl-CoA in the 
nucleus without inhibiting itself. However, mitochondrial suppression may be offset by 
competing mitogenic transcription factors, as acetylation inhibits peroxisome proliferator-
activated receptor-γ co-activator 1α (PGC1α) but activates nuclear respiratory factor 1 
(NRF1) and NRF2 (also known as NFE2L2)155,156. Similarly, acetylation has opposing 
effects on HIF1 and HIF2 (activating HIF1 and inhibiting HIF2). These transcription 
factors are known to have different roles in the cell, with HIF1 pre- dominantly mediating 
the effect of hypoxic signalling on tumour metabolism157. Thus, the overall effect of 
acetylation is likely to be cell type specific or context specific. 
Acetylation in the cytoplasm also promotes the trans- location of several glycolytic 
enzymes to the nucleus where they are proposed to ‘moonlight’ as transcriptional 
regulators in proliferative states, for example, glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH)158,159 and PKM2160, as well as the nuclear accumulation or 
increased activity of pro-proliferative transcription factors such as MYC161–163 and signal 
transducer and activator of transcription 3 (STAT3)164. The mTOR complex 2 (mTORC2) 
member, rapamycin-insensitive companion of mTOR (RICTOR) can also be acetylated 
in a metabolically responsive manner, promoting resistance to cancer therapies165. 
Acetylation in the cytoplasm may also redirect carbon sources towards biomass 
generation by increasing the production of nucleosides by the pentose phosphate 
pathway (PPP) through stimulation of the activity of 6-phosphogluconate dehydrogenase 
(PGD)166,167. 
Importantly, ACLY itself can be acetylated in a glucose-sensitive manner, promoting its 
stability168. This increase in ACLY activity increases generation of lipogenic acetyl-CoA 
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in tumour cells from citrate derived from either the Krebs cycle or the reductive glutamine 
pathway, which is upregulated in cancer68,69. Conversely, ACSS2 is deacetylated and 
activated by SIRT1, potentially providing a compensatory source of cytosolic acetyl-CoA 
under low-nutrient conditions169. 
Conversely, acetylation of p53 in response to DNA damage and tubulin acetylation are 
insensitive to silencing of ACLY or PDC, suggesting that modulating nuclear–cytosolic 
acetyl-CoA availability alone does not have a global impact on all cytoplasmic protein 
acetylation4,66. Identifying nuclear and cytoplasmic proteins that are acetylated in an 
acetyl-CoA-dependent manner will be a considerable step towards understanding how 
many cellular and molecular events respond to changes in nutrient availability. 
Translational implications 
Although cancer metabolism and epigenetic mechanisms, particularly histone 
acetylation, have independently been the focus of intensive efforts for drug development, 
many of which are in clinical trials, the presence of a metabolism–epigenome axis may 
have several important translational implications. For example, the effects of inhibitors 
that target metabolic pathways may reach epigenetic mechanisms and alter the levels of 
many gene products, beyond what their direct metabolic effects would have predicted. 
Thus the interpretation of their effects now needs to consider epigenetic mechanisms. 
Drug specificity may be increased by considering the targeting of histone modifications 
in a condition-specific manner. For example, loss of the 9p21 tumour suppressor locus, 
one of the most common deletion events in cancer, has recently been shown to cause 
deregulated methionine metabolism owing to deletion of the gene encoding the enzyme 
methylthioadenosine phosphorylase (MTAP)170–172. Importantly, these MTAP-deficient 
cancer cells are now sensitized to inhibition of the protein arginine N-methyltransferase 5 
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(PRMT5), opening a new therapeutic opportunity based on this interaction of methionine 
metabolism and the epigenome170–172. 
Given the direct effects of the nuclear acetyl-CoA producers on histone acetylation, 
inhibitors of ACLY, ACSS2 and PDC may now be seen as perhaps a new class of drugs 
that target the metabolism–epigenome axis, compared with their current approach as 
metabolic modulators. Several of these drugs under development (previously or 
currently) include the ACLY inhibitors SB-204990 (pre- clinical)173,174, BMS-303141 
(preclinical)175, ETC-1002 (phase II clinical trial)176–178, and hydroxycitrate (phase IV 
clinical trial)179,180  and the ACSS2 inhibitor, N-(2,3-di-2-thienyl-6-quinoxalinyl)-Nʹ-(2-
methoxyethyl)urea (pre-clinical)70. Following preclinical studies, the PDC activator 
dichloroacetate (DCA) which activates PDC by inhibiting PDK20, has entered clinical 
development in phase I clinical trials in cancer181–183. By increasing the activity of the 
Krebs cycle, DCA can increase acetyl-CoA production in the mitochondria and 
cytoplasm. However, at least in some cancers, PDK, despite forming a complex with 
PDC in mitochondria, does not follow the translocation of PDC to the nucleus4, 
suggesting that nuclear PDC may be constitutively active or ‘immune’ to DCA. In 
contrast, as PDC is directly inhibited by tyrosine kinases (TKs), TK inhibitors may 
activate both mitochondrial and nuclear PDC86,88,184. 
The conflicting results in the efficacy of KDAC inhibitors in cancer treatment may be 
because many of these inhibitors target multiple KDACs instead of a single target and 
histone remodelling is heterogeneous depending on context, tissue and cancer type185–
187. Moreover, the large number of acetylated proteins in addition to histones adds to the 
complexity of responses to KDAC inhibition. Further investigation is needed to clarify 
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contexts for effective use of existing KDAC inhibitors, as well as for development of more 
effective and specific drugs. 
The consideration of a metabolism–epigenome axis may alter the way we approach 
biomarker studies in cancer (BOX 1). For example, metabolomic studies should be 
considered in parallel with transcriptomic studies under the same experimental 
conditions. Several parameters that take into account dietary intake are controlled in 
metabolomic studies, but currently this is not typically done in transcriptomic studies 
from human specimens, potentially influencing the accuracy and variability in these 
studies. Notably, it has been shown that serum methionine levels in humans are variable 
between individuals over a range that could affect histone methylation; moreover, 
approximately 30% of the variation in methionine concentration is explained by dietary 
factors111.  
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Conclusions and perspectives 
Although considerable progress has been made in understanding the link between 
metabolism and epigenetics, several outstanding questions remain. The list of metabolic 
Box 1 | The metabolism–epigenetics axis and its systemic effects on multi-
organ organisms in vivo 
Most of the discussion in this Review is focused on the regulation of the metabolism–
epigenome axis in a single cell. In complex organisms, additional levels of complexity are 
likely to be activated to optimize and synchronize energy use with growth, perhaps via the 
circadian rhythm machinery and peripheral clocks, which are closely linked to metabolism and 
acetylation353,354. Starvation reduces acetyl-CoA and protein acetylation levels in several 
organs, including the heart and muscle. This is prevented by strategies that promote acetyl-
CoA production: for example, the pyruvate dehydrogenase complex (PDC) activator 
dichloroacetate (DCA)126. However, starvation does not affect acetyl-CoA levels in the brain126 
although it increases acetyl-CoA and protein acetylation levels in the liver355. Circulating 
ketone bodies produced by one organ, for example, the liver under starvation, may regulate 
acetylation mechanisms in other organs and may be involved in the explanation of these 
organ-specific effects. For example, β-hydroxybutyrate can inhibit several lysine deacetylases 
(KDACs)63. In addition, alternative sources of acetyl-CoA exist in specific cell types such as 
neurons, which can generate acetyl-CoA through β-hydroxybutyrate356, or hepatocytes, which 
can generate acetyl-CoA from ethanol357. These data underlie the importance of recognizing 
that often acetyl-CoA homeostasis mechanisms can be context, cell type or organ specific. 
This needs to be considered in the studies of cancers arising from different organs or in the 
interpretation of the global effects of cancer therapies or metabolic modulators on the 
metabolism–epigenetic axis in the whole organism. Similarly, dysregulation of metabolic 
homeostasis is likely to prove important in our understanding of cancer cachexia. 
.  
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enzymes present in the nucleus has grown extensively in recent years. As more 
metabolic enzymes are identified in the nucleus, understanding their role in this 
compartment will be crucial in elucidating the links between metabolism and epigenetic 
regulation. Of particular importance, many of these nuclear metabolic enzymes function 
in complex with one or multiple other proteins. Thus, uncovering interacting partners of 
metabolic enzymes in the nucleus will be telling with regard to their function. Additionally, 
although we have focused here on metabolic enzymes that use their metabolic activity to 
produce substrates for chromatin modification, several metabolic enzymes have been 
reported to use alternative, non-metabolic functions in the nucleus; distinguishing 
metabolic and other moonlighting functions of these enzymes is crucial to understanding 
their biological roles in the nucleus. Lastly, although many metabolic enzymes have now 
been found in the nucleus, how they arrive there remains unclear, as many lack a 
canonical nuclear localization sequence. 
Metabolic rewiring in cancer affects the epigenome in a manner that facilitates tumour 
development and/or progression. Furthering our understanding of the roles of metabolic 
enzymes in affecting epigenetics and cell fate decisions has great potential to lead to 
novel strategies to battle cancer. 
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Figure 1.2 | Histone code writers require metabolites as ink to write 
epigenetic marks.  
N-Acetylglucosamination (GlcNAcylation) by O-GlcNAc transferase (OGT) uses the metabolite 
UDP-glucosamine (UDP-GlcNAc) synthesized by the hexosamine biosynthetic pathway from 
inputs such as glucose and glutamine (top left). Acetylation uses the metabolite acetyl-CoA, 
which is synthesized in the cytoplasm and nucleus from acetate, citrate or pyruvate by acyl-CoA 
synthetase short-chain family member 2 (ACSS2), ATP-citrate lyase (ACLY) and pyruvate 
dehydrogenase complex (PDC), respectively. The lysine acetyltransferase (KAT) reaction 
releases CoA-SH, a product that can inhibit these enzymes. Certain fatty acyl-CoAs have also 
been shown to inhibit KAT enzymes (top right). Lactate, a glycolytic product, and β‑
hydroxybutyrate, a ketone body, have been identified as endogenous lysine deacetylase (KDAC) 
inhibitors. S-Adenosylmethionine (SAM), synthesized from the essential amino acid methionine 
and ATP by methionine adenosyltransferase (MAT) enzymes, is the substrate for histone 
methyltransferases (HMTs) and DNA methyltransferases (DNMTs), resulting in the production of 
S-adenosylhomocysteine (SAH), which in turn can inhibit HMTs and DNMTs. Other metabolites, 
such as fumarate, succinate and 2-hydroxyglutarate (2-HG), have been identified as inhibitors of 
Jumonji-C (JMJC) domain-containing histone demethylases (JHDMs) and TET demethylases, 
which rely on the structurally similar metabolite α‑ketoglutarate (α-KG) as a co-substrate (bottom 
right). Energetic stress can also affect epigenetic regulation by activating AMP-activated protein 
kinase (AMPK), leading to stress-induced histone phosphorylation (bottom left). SIRT, sirtuin. 
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Figure 1.3 | Histone acetylation may be mediated by global or local 
production of acetyl-CoA.  
a, Nuclear acetyl-CoA producers ATP-citrate lyase (ACLY), acyl-CoA synthetase short-chain 
family member 2 (ACSS2) and pyruvate dehydrogenase complex (PDC) create pools of acetyl-
CoA that can be accessed non-specifically by lysine acetyltransferases (KATs) in the nuclear 
domain.  
b, Acetyl-CoA is generated locally in a subnuclear domain by a complex of proteins that directly 
link production of acetyl-CoA (that is, pyruvate kinase M2 (PKM2)) with acetyl-CoA production 
(that is, PDC) with a KAT to locally acetylate specific histone targets. Ac, acetylation; PEP, 
phosphoenolpyruvate. 
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Figure 1.4 | Models of coordination between metabolism and the 
epigenome.  
a, Model 1: inhibitor metabolite production and chromatin regulation. The production of inhibitor 
metabolites such as R-2-hydroxyglutarate (R-2HG) and S-2HG by mutant isocitrate 
dehydrogenase (IDH) and promiscuous lactate dehydrogenase (LDH) activity, respectively, 
increases histone and DNA methylation by competitively inhibiting the α‑ketoglutarate (α-KG)-
dependent Jumonji-C (JMJC) domain-containing histone demethylases (JHDMs) and TET 
demethylases.  
b, Model 2: nutrient sensing and chromatin regulation. The availability of metabolites used as the 
ink for histone writers fluctuates based on the energy status of the cell. For example, a nutrient-
poor cell may have activation of AMP-activated protein kinase (AMPK) and a reduction in 
methionine and acetyl-CoA levels, leading to altered expression of adaptive response genes 
owing to changes in the phosphorylation (P), methylation (Me) and acetylation (Ac) of chromatin.  
c, Model 3: localized metabolite production and chromatin regulation. Direct recruitment of 
metabolic enzymes to specific sites on chromatin facilitates site-specific substrate production and 
histone modification. For example, S-adenosylmethionine (SAM) synthase isoform type 2 
(MAT2A) locally produces SAM for histone methylation (Me) at specific sites. Similarly, nuclear 
ATP-citrate lyase (ACLY), acyl-CoA synthetase short-chain family member 2 (ACSS2) and 
pyruvate dehydrogenase complex (PDC) locally generate acetyl-CoA to be used by lysine 
acetyltransferases (KATs) to acetylate (Ac) histones, resulting in regulation of specific genes. MT, 
methyltransferase; TF, transcription factor. 
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Figure 1.5 | Metabolites as rheostats of cellular nutritional state. 
Metabolic state can be conveyed to chromatin through fluctuations in concentrations of several 
metabolites that are substrates or regulators of chromatin modifiers. Levels of S-
adenosylmethionine (SAM) and acetyl-CoA increase in high-nutrient conditions (abundant 
methionine or glucose, respectively), favouring increased histone methylation and acetylation 
(top). Under low-nutrient conditions (bottom), AMP levels rise, activating AMP-activated protein 
kinase (AMPK) and inducing targeted histone phosphorylation. NAD+ levels also rise under low-
nutrient conditions, leading to the activation of sirtuin deacetylases. Furthermore, levels of 
product metabolites S-adenosylhomocysteine (SAH) and CoA may increase with nutrient 
limitation in a context-dependent manner, feeding back to inhibit methyltransferases and 
acetyltransferases, respectively. These feedback mechanisms enable cells to dynamically 
modulate their chromatin modification landscape in response to metabolic conditions. Ac, 
acetylation; DNMT, DNA methyltransferase; HMT, histone methyltransferase; KAT, lysine 
acetyltransferase; Me, methylation; P, phosphorylation. 
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Figure 1.6 | The metabolic–epigenome axis regulates major cell decisions.  
a, A high acetyl-CoA/CoA-SH ratio promotes the acetylation (Ac) of histones and transcription 
factors involved in proliferation. Conversely, reduction in the acetyl-CoA/CoA-SH ratio and thus 
histone deacetylation signals a change from proliferation to differentiation. Depletion of acetyl-
CoA favours the deacetylated, active versions of proteins involved in autophagy (autophagy-
related genes (ATGs)), and an AMP-activated protein kinase (AMPK)-dependent inhibition of 
mTOR complex 1 (mTORC1), causing activation of several enzymes crucial for the biogenesis of 
autophagosomes.  
b, Increased histone and DNA methylation (Me) due to inhibition of histone and DNA 
demethylases by fumarate, succinate and 2-hydroxyglutarate (2-HG) (from loss-of-function (LoF) 
or mutant isocitrate dehydrogenase (IDH), fumarate hydratase (FH) and succinate 
dehydrogenase (SDH)) promotes proliferation over differentiation. Conversely, histone and DNA 
demethylation stimulated by production of the demethylase reaction cofactor α‑ketoglutarate (α-
KG) promotes pluripotency. JHDM, Jumonji-C domain-containing histone demethylases. 
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Figure 1.7 | Acetylation promotes molecular and metabolic rewiring in 
cancer.  
Acetylation (Ac) of proteins may activate, inhibit or promote their translocation to a different 
subcellular compartment. Mitochondrial suppression: acetylation globally suppresses 
mitochondria by inhibiting the Krebs cycle enzymes isocitrate dehydrogenase 2 (IDH2) and 
succinate dehydrogenase (SDH) as well as complex I (I) in the electron transport chain and 
mitochondrial superoxide dismutase (MnSOD). Furthermore, acetylation prevents the entry of 
acetyl-CoA into the Krebs cycle by inhibiting β‑oxidation (inhibition of long-chain acyl-CoA 
dehydrogenase (LCAD)) and glucose oxidation (inhibition of pyruvate dehydrogenase complex 
(PDC)), which is potentiated by the upregulation of PDC inhibitor pyruvate dehydrogenase kinase 
(PDK) secondary to activating acetylation of hypoxia-inducible factor 1α (HIF1α) in the nucleus. 
Proliferation: acetylation of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and pyruvate 
kinase M2 (PKM2) promotes the nuclear translocation and moonlighting of these glycolytic 
enzymes, whereby they join MYC and signal transducer and activator of transcription 3 (STAT3) 
(each activated by acetylation in the nucleus) to promote proliferation. Biomass generation: in the 
cytoplasm, acetylation activates ATP-citrate lyase (ACLY) to generate lipogenic acetyl-CoA from 
citrate derived from both the Krebs cycle and the reductive glutamine pathway, while reducing 
acetyl-CoA derived from acetate by inhibiting acyl-CoA synthetase short-chain family member 2 
(ACSS2). Also in the cytoplasm, acetylation activates 6-phosphogluconate dehydrogenase (PGD) 
in the anabolic pentose phosphate pathway (PPP) to produce NADPH and nucleoside 
precursors. Thus, a global increase in acetylation is associated with suppression of mitochondria 
and a proliferative phenotype, a fact that may be applicable to other proliferative diseases, 
beyond cancer. ACO2, aconitase 2; α-KG, α‑ketoglutarate; CS, citrate synthase; FFA, free fatty 
acid; FH, fumarate hydratase; MDH, malate dehydrogenase; OGDC, oxoglutarate 
dehydrogenase complex; SCS, succinyl-CoA synthetase. 
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Acetyl-CoA production provides the substrate for de novo 
lipogenesis. 
 
In addition to its role as a substrate for histone and non-histone protein acetylation, 
acetyl-CoA is also the substrate for de novo lipogenesis (DNL), which is the intracellular 
synthesis of lipids such as fatty acids and sterols (Figure 1.1, Figure 1.8).  
 
  
Figure 1.8 | Nuclear-cytosolic acetyl-CoA is required for de novo 
lipogenesis.  
ACLY and ACSS2 synthesize nuclear-cytosolic acetyl-CoA, which is further metabolized into 
malonyl-CoA by acetyl-CoA carboxylase (ACC). Fatty acid synthase (FASN) utilizes acetyl-CoA 
and multiple malonyl-CoA molecules to synthesize nascent fatty acids, such as palmitic acid. 
Acetyl-CoA can also be metabolized into HMG-CoA, which is converted into mevalonate for sterol 
synthesis. Inhibitors of these reactions that have been used in human patients are indicated.  
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During fatty acid synthesis, nutrients such as carbohydrates or amino acids are broken 
down into acetyl-CoA, and following export from the mitochondria, acetyl-CoA is 
metabolized into malonyl-CoA by Acetyl-CoA Carboxylase (ACC) at the rate-limiting step 
of fatty acid synthesis188. Subsequently, Fatty Acid Synthase (FASN) utilizes acetyl-CoA 
and multiple molecules of malonyl-CoA to produce nascent fatty acids. These fatty acids 
can be further modified into more complex lipids, which often play structural roles within 
cellular membranes189. At the organismal level, fatty acid synthesis is thought to be an 
energy storage process, whereby excess nutrients are broken down and converted into 
fatty acids for storage as triglycerides in lipid droplets190. As such, many nutrients 
activate molecular signals that promote production of lipogenic acetyl-CoA and 
downstream lipid products. These signals can be at the transcriptional or post-
translational levels. For instance, the transcription factor Sterol Regulatory Element 
Binding Protein 1 (SREBP-1) is activated downstream of insulin signaling following 
carbohydrate consumption191. SREBP-1 promotes the transcription of lipogenic enzymes 
such as ACLY, ACC, and FASN, among others192. At the post-translational level, 
production of lipogenic acetyl-CoA and malonyl-CoA are tightly regulated. For instance, 
ACLY is phosphorylated downstream of insulin action by the kinase AKT, resulting in a 
several-fold induction of activity84,85,193. Additionally, ACLY has been reported to be 
phosphorylated by the Branch Chain Ketoacid Dehydrogenase Kinase (BCKDK)194, 
which also regulates amino acid catabolism, thereby linking the two processes. 
Conversely, ACC is negatively regulated by phosphorylation downstream of the energy 
stress sensor, AMPK195,196. Importantly, malonyl-CoA is itself a negative regulator of fatty 
acid catabolism through its interaction with Carnitine Palmitoyltransferase 1 (CPT1)197. 
Thus, the balance between nutrient catabolism for energy production and anabolism for 
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energy storage can be tightly regulated. When this balance is disrupted, lipid 
accumulation in adipose tissue, as well as ectopic lipid deposition, can occur, resulting in 
obesity, insulin resistance, and other metabolic diseases198. In many cancers, DNL is 
markedly elevated, a phenomenon believed to support biogenesis of cellular membrane 
for rapid cell division199,200. As such, inhibitors of ACC and FASN are being investigated 
as therapeutic target for treatment of cancer and metabolic diseases, and have reached 
various stages of clinical trials201–204.  
In addition to fatty acids, sterols comprise another major lipid fate of acetyl-CoA. Sterols 
are a product of the mevalonate pathway, a multistep process in which acetyl-CoA is 
converted into 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). HMG-CoA is then 
metabolized into mevalonate by the enzyme HMG-CoA Reductase (HMGCR) in what is 
considered the rate-limiting step of the mevalonate pathway, and is also the mechanistic 
target of the statin class of drugs (Figure 1.8). Like fatty acids and their derivatives, 
sterols are also an important component of intracellular lipid pools due to their role in 
maintaining fluidity of cellular membranes189. As such, cholesterol synthesis is also 
frequently deregulated in diseases such as cancer205. This can be achieved through 
activation of the transcription factor SREBP-2, which controls the expression of 
cholesterol biosynthetic and uptake genes192. Unlike SREBP-1 which is stimulated by 
nutrient availability, SREBP-2 is regulated by a sterol feedback mechanism in which high 
levels of cholesterol prevent its activation, thereby ensuring its activation when 
cholesterol is in demand206.  
Among tissues in mammals, the liver and adipose tissues display the highest levels of 
DNL207. At normal levels in these tissues, DNL helps to maintain lipid homeostasis in 
 41 
 
tissues and circulation. However, improperly regulated DNL serves an important role in 
promoting both cancer and metabolic diseases, particularly in the liver, as discussed 
below.  
Role of de novo lipogenesis and ACLY in hepatic maladies. 
 
Liver cancer is now the fifth most common cancer worldwide with over half a million new 
cases diagnosed each year208. Hepatocellular carcinoma (HCC) is the most common 
cancerous malignancy of the liver, accounting for up to 90% of all primary liver 
cancers209. HCC incidence in the United States has increased over 3-fold since the 
1970s208,210, and is one of the fastest rising causes of cancer deaths in the United States, 
owing to a poor 5-year survival rate of 17%211. This is largely due to the fact that most 
HCC patients are diagnosed at advanced stages of disease when treatment options are 
limited. Moreover, HCC does not present with a predominant oncogenic driver in 
patients, which is an obstacle towards developing targeted therapies212,213. This lack of a 
defined oncogenic driver reflects the multitude of causes linked to HCC. In many 
countries, fibrosis resulting from hepatitis B and C virus infection remains the most 
significant identifiable cause of HCC209. However, epidemiological evidence from the 
United States and many other Western countries estimates that up to 40% of HCC 
cases present without viral origins214,215, highlighting the need to identify and understand 
non-viral causes of HCC. One such cause linked to HCC is the growing epidemic of 
metabolic syndrome.  
 
Metabolic syndrome is an umbrella term for a collection of metabolic diseases including 
obesity, diabetes, and dyslipidemia. Over one third of the United States population fits 
the criteria for metabolic syndrome, and over two thirds are considered overweight or 
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obese216,217, underscoring the significant public health challenge presented by these 
diseases. Obesity has been implicated in increasing the risk of death from multiple 
cancer types, including liver cancer218,219. In addition to obesity, type-2 diabetes mellitus 
(DM) has also been implicated in increasing cancer risk. Two recent meta-analyses 
examining the association between DM and HCC from multiple case-control and cohort 
studies concluded that DM increases the risk of developing HCC and HCC-associated 
mortality rate by 2 to 2.5-fold220,221. In the liver, metabolic syndrome manifests as non-
alcoholic fatty liver disease (NAFLD). NAFLD is characterized by excess lipid 
accumulation in the liver, termed steatosis, and when combined with inflammation 
eventually progresses to non-alcoholic steatohepatitis (NASH). NASH can progress to 
fibrosis and cirrhosis, which ultimately gives rise to HCC (Figure 1.9). Patient studies in 
the United States and other Western countries have linked NAFLD with causing 
HCC222,223, and it is projected that NAFLD will soon become the predominant cause of 
HCC as a result of the obesity epidemic224. In light of this, multiple recent studies have 
shown that high-fat diet-induced obesity can promote HCC development in mice225–228.  
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Figure 1.9 | Stage-wise progression of hepatic disease.  
Progression from healthy liver to NAFLD is associated with an increase in DNL, followed by 
inflammatory responses that promotes progression to NASH, fibrosis and ultimately cirrhosis. 
Hepatocellular carcinomas frequently develop in cirrhotic livers, and there is growing evidence for 
increased HCC incidence in patients who have not progressed beyond NAFLD or NASH. 
De novo lipogenesis links non-alcoholic fatty liver disease and 
hepatocellular carcinoma 
 
A common molecular feature to NAFLD and HCC is de novo lipogenesis of both fatty 
acids229,230 and cholesterol231. Notably, DNL accounts for roughly a quarter of liver lipid 
content, and that DNL contributes over two-fold more to liver lipid content in obese 
patients with severe steatosis than in those with mild steatosis, implicating hepatic DNL 
as a key contributor to NAFLD development229,230. DNL also plays a prominent role in 
HCC, where it has been shown that expression of lipogenic genes is high compared to 
healthy liver tissue232. High-carbohydrate diets promote DNL by inducing expression of 
lipogenic genes, and fructose is an even stronger inducer of DNL compared to other 
carbohydrate sources such as glucose233,234. In contrast, high-fat diets actually suppress 
expression of lipogenic genes235,236. Thus, while high-fat diets and high-fructose diets 
both promote development of NAFLD, the mechanisms by which they do so likely differ. 
This is supported by studies demonstrating that a high-fructose and fat diet promotes 
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more liver lipid accumulation than a high-fructose or high-fat diet alone237. 
Epidemiological data shows that between the 1970s and 1990s, consumption of fructose 
increased by 1000% due to the increased usage of high fructose corn syrup as a food 
sweetener238,239. Fructose has been shown to be a potent promoter of hepatic lipid 
accumulation and inflammation in rodent and human studies233,240–246. While limited in 
number, studies on dietary fructose and HCC in rodents have shown a pro-tumorigenic 
role247,248, though the exact mechanisms behind this require further investigation. Given 
the growing disease burden spurred by dietary obesity, uncovering the mechanisms by 
which modern dietary factors promote HCC development will be crucial for effective 
diagnosis and treatment of this disease. 
 
ACLY levels are dysregulated in metabolic disease of the liver and 
HCC. 
  
ACLY is highly expressed in metabolic organs such as adipose, pancreas, and liver249. 
ACLY levels in the liver are sensitive to diet and the whole-body metabolic state; high-fat 
feeding suppresses ACLY levels in the liver and fat tissues235,236. In contrast, a high-
carbohydrate diet elevates ACLY expression in the liver, but this effect is blunted in 
diabetic animals250. Furthermore, leptin receptor-deficient (db/db) mice, an established 
model for studying obesity and diabetes, display elevated ACLY expression specifically 
in the liver and not adipose tissues251. RNA interference-mediated silencing of Acly in 
livers of (db/db) mice suppressed DNL and protected against hepatic lipid accumulation. 
These data suggest that hepatic ACLY is an important regulator of metabolic function in 
the liver. Moreover, studies have identified that ACLY is upregulated or activated in 
HCC252,253. Thus, ACLY may be a promising therapeutic target for the treatment and 
prevention of NAFLD and HCC.  
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ACLY has been envisioned as a therapeutic target for decades, beginning with 
the competitive citrate analogue hydroxycitrate254–258. ACLY inhibitors decrease serum 
fatty acid and cholesterol levels in humans, dogs, and rodents174,176,178,259. These studies 
have contributed to the development of a hepatotropic ACLY inhibitor, ETC-1002, that is 
currently in clinical trials for treatment of dyslipidemia as a statin alternative, and appears 
to be safe and well-tolerated176–178,259–261. However, the use of ETC-1002 as an anti-
cancer therapeutic has not been clinically tested to date. A significant hurdle in 
combating HCC has been identifying effective targeted therapies, with Sorafenib 
remaining the stand-alone targeted therapy used as a standard of care212,262. A key point 
to note is that the average age of diagnosis for HCC is 65263, whereas obesity, diabetes 
and NAFLD are diagnosed throughout adulthood. This suggests that progression to 
HCC is a prolonged process, which presents a window for therapeutic intervention. 
Unfortunately, efforts to further understand how ACLY loss affects development of 
NAFLD, HCC and other hepatic maladies have been hampered because the Acly 
knockout mouse is early embryonic lethal5. Thus, whether targeting ACLY is beneficial in 
treatment of hepatic diseases has remained largely unexplored, and is the question that 
the following work in this dissertation addresses.      
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CHAPTER 2: ATP-Citrate Lyase Controls a Glucose-to-Acetate 
Metabolic Switch264. 
 
SUMMARY 
Mechanisms of metabolic flexibility enable cells to survive under stressful conditions and 
can thwart therapeutic responses. Acetyl-coenzyme A (CoA) plays central roles in 
energy production, lipid metabolism, and epigenomic modifications. Here, we show that, 
upon genetic deletion of Acly, the gene coding for ATP-citrate lyase (ACLY), cells remain 
viable and proliferate, although at an impaired rate. In the absence of ACLY, cells 
upregulate ACSS2 and utilize exogenous acetate to provide acetyl-CoA for de novo 
lipogenesis (DNL) and histone acetylation. A physiological level of acetate is sufficient 
for cell viability and abundant acetyl-CoA production, although histone acetylation levels 
remain low in ACLY-deficient cells unless supplemented with high levels of acetate. 
ACLY-deficient adipocytes accumulate lipid in vivo, exhibit increased acetyl-CoA and 
malonyl-CoA production from acetate, and display some differences in fatty acid con- 
tent and synthesis. Together, these data indicate that engagement of acetate 
metabolism is a crucial, although partial, mechanism of compensation for ACLY 
deficiency. 
INTRODUCTION 
Acetyl-coenzyme A (CoA) is a central molecule in cell metabolism, signaling, and 
epigenetics. It serves crucial roles in energy production, macromolecular biosynthesis, 
and protein modification21,265. Within mitochondria, acetyl-CoA is generated from 
pyruvate by the pyruvate dehydrogenase complex (PDC), as well as from catabolism of 
fatty acids and amino acids. To enter the tricarboxylic acid (TCA) cycle, acetyl-CoA 
condenses with oxaloacetate, producing citrate, a reaction catalyzed by citrate synthase. 
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Transfer of acetyl-CoA from mitochondria to the cytosol and nucleus involves the export 
of citrate and its subsequent cleavage by ATP-citrate lyase (ACLY), generating acetyl-
CoA and oxaloacetate. This acetyl-CoA is used for a number of important metabolic 
functions, including synthesis of fatty acids, cholesterol, and nucleotide sugars such as 
UDP-N-acetylglucosamine. Acetyl-CoA also serves as the acetyl-group donor for both 
lysine and N-terminal acetylation21,265. ACLY plays an important role in regulating histone 
acetylation levels in diverse mammalian cell types1,6,113,266. 
In addition to ACLY, nuclear-cytosolic acetyl-CoA is produced from acetate by acyl-CoA 
synthetase short chain family member 2 (ACSS2)9. Recent studies have revealed an 
important role for this enzyme in hypoxia and in some cancers7,70–74,267. Acetate can be 
produced intracellularly by histone deacetylase reactions or can be imported from the 
environment265. Levels of acetate in circulating blood are rather low, ranging from 50 to 
200 M in humans, although acetate concentrations can increase substantially in 
certain conditions, such as following alcohol consumption, high-fat feeding, or infection, 
or in specific locations such as the portal vein268–274. Acetate is also exported by cells 
under certain conditions, such as low intracellular pH34, and thus could potentially be 
made available for uptake by other cells in the immediate microenvironment. Two 
additional acetyl-CoA-producing enzymes, the PDC and carnitine acetyltransferase 
(CrAT), have been reported to be present in the nucleus and to contribute acetyl-CoA for 
histone acetylation4,275. The PDC was shown to translocate from mitochondria to the 
nucleus under certain conditions, such as growth factor stimulation; within the nucleus, 
the complex is intact and retains the ability to convert pyruvate to acetyl-CoA4. The 
relative contributions of each of these enzymes to the regulation of histone acetylation 
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and lipid synthesis, as well as the mechanisms of metabolic flexibility between these 
enzymes, are poorly understood. 
Whole-body loss of ACLY is early embryonic lethal, indicating that it serves non-
redundant roles during development5. Silencing or inhibition of ACLY suppresses the 
proliferation of many cancer cell lines and impairs tumor growth173,276–280. Depending on 
the context, ACLY silencing or inhibition can also promote senescence281, induce 
differentiation173, or suppress cancer stemness282, further pointing to its potential as a 
target for cancer therapy. Inhibition of ACLY in adult animals and humans is reasonably 
well tolerated and produces blood lipid-lowering effects174,176,178. Thus, there may be a 
therapeutic window for ACLY inhibition in treatment of cancer and/or metabolic dis- 
eases; although the extent to which cells could leverage other compensatory 
mechanisms upon reduced ACLY function is not clear. 
In this study, we aimed to elucidate two questions: first, does use of glucose-derived 
carbon for fatty acid synthesis and histone acetylation require ACLY; and second, can 
cells compensate for ACLY deficiency and, if so, by which mechanisms or pathways? To 
address these questions, we generated a conditional mouse model of Acly deficiency 
(Aclyf/f mice), as well as immortalized mouse embryonic fibroblast (MEF) cell lines (Aclyf/f 
MEFs). As a complement to these models, we used CRISPR-Cas9 genome editing to 
delete ACLY from human glioblastoma cells. ACLY deficiency in both MEFs and 
glioblastoma cells potently impaired proliferation and suppressed histone acetylation 
levels. Both lipid synthesis and histone acetylation from glucose-derived carbon were 
severely impaired in ACLY-deficient MEFs. Cells partially compensated for the absence 
of ACLY by upregulating ACSS2, and ACLY-deficient MEFs became dependent on 
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exogenous acetate for viability. Acetate was used to supply acetyl-CoA for both lipid 
synthesis and histone acetylation, although global histone acetylation levels remained 
low unless cells were supplemented with high levels of acetate. ACSS2 upregulation in 
the absence of ACLY was also observed in vivo upon deletion of Acly from adipocytes in 
mice. AclyFAT-/- mice exhibited normal body weight and adipose tissue architecture, and 
production of acetyl-CoA and malonyl-CoA from acetate was enhanced in ACLY-
deficient adipocytes. Upon deuterated-water (D2O) labeling of wild-type (WT) and 
AclyFAT-/-  mice, we observed that de novo synthesized fatty acids were present in white 
adipose tissue (WAT) in both genotypes, although some differences between depots 
were apparent. Visceral (epididymal) WAT (VWAT) exhibited no significant differences 
between WT and AclyFAT-/- mice in quantities of de novo synthesized fatty acids, while 
synthesized saturated fatty acids were reduced in subcutaneous (inguinal) WAT (SWAT) 
of AclyFAT-/- mice. Histone acetylation levels were also significantly altered in AclyFAT-/- 
SWAT. Taken together, this study demonstrates that ACLY is required for glucose-
dependent fatty acid synthesis and histone acetylation and that a major, albeit partial, 
compensatory mechanism for ACLY deficiency involves engagement of acetate 
metabolism. 
RESULTS 
 
Genetic Deletion of Acly in Cells Is Consistent with Viability but Impairs 
Proliferation 
To facilitate investigation of the role of ACLY in vitro and in vivo, we generated a 
conditional mouse model of Acly deficiency, using a conventional Cre-lox strategy (Aclyf/f 
mice) (Figure S2.1A). MEFs from Aclyf/f mice were immortalized (Aclyf/f MEFs). Acly was 
efficiently deleted from Aclyf/f MEFs upon administration of Cre recombinase (Figure 
S2.1B). Acly∆/∆ MEFs continued to proliferate, although more slowly than parental cells 
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(Figure S2.1C). However, over time, these cells regained ACLY expression, indicating 
that deletion occurred in less than 100% of cells and that those that retained ACLY had 
a growth advantage over Acly∆/∆ cells (Figure S2.1B). To address this, we generated 
three clonal Acly knockout (KO) cell lines, designated PC7, PC8, and PC9 (Figure 2.1A). 
ACSS2 was strikingly upregulated in these cell lines (Figure 2.1A). Proliferation in the 
absence of ACLY was significantly slower in each of the KO cell lines than in the 
parental Aclyf/f cells (Figure 2.1B). We also used CRISPR-Cas9 to delete ACLY from 
LN229 glioblastoma cells (Figure 2.1C). ACSS2 levels were high at baseline in LN229 
cells and only modestly increased with ACLY deletion (Figure 2.1C). However, similar to 
the ACLY-deficient MEFs, ACLY-deficient LN229 clones exhibited a marked proliferative 
impairment (Figure 2.1D). Two of the ACLY-KO clones, PC7 and PC9, were 
reconstituted with wild-type ACLY (ACLY-WT) or a catalytically inactive ACLY mutant 
(ACLY-H760A) (Figures 2.1E and S2.1D). ACLY-WT, but not ACLY-H760A, significantly 
restored proliferation in the KO clones (Figures 2.1F and S2.1E). Of note, despite 
comparable expression upon initial reconstitution (data not shown), ACLY-H760A failed 
to stably express as highly as ACLY-WT (Figure S2.1D), further pointing to a strong 
selective advantage for cells expressing catalytically active ACLY. ACSS2 levels were 
elevated in both the nucleus and cytoplasm of ACLY-deficient cells, and this was 
reversed upon reconstitution of ACLY-WT (Figure 2.1E). Next, we inquired whether 
ACSS2 upregulation was induced by ACLY deletion or whether growing up ACLY-
deficient clones selected for those that already had high ACSS2 expression. To test this, 
we examined the timing of ACSS2 upregulation upon loss of ACLY function. In Aclyf/f 
MEFs, ACSS2 was rapidly upregulated in parallel to loss of ACLY protein following Cre 
administration (Figure 2.1G). Moreover, treatment of MEFs with an ACLY inhibitor (BMS-
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303141) led to increased ACSS2 within 96 hr (Figure 2.1H). Thus, we conclude that the 
loss of ACLY activity induces ACSS2 upregulation. 
ACLY-Deficient MEFs Require Use of Exogenous Acetate for Viability 
The amount of acetate in the serum used in these experiments was quantified by 
nuclear magnetic resonance (NMR). Undiluted calf serum (CS) contained ~800–900 M 
acetate, while acetate was undetectable in dialyzed fetal bovine serum (dFBS) (Figures 
2A and S2A). Given that acetate was also undetectable in DMEM, our standard culture 
conditions (DMEM + 10% CS) exposed cells to slightly less than 100M acetate. ACLY-
deficient cells began to die when cultured in the absence of exogenous acetate (DMEM 
+ 10% dFBS) (Figures 2.2B–2D), and adding 100 M acetate was sufficient to restore 
viability (Figures 2.2C and 2.2E). No added proliferative benefit was gained by further 
increasing the amount of acetate supplemented (Figure 2.2F). Additionally, 
reconstitution of ACLY-WT, but not ACLY-H760A, restored the ability of KO cells to grow 
in acetate-depleted conditions (Figures 2.2B and 2.2E). To test whether acetyl-CoA 
production by ACSS2 was required for viability, we used CRISPR-Cas9 to delete Acss2 
in Aclyf/f MEFs (Figure S2.2B). Little to no difference in the proliferation rate was 
observed upon Acss2 deletion when Acly was intact (Figure S2.2C). However, 
subsequent deletion of Acly resulted in extensive toxicity (Figures 2.2G and S2.2D), 
which was not observed in cells expressing Acss2, confirming that cells rely on ACSS2 
for survival in the absence of ACLY. 
Physiological Levels of Acetate Support Lipid Synthesis in the Absence of 
ACLY 
ACLY deficiency did not alter rates of glucose or glutamine consumption, although 
lactate and glutamate production were elevated (Figure 2.3A). To confirm the 
requirement for ACLY for glucose-dependent fatty acid synthesis and test the use of 
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acetate, we set up parallel stable isotope tracer experiments in which Aclyf/f, PC9, PC9-
ACLY-WT, and PC9-ACLY-H760A cells were incubated for 48 hr either with [U-
13C]glucose (10 mM) and unlabeled acetate (100 M) or with [1,2-13C]acetate (100 M) 
and unlabeled glucose (10 mM) (Figure 2.3B). In ACLY-proficient cells, palmitate was 
strongly labeled from glucose-derived carbon, as expected. In PC9 ACLY-KO cells, 
labeling of palmitate from 13C-glucose was nearly abolished; this could be restored by 
reconstitution of ACLY-WT but not ACLY-H760A (Figure 2.3C). Conversely, a marked 
increase in use of acetate for fatty acid synthesis was observed in PC9 and PC9-ACLY-
H760A cells (Figure 2.3D). We also examined the use of glucose and acetate carbon for 
synthesis of HMG (hydroxymethylglutaryl)-CoA, an intermediate in the mevalonate 
pathway and ketone body synthesis. Again, parental and PC9-ACLY-WT cells used 
glucose-derived carbon for HMG-CoA synthesis (Figure 2.3E). In the absence of ACLY, 
glucose carbon use for HMG-CoA synthesis was extremely limited (Figure 2.3E); 
instead, acetate was used (Figure 2.3F). Total levels of HMG-CoA trended slightly lower 
in the PC9 cells, though this difference was not statistically significant (Figure 2.3G). The 
data thus show that, in MEFs, glucose-dependent synthesis of fatty acids and HMG-CoA 
is nearly completely dependent on ACLY, and a physiological level of acetate can at 
least partially support lipid synthesis in its absence. 
ACLY Is the Primary Supplier of Acetyl-CoA for Maintaining Global Histone 
Acetylation 
Histone acetylation is another major fate of nuclear-cytosolic acetyl-CoA. Consistent with 
previous data using RNAi-mediated ACLY silencing1,66, global levels of histone 
acetylation were strikingly reduced upon genetic deletion of Acly, despite increased 
ACSS2. Moreover, although 100 M acetate was sufficient to restore survival in dFBS- 
cultured KO cells, it failed to rescue histone acetylation levels. However, incubating cells 
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with a high level of acetate (1 mM) markedly increased histone acetylation levels in KO 
cells (Figure 2.4A). Reciprocally, histone acetylation levels were low in WT MEFs when 
cultured in 1 mM glucose and increased with greater glucose concentrations. In KO 
cells, histone acetylation levels were low at all concentrations of glucose tested, up to 25 
mM (Figure S2.3A). Reconstitution of PC9 cells with ACLY-WT but not, ACLY-H760A, 
restored histone acetylation levels to those in the parental cells (Figure 2.4A). 
To determine the respective use of glucose- and acetate- derived carbon for histone 
acetylation in each of the MEF cell lines, we conducted stable isotope tracer 
experiments under three conditions: (1) [U-13C]glucose (10 mM) and unlabeled acetate 
(100 M), (2) physiological [1,2-13C]acetate (100 M) and unlabeled glucose (10 mM), or 
(3) high [1,2-13C]acetate (1 mM) and unlabeled glucose (10 mM) (Figure S2.3B). In 
condition 1, histone acetyl groups were strongly labeled from 13C-glucose in Aclyf/f and 
PC9-ACLY-WT cells (Figures 2.4B, 2.4E, and S2.3C). In PC9 and PC9-ACLY-H760A 
cells, labeling of histone acetyl groups from glucose carbon was severely compromised 
(Figures 2.4B, 2.4E, and S2.3C). Moreover, aligning with western blot data, total levels 
of histone acetylation were lower in cells lacking functional ACLY (Figure 2.4E). Thus, 
the data indicate that ACLY is required for the majority of glucose-dependent histone 
acetylation. In cells lacking functional ACLY (PC9 and PC9-ACLY-H760A), 100 M 
acetate contributed carbon to histone acetylation with ~40%–60% of the acetyl groups 
derived from acetate after 24-hr labeling (Figure 2.4C), but total acetylation remained 
low (Figures 2.4F and S2.3D). In 1 mM 13C-acetate, total histone acetylation levels rose 
(Figures 2.4G and S2.3E), consistent with western blot data, and acetate carbon 
constituted the majority of histone acetyl groups (Figure 2.4D). These data indicate that 
ACLY is the dominant supplier of acetyl-CoA for histone acetylation in standard, nutrient-
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rich conditions and that, in its absence, cells can use acetate to supply acetyl-CoA for 
histone acetylation, although high exogenous acetate availability is needed to bring 
histone acetylation up to levels matching those of ACLY-proficient cells. Of note, high 
acetate did not produce a corresponding rescue of proliferation (Figure 2.2F). Thus, 
while ACLY-deficient cells exhibit both slower proliferation and lower histone acetylation 
levels, histone acetylation can be raised with high acetate without restoration of normal 
rates of proliferation, supporting the notion that metabolism regulates histone acetylation 
at least partially independently of proliferation. 
We previously defined acetyl-CoA-responsive gene sets in LN229 glioblastoma cells1. 
Cell-cycle- and DNA-replication-related genes were enriched among those genes that 
were suppressed in low glucose and increased by both glucose and acetate, although 
only glucose impacted doubling time1. As observed in MEFs, ACLY deletion in LN229 
cells abolished glucose-dependent regulation of global histone acetylation (Figure 
S2.4A). Acetate supplementation increased histone acetylation in ACLY null LN229 cells 
in a dose-dependent manner (Figure S2.4A). Consistently, the ability of glucose to 
promote expression of proliferation-related genes (E2F2, MCM10, and SKP2) was 
potently inhibited in ACLY-deficient cells. Expression of these genes exhibited dose-
dependent rescue by acetate (Figure S2.4B), correlating with global histone acetylation 
levels, despite the lack of a proliferation rescue (Figure S2.4C). In addition, we were 
surprised to find that whole-cell acetyl-CoA levels were minimally impacted in ACLY-KO 
as compared to WT LN299 cells in high-glucose conditions (Figure S2.4D). 
Acetyl-CoA Levels Are Maintained by Acetate in ACLY-Deficient Cells 
In prior studies, global histone acetylation levels have tracked closely with cellular acetyl-
CoA levels1,64,112. It was, therefore, unexpected to find these uncoupled in ACLY-KO 
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LN229 cells (Figure S2.4D). We further explored this in ACLY-KO MEFs and found that 
acetyl-CoA levels were significantly higher in the KO cells than in the WT Aclyf/f cells 
when cultured in 10 mM glucose and 100 M acetate (Figure 2.5A). These data 
suggested either that mitochondrial acetyl-CoA, which is inaccessible for histone 
acetylation75, is elevated in ACLY-KO cells or that ACSS2 compensation allows plentiful 
nuclear-cytosolic acetyl-CoA production from acetate but that this acetate-derived acetyl-
CoA is used less effectively than glucose-derived acetyl-CoA for histone acetylation. We 
reasoned that mitochondrial and extra-mitochondrial acetyl-CoA pools in ACLY KO cells 
could be distinguished based on whether whole-cell acetyl-CoA is derived from glucose 
or from acetate (Figure 2.5B). This is because, in the absence of ACLY, glucose carbon 
does not meaningfully contribute to nuclear-cytosolic acetyl-CoA, as determined by its 
minimal use for either lipid synthesis or histone acetylation (Figures 2.3 and 2.4). Within 
mitochondria, both glucose (via PDC) and acetate (via mitochondrial acetyl-CoA 
synthetases) can be used to generate acetyl-CoA for citrate synthesis. However, as 
assessed by enrichment of citrate and malate, acetate contributes minimally to 
mitochondrial metabolism in both WT and KO cells, while glucose is oxidized in both cell 
lines under these conditions (albeit to a somewhat lesser extent in KO cells) (Figures 
2.5C, 2.5D, S2.5A, and S2.5B). These data suggest that, in ACLY-KO cells, any 
glucose-derived acetyl-CoA is mitochondrial, whereas acetate-derived acetyl-CoA is 
predominantly nuclear cytosolic (Figure 2.5B). Thus measuring the contribution of 
glucose and acetate to whole-cell acetyl-CoA should allow us to distinguish whether the 
increase in acetyl-CoA in ACLY-KO MEFs reflects elevated mitochondrial or extra-
mitochondrial acetyl-CoA. Therefore, we incubated cells with [U-13C]glucose (10 mM) 
and 100 M unlabeled acetate or, reciprocally, [1,2-13C]acetate (100 M) and 10 mM 
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unlabeled glucose. In WT (Aclyf/f) cells, as expected, acetyl-CoA, malonyl-CoA, and 
succinyl-CoA were more strongly enriched from glucose than acetate (Figures 2.5E–
2.5G). Interestingly, despite minimal labeling of malonyl-CoA from acetate in WT cells 
(consistent with palmitate enrichment in Figure 2.3D), 20% of the acetyl-CoA pool was 
enriched from 13C-acetate (Figures 2.5E and 2.5F), further hinting at differential 
partitioning of acetate- and glucose-derived acetyl-CoA. In contrast, in the PC9 ACLY-
KO cells, acetyl-CoA was minimally labeled from glucose, and ~80% of the acetyl-CoA 
pool was labeled from acetate after 6 hr (Figure 2.5E). Malonyl-CoA, but not succinyl-
CoA, was also strongly enriched from 13C-acetate in PC9 cells (Figures 2.5F and 2.5G). 
In sum, these data indicate that acetate is the major source of acetyl-CoA in the absence 
of ACLY, and it appears to predominantly supply the extra-mitochondrial pool. 
A second implication of these data is that, at least in KO cells, the mitochondrial acetyl-
CoA pool is likely quite low in comparison to the extra-mitochondrial pool, since acetyl-
CoA is minimally labeled from glucose-derived carbon. A large difference in relative 
acetyl-CoA pool size can explain the apparently paradoxical finding that, in KO cells, 
citrate is labeled from glucose, despite minimal acetyl-CoA enrichment (Figures 2.5C 
and 2.5E). This interpretation is consistent with findings from a recent study of the 
mitochondrial metabolome, which found that matrix acetyl-CoA levels are very low 
unless complex I is inhibited, which increases the NADH/NAD ratio, reducing the activity 
of citrate synthase283. Notably, another implication of this result is that a much larger 
nuclear-cytosolic acetyl-CoA pool in cultured cells would explain why whole-cell acetyl-
CoA measurements in ACLY-proficient cells correlate closely with histone acetylation 
levels1,64. Together, these data indicate that acetate carbon is used to supply acetyl-CoA 
for nuclear and cytosolic processes in the absence of ACLY. Nevertheless, histone 
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acetylation levels remain low in the absence of ACLY unless a high level of acetate is 
supplied, and proliferation remains constrained even in the presence of high acetate. 
Thus ACSS2 is a key, but partial, mechanism of compensation for ACLY deficiency. 
ACSS2 Is Upregulated In Vivo upon Deletion of Acly from Adipocytes 
Finally, we sought to determine whether ACSS2 is upregulated upon loss of ACLY in 
vivo. Glucose uptake and glucose-dependent lipid synthesis in adipocytes are closely 
associated with insulin sensitivity and systemic metabolic homeostasis284,285. Moreover, 
our prior work implicated ACLY in regulating histone acetylation levels and expression of 
key genes in glucose metabolism, such as Glut4, in 3T3-L1 adipocytes66. To interrogate 
the role of adipocyte ACLY in vivo, we bred Aclyf/f mice to Adiponectin-Cre transgenic 
mice, which express Cre specifically in adipocytes286. ACSS2 was upregulated in SWAT 
and VWAT upon deletion of Acly (Figures 2.6A and 2.6B). In VWAT, ACSS2 
upregulation was more apparent at the protein level than the mRNA level (Figures 2.6A 
and 2.6B). Fatty acid synthase (FASN) protein levels were also elevated in the absence 
of ACLY, particularly in SWAT (Figure 2.6A). Lipid droplets formed normally in AclyFAT-/- 
adipocytes; in VWAT, adipocytes were larger than in WT mice, while in SWAT, 
adipocyte lipid droplet size was comparable between genotypes (Figure 2.6C). Body 
weight was indistinguishable between WT and AclyFAT-/- mice fed a regular chow diet 
(Figure 2.6D). However, overall gene expression patterns were altered, with lower 
expression of adipocyte genes such as Glut4 in the AclyFAT-/- mice (Figure 2.6E). 
Adipocyte Acetyl-CoA and Lipid Metabolism Is Altered in the Absence of 
ACLY 
These data suggested that acetate metabolism might, at least partially, compensate for 
ACLY deficiency in adipocytes in vivo. Similar to that observed in MEFs, acetyl-CoA 
levels were higher in both VWAT and SWAT from AclyFAT-/- as compared to WT mice, 
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while liver acetyl-CoA levels were slightly reduced (Figure 2.7A). To test whether AclyFAT-
/- adipocytes supply acetyl-CoA and dependent biosynthetic processes using acetate, we 
isolated primary visceral adipocytes and tested acetate uptake. Indeed, acetyl-CoA, as 
well as malonyl-CoA and HMG-CoA, were more enriched from [1,2-13C]acetate in 
primary adipocytes from AclyFAT-/- mice as compared to those from WT mice (Figures 
2.7B–2.7D). 
Next, we investigated the extent to which de novo synthesized fatty acids were present 
in adipose tissue in the absence of ACLY. To capture rates of de novo lipogenesis (DNL) 
in vivo, D2O was administered to mice via a bolus injection and subsequent addition to 
drinking water for 3 weeks. At the conclusion of labeling VWAT, SWAT, and liver were 
collected, and total (saponified) fatty acids from each were analyzed by gas 
chromatography-mass spectrometry (GC-MS). Plasma D2O enrichment was confirmed 
to be equivalent between genotypes (Figure S2.6A). In both VWAT and SWAT, 
abundance of the saturated fatty acids palmitic acid (C16:0) and stearic acid (C18:0) 
was significantly reduced (Figures S2.6B and S2.6C). Conversely, monounsaturated 
fatty acids, oleic acid (C18:1n9), and palmitoleic acid (C16:1n7), as well as the essential 
fatty acid linoleic acid (C18:2n6), were elevated in SWAT from AclyFAT-/- mice (Figure 
S2.6B). A slight reduction in palmitic acid was also observed in liver (Figure S2.6D). 
Fractional enrichment of fatty acids was not significantly different in VWAT between 
genotypes, although SWAT exhibited a moderate reduction in palmitic acid fractional 
synthesis (Figures S2.6E and S2.6F). Fractional synthesis was not different between 
genotypes in the liver, except for a small reduction for palmitoleic acid (Figure S2.6G). 
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The relative quantities of de novo synthesized fatty acids present in each tissue were 
calculated using plasma D2O enrichment, fatty acid labeling, and abundance. Notably, 
DNL-derived fatty acids present in WAT may be synthesized in adipocytes or produced 
in the liver and transported to fat. In the SWAT of AclyFAT-/- mice, total de novo 
synthesized palmitic acid and stearic acid were significantly reduced (Figure 2.7E). In 
contrast, no significant differences in the quantities of DNL-generated fatty acids were 
detected between AclyFAT-/- and Aclyf/f mice in VWAT (Figure 2.7F). Liver DNL was 
largely unchanged by adipocyte ACLY deficiency, although a slight reduction in palmitic 
acid synthesis was observed (Figure 2.7G). Since DNL-derived fatty acids were reduced 
in SWAT of AclyFAT-/- mice, this depot may maintain lipid droplet size through greater 
storage of diet-derived fatty acids, as suggested by elevated levels of linoleic acid 
(Figure S2.6B). 
Histone acetylation levels were also analyzed. Despite ACSS2 upregulation and 
elevated acetyl-CoA levels, H3K9ac and H3K23ac were significantly lower, and 
H3K18ac trended lower, in the SWAT of AclyFAT-/- mice (Figure 2.7H). Interestingly, this 
difference was not observed in VWAT, suggesting that acetate compensation for ACLY 
deficiency may be more complete in this depot or that other factors are dominant in 
determining histone acetylation levels (Figure 2.7I). No differences in histone H3 
acetylation were detected in the liver (Figure 2.7J). Altogether, the data suggest that, in 
vivo, adipocytes lacking ACLY partially compensate by engaging acetate metabolism. 
DISCUSSION 
The findings of this study demonstrate that ACLY is required for the vast majority of 
glucose-dependent fatty acid syntheses and histone acetylations under standard culture 
conditions and that ACSS2 upregulation and use of acetate carbon is a major 
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mechanism of compensation for ACLY deficiency. Additionally, despite ACSS2 
upregulation and higher acetyl-CoA levels, ACLY deficiency results in lower overall 
histone acetylation levels, slower proliferation, and altered gene expression patterns. 
The data suggest that ACLY and ACSS2 likely play distinct roles in the regulation of 
histone acetylation and gene expression but also indicate that the potential for metabolic 
compensation from acetate should be considered if ACLY is pursued as a therapeutic 
target. From a clinical perspective, prior study of PET (positron emission tomography) 
imaging in human hepatocellular carcinoma patients using 11C-acetate and 18F-
fluorodeoxyglucose (FDG) revealed a dichotomy between acetate and glucose uptake. 
Patient tumors, or regions within tumors, with high 11C-acetate uptake demonstrated low 
18F-FDG uptake and vice versa. More- over, tumors with high 18F-FDG uptake were 
more proliferative287. These data support the concept that mammalian cells – cancer 
cells, in particular – possess an intrinsic flexibility in their ability to acquire acetyl-CoA 
from different sources to adjust to changing metabolic environments in vivo. Further 
elucidation of the mechanisms connecting ACLY and ACSS2, as well as the differential 
phenotypes observed downstream of their activity, could point toward synthetic lethal 
strategies for cancer therapy or improved tumor imaging protocols. 
In considering the roles of these enzymes in normal physiology, given the importance of 
GLUT4-dependent glucose uptake and glucose-dependent fatty acid synthesis for 
systemic metabolic homeostasis284,285, deletion of Acly in adipocytes results in a 
surprisingly mild phenotype, with no overt metabolic dysfunction observed for mixed-
background mice on a regular chow diet. Nevertheless, larger adipocytes and reduced 
expression of genes, such as Glut4, observed in this model are also characteristic of 
obesity and are associated with poorer metabolic function. This suggests that AclyFAT-/- 
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mice may be more susceptible to metabolic dysfunction when nutritionally stressed, for 
example, with high fructose feeding. Another interesting question is whether these mice 
will exhibit exacerbated metabolic phenotypes under conditions that alter acetate 
availability in the blood- stream, such as ethanol consumption or antibiotic treatment. 
The differential impact of ACLY on SWAT and VWAT also warrants further investigation. 
It is not clear why SWAT, but not VWAT, exhibits reduced histone acetylation and de 
novo fatty acid synthesis, despite evidence for compensatory mechanisms such as 
FASN upregulation. One possible explanation relates to an overall greater fraction of 
fatty acids that are de novo synthesized in SWAT, as compared to VWAT (Figures 
S2.6E and S2.6F), placing a greater demand for acetyl-CoA. Potentially, in a tissue with 
a lower DNL rate, acetate may be more readily able to compensate in both DNL and 
histone acetylation. Distribution of fatty acids in AclyFAT-/- WAT depots is also altered; 
SWAT, in particular, exhibits increased levels of monounsaturated and essential fatty 
acids (Figure S2.6B). Palmitoleate, which has been implicated as an insulin-sensitizing 
lipokine288, is elevated in ACLY-deficient SWAT, raising questions about how altered 
levels of bioactive lipid species in the absence of ACLY may influence metabolic 
phenotypes. More mechanistic work is also clearly needed to elucidate the relationship 
between ACLY and gene regulation. The relationship between global histone acetylation 
and gene expression is not entirely consistent between VWAT and SWAT, possibly 
reflecting gene regulatory mechanisms that are specific to ACLY. 
A noteworthy observation in this study is that acetyl-CoA and histone acetylation levels 
appear to become uncoupled in the absence of ACLY, suggesting that acetate-derived 
acetyl-CoA may not be efficiently used for histone acetylation. Several possible 
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mechanisms could account for this. First, it may be that, in MEFs, an insufficient amount 
of ACSS2 is present in the nucleus to efficiently drive histone acetylation. ACSS2 has 
been found to localize prominently to the nucleus in some conditions70,76,77; thus, 
investigation of whether acetate more readily contributes to overall histone acetylation 
levels in these contexts will be informative. However, potentially arguing against this 
possibility, hypoxia promotes ACSS2 nuclear localization77; yet, although acetate does 
regulate histone acetylation in hypoxic cells, a high level of acetate (~2.5 mM) is 
required74. A second possibility is that, within the nucleus, acetyl-CoA producing 
enzymes are channeled, compartmentalized into niches, or sequestered with particular 
binding partners. Through such a mechanism, acetylation of specific proteins may be 
regulated not only by the relevant acetyltransferase but also by a specific acetyl-CoA-
producing enzyme. Consistent with this possibility, acetylation of HIF2a was shown to be 
exclusively dependent on ACSS2 as a source of acetyl-CoA76,77. A third possibility is that 
ACLY-deficient conditions may result in altered lysine acetyltransferase (KAT) or HDAC 
(histone deacetylase) activity. Finally, a fourth possibility is that lower use of acetyl-CoA 
for histone acetylation could be a feature of slow proliferation in the absence of ACLY 
(i.e., secondary to the proliferation defect). However, prior findings that histone 
acetylation is sensitive to glucose availability over a range that did not impact 
proliferation1 and that the TCA cycle (which supplies ACLY substrate citrate) and 
mitochondrial membrane potential have distinct and separate roles in regulating histone 
acetylation and proliferation, respectively289, as well as data in the present article 
showing that histone acetylation can be boosted by high acetate without a corresponding 
rescue of proliferation, argue against this as a sole explanation. Nevertheless, 
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elucidation of the mechanisms that constrain proliferation in the absence of ACLY could 
help to definitively address this. 
Investigating these possibilities will illuminate whether cells possess mechanisms to 
differentially detect ACLY-generated versus ACSS2-generated acetyl-CoA as well as 
define the functional relationship between histone acetylation levels and cellular 
functions and phenotypes. Given that ACLY dominates in nutrient- and oxygen-replete 
conditions, whereas ACSS2 becomes important in nutrient- and oxygen-poor 
conditions73,74, having mechanisms such as different acetylation substrates to distinguish 
between acetyl-CoA produced by each enzyme could be advantageous to cells. For 
example, such mechanisms could potentially cue cells to grow when ACLY serves as 
the acetyl-CoA source and to mediate adaptive responses when ACSS2 is the primary 
acetyl-CoA source. The roles of these enzymes in gene regulation appear to be 
complex, and in-depth analysis of the respective roles of ACLY and ACSS2 in genome-
wide histone acetylation and acetylation of other protein substrates is needed to begin 
addressing these questions. 
Recent work has shown that the PDC is present in the nucleus and is able to convert 
pyruvate to acetyl-CoA for use in histone acetylation4, raising the question of how the 
findings of the present study can be aligned with the described role of nuclear PDC. We 
suggest two potential models that are consistent both with our data and with a role for 
nuclear PDC in histone acetylation. In the first model, ACLY is the primary acetyl-CoA 
producer for regulation of global levels of histone acetylation, while PDC (and, 
potentially, other nuclear acetyl-CoA sources such as CrAT) could participate in 
mediating histone acetylation at specific target genes but not globally. A recent report 
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that PDC forms a complex with PKM2, p300, and the arylhydrocarbon receptor (AhR) to 
facilitate histone acetylation at AhR target genes is consistent with such a possibility120. 
In the second model, the role of ACLY in glucose-dependent histone acetylation 
regulation could be context dependent, with a larger role for PDC emerging in certain 
conditions or cell types. This possibility is supported by observations that PDC nuclear 
translocation is stimulated by conditions such as growth factor stimulation and 
mitochondrial stress4. Further investigation will be needed to evaluate these models. 
In sum, this study points to a crucial interplay between glucose and acetate metabolism 
to supply the nuclear-cytosolic acetyl- CoA pool for fatty acid synthesis and histone 
acetylation. At the same time, it shows that, despite compensatory mechanisms, ACLY 
is required for optimal proliferation, and simply increasing nuclear-cytosolic acetyl-CoA 
production is insufficient to fully replace ACLY. This could point to the importance of 
ACLY’s other product, oxaloacetate; a build-up of ACLY’s substrate citrate; deficiencies 
in anapleurosis and/or mitochondrial function upon loss of a major catapleurotic 
pathway; or a signaling mechanism that is specific to ACLY. Clearly, more work is 
needed both to understand the mechanisms through which ACLY facilitates cell 
proliferation and to further define the ways that cells partition and use acetyl-CoA 
produced by different enzymes. The findings of this study raise a number of important 
questions for future investigation, as discussed earlier. They also clarify the importance 
of ACLY in glucose-dependent acetyl-CoA production outside of mitochondria and 
provide key insights into the mechanisms of metabolic flexibility used for production of 
nuclear-cytosolic acetyl-CoA. Understanding these compensatory mechanisms will be 
important to consider for therapeutic targeting of acetyl-CoA metabolic pathways. 
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EXPERIMENTAL PROCEDURES 
 
Generation of Aclyf/f and AclyFAT-/- Mice 
A Knockout First targeting vector was obtained from the Knockout Mouse Project 
(KOMP) that targets exon 9 of Acly (KOMP: 80097), predicted to result in a truncated 
protein subject to nonsense-mediated decay. The Knockout First allele is initially null but 
can be converted to a conditional floxed allele upon Flp recombination290. Recombinant 
129/B6 hybrid embryonic stem cells (ESCs) were generated in Penn’s Gene Targeting 
Core, and blastocysts were injected at Penn’s Transgenic and Chimeric Mouse Core. 
Upon acquisition of the chimeric mice, animals were bred to obtain germline 
transmission. Aclyf/+ progenies were selected through sequential breeding with wild-type 
C57Bl/6J mice (purchased from Jackson Laboratory) and mice expressing Flp 
recombinase (B6.Cg-Tg(ACTFLPe) 9205Dym/J, Jackson Laboratory). Finally, Aclyf/f 
mice were generated by inter- breeding and selected by genotyping (see the 
Supplemental Information). Immortalized Aclyf/f MEFs were generated from these mice 
(see the Supple- mental Information). To produce AclyFAT-/- mice, Aclyf/f mice were bred to 
adiponectin-Cre transgenic mice (stock no: 010803; B6;FVB-Tg(Adipoq-cre) 1Evdr/J, 
Jackson Laboratory). The University of Pennsylvania’s Institutional Animal Care and Use 
Committee (IACUC) approved all animal experiments. 
In Vivo De Novo Lipogenesis 
13-week-old male Aclyf/f (n = 6) and AclyFAT-/- (n = 7) mice (C57Bl/6 back-crossed) were 
injected intraperitoneally (i.p.) with 0.035 mL/g of body weight of 0.9% NaCl D2O (Sigma-
Aldrich). For 3 subsequent weeks, mice were provided water bottles containing 8% D2O. 
At the end of 3 weeks, mice were fasted for 6 hr and sacrificed, and plasma, liver, 
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VWAT, and SWAT were collected and snap frozen. Plasma from four additional mice 
(two Aclyf/f and two AclyFAT-/- that were not given D2O was used as controls.  
 
Cell Culture and Proliferation Assays  
MEFs (generation described in the Supplemental Information) were cultured in DMEM 
(GIBCO) supplemented with 10% Cosmic Calf Serum (CS) (HyClone, SH30087.03, lot 
number AXA30096). LN229 cells were cultured in RPMI 1640 medium (GIBCO) 
supplemented with 10% CS (HyClone SH30087.03, lot number AXA30096) and 2 mM L-
glutamine. For experiments using dFBS, cells were cultured in glucose-free DMEM + 
10% dFBS (GIBCO 26400044), with indicated concentrations of glucose and sodium 
acetate added. For proliferation assays, cells were plated in triplicate at the indicated 
density and allowed to adhere overnight. Culture medium was changed the following 
day, and cells were allowed to proliferate until the indicated days following plating. Cells 
were collected and counted on a hemocytometer. Cell lines used for viral production 
included Phoenix E and HEK293T cells, which were purchased from ATCC. Cells were 
cultured in DMEM + 10% CS and used at low passage. All cell lines were routinely 
monitored and confirmed to be free of mycoplasma. 
Acyl-CoA Quantification and Isotopologue Analysis 
Acyl-CoA species were extracted in 1 mL 10% (w/v) trichloroacetic acid (Sigma-Aldrich, 
catalog #T6399). Isotopologue enrichment analysis to quantify the incorporation of 10 
mM [U-13C]glucose and 100 mM [1,2-13C]acetate into acyl-CoA thioesters was performed 
by liquid chromatograpy-mass spectrometry/high-resolution mass spectrometry (LC-
MS/HRMS). For quan- titation, internal standards containing [13C315N1]-labeled acyl-
CoAs generated in pan6-deficient yeast culture291 were added to each sample in equal 
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amounts. Samples were analyzed by an Ultimate 3000 autosampler coupled to a 
Thermo Q Exactive Plus instrument in positive electrospray ionization (ESI) mode using 
the settings described previously292.  
Statistics 
Student’s two-tailed t tests (two-sample equal variance, two-tailed distribution) were 
used for analyses directly comparing two datasets except tissue gene expression and 
acyl-CoA datasets (Figures 6 and 7), for which Welch’s t test was used. Significance 
was defined as follows: *p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001. 
Genotyping 
Tail-snips from mice were placed in digestion buffer (10% SDS, 5M NaCl, EDTA, 
Tris, H2O, proteinase K) for two hours while shaking at 56°C. Genomic DNA was 
isolated and then used for genotyping using the following primer sets: Cre-Fw: 
TGCCACGACCAAGTGACAGC; Cre-Rv: CCAGGTTACGGATATAGTTCATG; tm1c 
(floxed allele)-Fw: AAGGCGCATAACGATACCAC; tm1c-Rv: 
CCGCCTACTGCGACTATAGAGA; Acly wild-type allele: WT-Fw: 
TGCAATGCTGCCTCCAATGAT; WT-Rv: GGAGCCAGAGGAGAAAAAGGC 
Generation of Aclyf/f MEFs 
For mouse embryonic fibroblast (MEF) generation, two homozygous fertile females 
were placed on a dedicated mating cage with a homozygous fertile male. On day 
15.5, pregnant females were sacrificed and the fetuses were surgically removed and 
placed in a 10-cm dish, washed two timed with PBS. Head and liver were removed 
from each fetus, the remaining part was trimmed, pooled in a 50- mL tube and 
washed again with PBS. Tissue remnants were digested with 5mL of Trypsin 0.25% 
at room temperature for 30 minutes. The digestion was stopped with DMEM+10% 
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CS. Cells were pelleted and washed again with DMEM+10% CS. Finally cells were 
seeded in a 25-cm flask and cultured in DMEM+10% CS + 0.1 mM β-
mercaptoethanol. Cells were immortalized by serial passaging (plated at 1:3 dilution 
and passaged at confluency) and began recovering from proliferation crisis after 13 
(line 1) and 20 (line 2) passages. 
Acly deletion and reconstitution in MEFs 
For acute analysis, Aclyf/f MEFs (line 2) were infected with adenoviral Cre 
recombinase (University of Pennsylvania Vector Core).  For generation of stable 
lines PC7, PC8, and PC9, retroviral transduction of Aclyf/f MEFs (line 2) with Cre 
recombinase was conducted as follows: A retroviral vector containing Cre 
recombinase (pBabe-puro-Cre, gift of L. Busino, University of Pennsylvania) was 
used to produce retrovirus in Phoenix E cells. MEFs were transduced with retrovirus 
and selected with 3 µg/mL of puromycin for 48 hours 
until mock infected MEFs displayed no viable cells. Following selection, single cell 
clonal populations were generated by plating cells in a limiting dilution. Deletion of 
Acly was confirmed by Western blot. 
For reconstitution experiments, wild-type ACLY or catalytically inactive (H760A) 
ACLY were cloned into pBabe-hygro retroviral vector. Retrovirus was produced in 
Phoenix E cells. PC7 and PC9 cells were transduced with retrovirus and selected 
with hygromycin (400 µg/mL) for 48 hours until mock infected MEFs displayed no 
viable cells. Reconstitution was confirmed by immunoblotting for ACLY expression. 
CRISPR-Cas9 genetic editing 
Guide RNA sequences were generated using a CRISPR design tool 
(www.crispr.mit.edu). The guide sequences used are as follows: mAcss2 
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(GCTGCACCGGCGTTCTGTGG), hACLY (GACCAGCTGATCAAACGTCG). Guides 
were cloned into the LentiCRISPRv2 plasmid293 followed by lentiviral production in 
HEK-293T cells. Cells were infected and selected with puromycin until a separate 
mock-infected plate displayed complete cell death. Single-cell clonal expansion of 
the selected population was done to ensure complete loss of the target gene. Loss 
of target gene was determined by immunoblotting for the target protein. 
Analysis of AclyFAT-/- mice 
From 4 weeks to 16 weeks of age, mixed background Aclyf/f and AclyFAT-/- were fed 
normal chow and weighed weekly. At 16 weeks of age mice were sacrificed and 
white fat [visceral (epididymal) and subcutaneous (inguinal)] depots were harvested. 
Depots were dissected into thirds with a third of each being fixed in formalin for 
histological evaluation, a third being digested in Trizol for RNA expression analysis 
and the final third digested in protein lysis buffer for protein analysis. For analysis of 
histone acetylation and acetyl-CoA levels, a separate cohort of AclyFAT-/- (n=6) and 
WT (Aclyf/f ; n=7) mice, females aged 10 to 11 weeks, backcrossed onto a C57Bl/6 
background, were used. Mice were fasted for 6 hours, sacrificed, and liver, VWAT 
and SWAT were removed. Organs were split in half; half snap frozen for acyl CoA 
analysis and the other processed fresh for histone extraction, as described below. 
The University of Pennsylvania’s Institutional Animal Care and Use Committee 
(IACUC) approved all animal experiments. 
Immunoblotting 
Protein was extracted from cells using NP-40 lysis buffer (150 mM NaCl, 1.0% NP-
40, 50 mM Tris-HCl pH 8.0) with protease inhibitors (Roche). Mouse tissue was 
lysed in RIPA lysis buffer (1%NP-40, 0.5% Deoxycholate, 0.1% SDS, 150nM NaCl, 
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50mM Tris plus protease and phosphatase inhibitors). Fat was chopped with 
scissors on ice to fine pieces, followed by homogenization with TissueLyser (30 Hz 
for 20s x 2). Samples were chilled on ice for 30 min, spun down, and infranatant 
saved and then sonicated. Protein concentration was determined using the BCA 
protein assay (ThermoScientific). Proteins were separated by SDS-PAGE and 
transferred to a nitrocellulose membrane (GE Health Sciences). Membranes were 
probed with the specified antibodies (see Antibodies and Reagents), and developed 
on a LI-COR Odyssey CLx scanner. 
Antibodies and reagents 
Antibodies used for Western blotting: ACLY (previously described6 (Wellen et al., 
2009)), ACSS2 (Cell Signaling Technologies #3658S), Tubulin (Sigma T6199), 
FASN (Cell Signaling Technologies #3189S), Lamin A/C (Cell Signaling 
Technologies #2032S), Parp (Cell Signaling Technologies #9542S), Cleaved Parp 
(Cell Signaling Technologies #9544T), Cleaved Caspase 3 (Cell Signaling 
Technologies #9661S), Acetyl-H3 (Upstate 06-599), Acetyl-H4 (Millipore 06-866), 
H4K5Ac (Millipore 07-327), H3K14Ac (Cell Signaling #7627S), H3K18Ac (Cell 
Signaling 9675P), H3K23Ac (Cell Signaling 9674S), H3K27Ac (Abcam ab4729). 
Secondary antibodies were IRDye680RD Goat Anti-Mouse (LI-COR 926-68070) and 
IRDye800CW Goat Anti-Rabbit (LI-COR 926-32211). 
Reagents: ACLY inhibitor BMS-303141 (Tocris Bioscience) 
Nuclear-cytoplasmic subcellular fractionation: 
Fractionation was performed essentially as described6. Cells were harvested in cold 
Buffer A (10 mM HEPES pH 7.4, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM EDTA, 0.5 mM 
EGTA; Complete Mini (Roche) protease inhibitor (PIC) tablet and 0.1% NP-40 
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added fresh). Cells were lysed on ice for 15 minutes until the plasma membrane 
was broken (assessed by trypan blue staining). Cells were centrifuged at 1000 RCF 
for 5 min at 4ºC. Supernatant (cytosol) was transferred to a new microfuge tube and 
spun down again at high speed to clear debris. Pellet (nuclei) from initial spin was 
washed once with Buffer A without NP-40, then resuspended in equal volumes of 
cold Buffer B (10 mM HEPES pH 7.4, 0.42 M NaCl, 2.5% glycerol, 1.5 mM MgCl2, 
0.5 mM EDTA, 0.5 mM EGTA, 1 mM DTT; PIC added fresh). Samples were 
incubated on ice for 30 minutes with occasional vortexing, centrifuged 10 minutes at 
15,000 RCF to clear debris, and the supernatant transferred to new tube (nuclei). 
Lamin A/C and FASN were used as nuclear and cytoplasmic markers, respectively. 
Histone Acid Extraction for Immunoblotting 
Acid extraction on isolated nuclei was performed as previously described (Lee et al., 
2014). Histones for immunoblotting were extracted from nuclei by lysing cells with 
NIB-250 buffer (15 mM Tris-HCl (pH 7.5), 60 mM KCl, 15 mM NaCl, 5 mM MgCl2, 1 
mM CaCl2, 250 mM sucrose, 1 mM DTT, 10 mM sodium butyrate, 0.1% NP-40, 
protease inhibitors) for 5 minutes on ice. Nuclei were pelleted by spinning lysate at 
600 RCF for 5 minutes at 4oC. Nuclei were washed with NIB-250 buffer without NP-
40 twice. Histones were extracted from nuclei by resuspending the pellet in 0.4N 
H2SO4 and rotating overnight at 4oC, insoluble nuclear debris was cleared by 
spinning at 11,000 RCF for 10 minutes at 4oC. Histones were precipitated by adding 
100% trichloroacetic acid (TCA) until final solution reached 20% TCA and allowed to 
precipitate overnight at 4oC. Precipitated histones were spun down at 11,000 RCF 
for 10 minutes at 4oC and washed with 1 mL acetone + 0.1% 12 N HCl followed by a 
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wash of 1 mL acetone. Histone pellet was air dried at room temperature for at least 
30 minutes and resuspended in glass distilled H2O. 
YSI metabolite analysis: 
Culture medium (glucose-free DMEM (Gibco) supplemented with 10% dFBS 
(Gibson), 10 mM glucose, and 100 µM acetate) was collected from cells after 
culturing for 48 hours. Glucose, lactate, glutamine, and glutamate levels in culture 
medium were measured using a YSI 2950 Bioanalyzer. Because of differences in 
proliferation rate and cell volume between clones, measurements were normalized 
to cell volume (cell number X mean cell volume) area under the curve. Metabolite 
consumption was defined as v = V(xmedium control - xfinal)/A, where v is metabolite 
consumption/ production, V is medium volume, x is metabolite concentration, and A 
is total cell volume area under the curve. A was calculated as N(T)d/ln2(1-2-T/d), 
where N(T) is the final cell count, d is doubling time, and T is time of experiment. 
Cell counts and volume measurements were taken on a Coulter Counter (Beckman 
Coulter), and final cell count N(T) was multiplied by mean cellular volume to obtain 
total cellular volume per sample. Doubling time was calculated as d = 
(T)[log(2)/log(Q2/Q1)], where Q1 is starting cell number and Q2 is final cell number. 
Quantitative RT-PCR 
Cells were lysed using Trizol reagent (Ambion), and RNA was isolated as per Trizol 
extraction protocol. Adipose tissue were excised from animals and immediately 
frozen in liquid nitrogen, placed in Trizol, and lysed using a tissue homogenizer 
before RNA isolation as per Trizol extraction protocol. RNA was resuspended in 
DEPC H2O and quantified on a Biotek Synergy HT Plate Reader. cDNA was 
generated from isolated RNA using High Capacity RNA-to-cDNA Kit (Applied 
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Biosystems), and diluted 1:20 in nuclease free water for quantitative RT-PCR 
reactions (qRT-PCR). qRT-PCR was run using Power SYBR Green PCR Master Mix 
(Applied Biosystems) for 40 cycles at standard reaction speed on a ViiA 7 Real-Time 
PCR System (Applied Biosystems). Primer sequences listed in the table below. 
qRT-PCR primer sequences 
 
Gene Primer Sequence 
Acly (mouse) Forward TTCGTCAAACAGCACTTCC 
Acly (mouse) Reverse ATTTGGCTTCTTGGAGGTG 
Acss2 (mouse) Forward GCTTCTTTCCCATTCTTCGGT 
Acss2 (mouse) Reverse CCCGGACTCATTCAGGATTG 
Glut4 (mouse) Forward GCCCGAAAGAGTCTAAAGC 
Glut4 (mouse) Reverse CTTCCGTTTCTCATCCTTCAG 
FASN (mouse) Forward ATTGGTGGTGTGGACATGGTC 
FASN (mouse) Reverse CCCAGCCTTCCATCTCCTG 
FABP4 (mouse) Forward ACAAAATGTGTGATGCCTTTGTGGGAAC 
FABP4 (mouse) Reverse TCCGACTGACTATTGTAGTGTTTGATGCAA 
PPARg1 (mouse) Forward TGAAAGAAGCGGTGAACCACTG 
PPARg1 (mouse) Reverse TGGCATCTCGTGTCAACCATG 
PPARg2 (mouse) Forward TGGCATCTCTGTGTCAACCATG 
PPARg2 (mouse) Reverse GCATGGTGCCTTCGCTGA 
AdipoQ (mouse) Forward GCACTGGCAAGTTCTACTGCAA 
AdipoQ (mouse) Reverse GTAGGTGAAGAGAACGGCCTTGT 
18S (mouse) Forward AAATCAGTTATGGTTCCTTTGGTC 
18S (mouse) Reverse GCTCTAGAATTACCACAGTTATCCAA 
E2F2 (human) Forward TTTACCTCCTGAGCGAGTCA 
E2F2 (human) Reverse AGCACGTTGGTGATGTCATAG 
MCM10 (human) Forward CGGAACAAACCTAGTGGGATAA 
MCM10 (human) Reverse AGAAGGCTTCCACACAGATG 
SKP2 (human) Forward GTGTACAGCACATGGACCTAT 
SKP2 (human) Reverse CCAGGCTTAGATTCTGCAACT 
 
Gas Chromatography/Mass Spectrometry of Fatty Acid Methyl Esters 
(GC/MS-FAME) 
To measure glucose incorporation into lipids, 2x105 cells were plated and allowed to 
adhere overnight. Culture medium was changed the following day to DMEM without 
glucose (Gibco) supplemented with 10% dialyzed fetal bovine serum (dFBS) (Gibco 
26400044, Lot. 1616514), 10 mM [U-13C]glucose (Cambridge Isotope Laboratories), 
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and 100 µM sodium acetate, and incubated for 48 hours. To measure acetate 
incorporation into lipids, DMEM without glucose was supplemented with 10% dFBS, 
10 mM glucose, and 100 µM or 1 mM [1,2-13C]acetate (Cambridge Isotope 
Laboratories). On day of harvest, cells were washed with 1x PBS, followed by 1x 
PBS + fatty acid free BSA before detachment with trypsin. Cells were spun down, 
and frozen at -80°C until day of extraction. 
Fatty acids were extracted from cells by resuspending and sonicating cells in a 
mixture of methanol, distilled H2O, and chloroform (2:1:2). Mixture was spun at 
10,000 RCF for 10 minutes at 4oC to separate organic and aqueous phases. The 
organic phase was evaporated under nitrogen to obtain a dry lipid fraction for 
derivatization. Fatty acids were derivatized by adding 2 mL of IS solution (40 mL 
MeOH, 10 mL toluene, 5 mg butylated hydroxytoluene) and 2 µL of acetylchloride 
(Sigma) to the dried lipid fraction and heating at 95oC for 1 hour. Derivatized fatty 
acid methyl esters were then extracted by adding 5 mL of 6% potassium carbonate 
solution to separate hydrophobic and hydrophilic phases. The hydrophobic phase 
containing fatty acid methyl esters was analyzed by GC/MS on an Agilent GC/MS 
7890A/5975A with a DB-5 column. Enrichment of 13C into palmitate was determined 
using IsoCor294. 
Gas Chromatography/Mass Spectrometry of TCA cycle metabolites 
Measurements of citrate and malate were conducted essentially as described278. 
Briefly, 6x105 cells (for 6 hour labeling) or 4x105 cells (for 24 hour labeling) were 
plated and allowed to adhere overnight. Culture medium was changed the following 
day to DMEM without glucose (Gibco), supplemented with 10% dialyzed fetal bovine 
serum (dFBS) (Gibco 26400044, Lot. 1616514), 10 mM [U-13C]glucose (Cambridge 
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Isotope Laboratories), and 100 µM sodium acetate, and incubated for 6 or 24 hours. 
To measure acetate incorporation into TCA cycle metabolites, DMEM without 
glucose was supplemented with 10% dFBS, 10 mM glucose, and 100 µM [1,2-
13C]acetate (Cambridge Isotope Laboratories). At time of harvesting, media was 
removed from cells and cells were quickly scraped into 1 mL of cold methanol and 
collected into conical tubes. 0.3 mL of water was added to each sample, and 
samples were then sonicated for 60 seconds. Samples were then centrifuged for 15 
minutes at 8,500 RPM at 4oC. Following centrifugation, supernatant was transferred 
to a 4 ml vial, and samples were heated under nitrogen to evaporate methanol. For 
derivatization, pyridine and BSTFA-TCMS were added sequentially in a 1:1 ratio, 
and allowed to react at 54oC for 30 minutes. Finally, samples were spun down for 10 
minutes at 13,000 RPM at room temperature. Supernatants were transferred GC-
MS vials with pulled glass inserts and were analyzed by GC/MS on an Agilent 
GC/MS 7890A/5975A with a DB-5 column. Enrichment of 13C into TCA cycle 
intermediates was determined using IsoCor295. 
Mass Spectrometry Analysis of Histone Acetylation 
To measure glucose incorporation into histone acetyl-groups, 105 cells were plated 
and allowed to adhere overnight. Culture medium was changed the following day to 
glucose-free DMEM (Gibco) supplemented with 10% dFBS (Gibson), 10 mM [U-
13C]glucose, and 100 µM acetate, and incubated for 24 hours. Measurement of 
acetate incorporation into histone acetyl-groups was done in identical conditions, but 
with 100 µM or 1mM [1,2-13C]acetate and 10 mM glucose. Histones were acid 
extracted from cells using 0.4 N HCl. These samples were TCA precipitated, 
acetone washed, and prepared for mass spectrometry analysis as previously 
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described296. A Waters (Milford, MA) Acquity H-class UPLC system coupled to a 
Thermo (Waltham, MA) TSQ Quantum Access triple-quadrupole (QqQ) mass 
spectrometer was used to quantify modified histones. Selected reaction monitoring 
was used to monitor the elution of the acetylated and propionylated tryptic peptides. 
Transitions were created to distinguish between normal and heavy (13C) acetylation 
marks on the histone H3 tail: histone H3 lysine 9 (H3K9), H3K14, H3K18, and 
H3K23.  
QqQ MS Data Analysis:  
Each acetylated and/or propionylated peak was identified by retention time and 
specific transitions. The resulting peak integration was conducted using Xcalibur 
software (version 2.1, Thermo). The fraction of a specific peptide (Fp) is calculated 
as Fp =Is /(∑Ip), where Is is the intensity of a specific peptide state and Ip is the 
intensity of any state of that peptide. 
 77 
 
  
 78 
 
Determination of acetyl-CoA and 13C incorporation into acyl-CoAs: 
Internal standard generation: 
[13C315N1]-labeled acyl-CoA internal standard was generated by culturing pan6-
deficient Saccharomyces cerevisiae with [13C315N1]- pantothenate (Isosciences, King 
of Prussia, PA), as described previously291. A 500 ml culture at stationary phase was 
resuspended in 100 ml of 10% (w/v) trichloroacetic acid (Sigma-Aldrich, St. Louis, 
MO cat. #T6399). The cells were dismembranated in 10 ml aliquots by sonication 
(60 0.5 s pulses) with a probe tip sonicator (Thermo Scientific) and centrifuged at 
3000 g for 10 mins at 4°C. The cleared supernatant was stored at -80°C. 
Cell treatment and harvest: 
[U-13C]glucose and [U-13C]acetate incorporation into acyl-CoA thioesters were 
analysed in cells incubated in the presence of 10 mM [U-13C]glucose (Cambridge 
Isotope Laboratories CLM-1396-1) or 100 µM [U-13C]acetate (Cambridge Isotope 
Laboratories CLM- 440-1) for 6 hours. For relative acetyl-CoA determination cells 
were incubated in the same conditions in the absence of labeled substrate. Cells 
were removed from culture dish by scraping on ice and resuspended directly in the 
cell culture medium. Cell volume and concentration were determined by Coulter 
counter (Beckman-Coulter). An appropriate volume of each cell sample was pelleted 
by centrifugation (500 x g for 10 min at 4 °C) such that total cell volume in each cell 
pellet was equal. 
Short chain acyl-CoA extraction: 
Frozen tissue samples were cut to ~ 50 mg on a super chilled ceramic tile on dry 
ice. The weighed samples were added to 1 mL of thawed [13C315N1]-labeled acyl-
CoA internal standard in 1.5 mL Eppendorf tubes on ice. Cell pellets were 
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resuspended in 1 ml 10% (w/v) trichloroacetic acid. For relative acyl-CoA 
quantitation, 100 µl of [13C315N1]-labeled acyl-CoA internal standard was added to 
each sample. Internal standard was omitted for 13C labeling experiments. Samples 
were homogenized and dismembranated by 60 (for tissues) or 20 (for cell pellets) 
0.5 s pulses with a probe tip sonicator (Thermo Scientific). The homogenised 
samples were centrifuged at 13,000 × g for 10 min at 4 °C. Supernatants were 
purified by solid-phase extraction using Oasis HLB 1cc (30 mg) SPE columns 
(Waters). Columns were washed with 1 mL methanol, equilibrated with 1 mL water, 
loaded with supernatant, desalted with 1 mL water, and eluted with 1 mL methanol 
containing 25mM ammonium acetate. The purified extracts were evaporated to 
dryness under nitrogen then resuspended in 55 µl 5% (w/v) 5-sulfosalicylic acid in 
water. 
Liquid chromatography: 
Analytes were separated before introduction to the mass spectrometer using a 
reversed-phase Phenomenex HPLC Luna C18 column with 5 mM ammonium 
acetate in water as solvent A, 5 mM ammonium acetate in acetonitrile/water (95:5, 
v/v) as solvent B, and acetonitrile/water/formic acid (80:20:0.1, v/v/v) as solvent C. 
Gradient conditions were as follows: 2% B for 1.5 min, increased to 25% over 3.5 
min, increased to 100% B in 0.5 min and held for 8.5 min, washed with 100% C for 5 
min, before equilibration for 5 min. The flow rate was 200 µl/min. For determination 
of [13C]acetate incorporation into acetyl-CoA in primary mature adipocytes an 
alternative LC method was used, as described297. 
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Mass-spectrometry: 
For relative quantitation of acetyl-CoA levels in cells, samples were analyzed using 
an API 4000 triple-quadrupole mass spectrometer (Applied Biosystems, Foster City, 
CA, USA) in the positive ESI mode as described previously291. Acetyl-CoA was 
quantified by single reaction monitoring (SRM) of m/z 810.1/303.1 and the 
[13C315N1]-labeled internal standard at m/z 814.1/307.1. 
Samples (10 µl) were injected using a Leap CTC autosampler (CTC Analytics, 
Switzerland) and data were analyzed with Analyst 1.4.1 software (Applied 
Biosystems). 
For [U-13C]glucose and [U-13C]acetate labeling and mouse tissue experiments, 
samples were injected by an Ultimate 3000 autosampler and analytes were detected 
using a Thermo Q Exactive instrument in positive ESI mode as described 
elsewhere292. Briefly, scan parameters were alternating full scan from 760 to 1800 
m/z at 140,000 resolution and data-independent acquisition (DIA) looped three times 
with all fragment ions multiplexed at a normalized collision energy (NCE) of 20 at a 
resolution of 280,000. An isolation width of 7 m/z with an offset of 3 m/z was used to 
capture all relevant isotopologues for targeted acyl-CoA thioesters. Parent ion and 
product ion m/z transitions detected are indicated in the table below. 
Species Isotopologue Parent m/z Product 
m/z 
Acetyl-CoA M0 810.1331 303.1373 
Acetyl-CoA M1 811.1364 304.14066 
Acetyl-CoA M2 812.13976 305.14401 
Acetyl-CoA M3 814.14311 306.14737 
Acetyl-CoA M4 814.14647 307.15072 
Acetyl-CoA M5 815.14982 308.15408 
Acetyl-CoA [
13C315N1]-internal standard 814.1402 307.1444 
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Succinyl-CoA M0 868.13853 361.14278 
Succinyl-CoA M1 869.14188 362.14614 
Succinyl-CoA M2 870.14524 363.14949 
Succinyl-CoA M3 871.14859 364.15285 
Succinyl-CoA M4 872.15195 365.1562 
Succinyl-CoA M5 873.1553 366.15956 
Malonyl-CoA M0 854.12288 347.12713 
Malonyl-CoA M1 855.12623 348.13049 
Malonyl-CoA M2 856.12959 349.13384 
Malonyl-CoA M3 857.13294 350.1372 
Malonyl-CoA M4 858.1363 351.14055 
HMG-CoA M0 912.16474 405.169 
HMG-CoA M1 913.1681 406.17235 
HMG-CoA M2 914.17145 407.17571 
HMG-CoA M3 915.17481 408.17906 
HMG-CoA M4 916.17816 409.18242 
HMG-CoA M5 917.18152 410.18577 
HMG-CoA M6 918.18487 411.18913 
HMG-CoA M7 919.18823 412.192482 
 
For [13C]acetate incorporation into acetyl-CoA in primary mature adipocytes, 
samples were injected by an Ultimate 3000 autosampler and analytes were detected 
using a Thermo Q Exactive HF instrument with HESI in negative mode. Instrument 
parameters were as follows, spray voltage 3000 V, capillary temperature 325 °C 
sheath gas 40 arbitrary units, auxillary gas 10 arbitrary units, spare gas 2 arbitrary 
units, S-lens RF level 55. Scan parameters were alternating full scan from 70 to 950 
m/z at 120,000 resolution. Acetyl-CoA isotopologue ions were detected as listed in 
the table below. 
 
 Species Isotopologue m/z 
 Acetyl-CoA M0 808.1185 
 Acetyl-CoA M1 809.12185 
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 Acetyl-CoA M2 810.12521 
 Acetyl-CoA M3 811.12856 
 Acetyl-CoA M4 812.13192 
 
Data were processed in Xcalibur, TraceFinder (Thermo), and isotopic enrichment 
was calculated to compensate for the non-linearity of isotopic enrichment as outlined 
and applied previously298,299. For acetyl-CoA determination in mouse tissues, the 
parent ion peak for acetyl-CoA M0 and the [13C315N1]-acetyl-CoA internal standard 
were integrated to determine relative abundance between samples. 
In vivo de novo lipogenesis analysis 
Plasma D2O enrichment: 
The 2H labeling of water from samples or standards was determined via deuterium 
acetone exchange300,301. 5 ls of sample or standard was reacted with 4 ls of 10N 
NaOH and 4 ls of a 5% (v/v) solution of acetone in acetonitrile for 24 hours. 
Acetone was extracted by the addition of 600 l chloroform and 0.5 g Na2SO4 
followed by vigorous mixing. 100 ls of the chloroform was then transferred to a 
GCMS vial. Acetone was measured using an Agilent DB-35MS column (30 m 3 
0.25mm i.d. 3 0.25 mm, Agilent J&W Scientific) installed in an Agilent 7890A gas 
chromatograph (GC) interfaced with an Agilent 5975C mass spectrometer (MS) with 
the following temperature program: 60 °C initial, increase by 20 °C/min to 100 °C, 
increase by 50 °C/min to 220 °C, and hold for 1 min. The split ratio was 40:1 with a 
helium flow of 1 ml/min. Acetone eluted at approximately 1.5min. The mass 
spectrometer was operated in the electron impact mode (70 eV). The mass ions 58 
and 59 were integrated and the % M1 (m/z 59) calculated. Known standards were 
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used to generate a standard curve and plasma % enrichment was determined from 
this. All samples were analyzed in triplicate. 
Total fatty acids were extracted from tissues and plasma using a Bligh and Dyer 
based methanol/chloroform/water extraction with C16 D31 as an internal standard. 
Briefly, 500 ls MeOH, 500 ls CHCL3, 200 ls H2O and 10 ls 10 mM C16 D31/ 10 
mgs tissue were added to weighed pre-ground tissue. This was vortexed for 10 
minutes followed by centrifugation at 10,000 g for 5 minutes. The lower chloroform 
phase was dried and then derivitised to form fatty acid methyl esters via addition of 
500 ls 2% H2SO4 and incubation at 50°C for 2 hours. FAMES were extracted via 
addition of 100 ls saturated salt solution and 500 ls hexane and these were 
analyzed using a Select FAME column (100m x 0.25mm i.d.) installed in an Aglient 
7890A GC interfaced with an Agilent 5975C MS using the following temperature 
program: : 80 °C initial, increase by 20 °C/min to 170 °C, increase by 1 °C/min to 
204 °C, then 20 °C/min to 250 °C and hold for 10 min. 
Calculations: 
The % mass isotopomer distributions of each fatty acid was determined and 
corrected for natural abundance using in-house algorithms adapted from Fernandez 
et al.302. Calculation of the fraction of newly synthesized fatty acids (FNS) was based 
on the method described by Lee et al.303, where FNS is described by the following 
equation: 
FNS=ME/(n x p) 
Where ME is the average number of deuterium atoms incorporated per 
molecule(ME =1 x m1 + 2 x m2 +3 x m3 ... ), p is the deuterium enrichment in water 
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and n is the maximum number of hydrogen atoms from water incorporated per 
molecule. N was determined using the equation: 
m2/m1 = (N-1) /2 x p/q 
As described by Lee et al.304 where q is the fraction of hydrogen atoms and p + q = 
1. The molar amount of newly synthesized fatty acids was determined by: 
MNS = FNS x total fatty acid amount (nmoles/mg tissue). 
 
Acetate measurements: 
Protein filtration from the samples:  
200 ml of sample was filtered through 3 kDa cutoff nanosep centrifugation device 
(Pall Inc. Port Washington, NY), and recovered volume of the filtrate noted. 
Sample preparation for NMR spectroscopy:  
180 µl of filtrate was added to 20 µl of DSS (4,4-Dimethyl-4-silapentane-1-sulfonic 
acid, Cambridge Isotope Limited, Andover, MA) in D2O to a final concentration of 
0.16 mM. 
Nuclear Magnetic Resonance (NMR) Spectroscopy:  
All NMR spectra were acquired in Bruker Avance III HD NMR spectrometer 
equipped with a triple resonance inverse (TXI) 3 mm probe (Bruker Biospin, 
Billerica, MA) and a Bruker Samplejet for sample handling. One-dimensional NMR 
spectra were acquired using the first transient of a 2 dimensional NOESY and 
generally of the form RD-90-t-90-tm-90-ACQ305. Where RD = relaxation delay, t = 
small time delay between pulses, tm = mixing time and ACQ = acquisition. The water 
signal was saturated using continuous irradiation during RD and tm. The spectra 
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were acquired using 76K data points and a 14 ppm spectral width over 384 scans 
with a 1 second interscan (relaxation) delay and 0.1 second mixing time. The FIDs 
were zero filled to 128K; 0.1 Hz of linear broadening was applied followed by Fourier 
transformation, baseline and phase correction using an automated program 
provided by Bruker Biospin. 
Profiling of acetate signal from the NMR spectra:  
The acetate signal was quantitatively profiled from the spectra using Chenomx v 8.0 
(Edmonton, Canada)306 by quantifying the acetate peak at 1.90 ppm (Supplementary 
Fig. 2A) relative to the DSS peak area. Proper care was taken to omit the effects of 
the overlapping signals (for example, lysine and arginine overlapping with the 1.90 
ppm acetate peak) using the Chenomx targeted spectral fitting algorithm307. 
Histology 
For histology, subcutaneous and visceral white fat tissue was fixed in formalin 
overnight, deyhydrated and submitted to the AFCRI Histology Core for paraffin 
embedding, sectioning and hematoxylin and eosin staining. 
Primary adipocyte 13C-acetate uptake 
Primary adipocyte isolation was conducted as previously described308, with minor 
modifications. Briefly, visceral white adipose tissues (VWAT) were removed from 
mice ages 12-16 weeks and weighed. Isolation buffer (1X Krebs-Ringer- Phosphate 
Buffer, 2% Hepes, 25 mg/mL BSA, 0.2 mM adenosine, 10 mM glucose, 100 µM 
[1,2-13C]acetate, pH 7.5) and 1 mg/mL collagenase was prepared ahead of time and 
added to VWAT at 2 mL per gram of tissue while on ice. VWAT fat pads were 
chopped with scissors in the buffer for 5 minutes until no large chunks of tissue 
remained, and then incubated at 37oC for 45 minutes while shaking to allow 
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collagenase digestion to occur. Following collagenase digestion, tissue suspension 
was passed through a 100 µm mesh filter and allowed to sit at room temperature 
until primary adipocytes separated from infranatant. Infranatant was subsequently 
removed and remaining adipocytes were washed 3x in isolation buffer without 
collagenase. Following washes, primary adipocytes were re-suspended in 3x cell 
volume of isolation buffer containing 100 µM [1,2-13C]acetate and incubated at 37oC 
for 4 hours while shaking. Following incubation, suspension was allowed to sit at 
room temperature until primary adipocytes separated from infranatant. Infranatant 
was subsequently removed and the remaining primary adipocytes were re-
suspended in ice cold 10% tricholoroacetic acid, and frozen at -80oC until samples 
could be analyzed for acyl-CoA species by mass spectrometry as described above. 
FIGURES 
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Figure 2.1 | Genetic Deletion of Acly Is Consistent with Cell Viability but 
Impairs Proliferation 
(A) Western blot of three clonal ACLY-deficient (KO) cell lines (PC7, PC8, and PC9) generated 
from Aclyf/f MEFs. 
(B) Proliferation curve of Aclyf/f and ACLY-KO MEFs over 5 days; mean ± SEM of triplicate wells, 
statistical significance compared to Aclyf/f. 
(C) Western blot verification of ACLY knockout by CRISPR-Cas9 in LN229 glioblastoma cells. 
(D) Proliferation curve of LN229 and two ACLY-knockout clonal cell lines over 5 days; error bars 
indicate mean ± SEM of triplicate wells, statistical significance compared to LN229. 
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(E) Western blot of nuclear and cytoplasmic fractions of Aclyf/f, PC9, and reconstituted ACLY-WT 
and ACLY-H760A PC9 cells. FASN and LMNA (lamin A/C) are cytoplasmic and nuclear markers, 
respectively. 
(F) Proliferation curve of Aclyf/f MEF and PC9 lines compared to PC9 reconstituted with ACLY-
WT or ACLY-H760A over 5 days; error bars indicate mean ± SEM of triplicate wells, statistical 
significance compared to PC9. 
(G) Western blot of ACLY and ACSS2 protein levels in Aclyf/f MEFs over 144 hr following 
administration of Cre recombinase. 
(H) Western blot of ACLY and ACSS2 protein levels in Aclyf/f MEFs over 144 hr with 
pharmacological inhibition of ACLY (50 M BMS-303141). 
For all panels: **p < 0.01; ***p < 0.001; ****p < 0.0001; n.s., not significant. See also Figure S2.1. 
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Figure 2.2 | ACLY-Deficient MEFs Require Exogenous Acetate for Viability 
(A) Acetate concentrations in DMEM, RPMI, 100% dialyzed fetal bovine serum (dFBS), and 
100% calf serum (CS); error bars indicate mean ± SEM of triplicate aliquots. See Figure S2.2A for 
spectrum. n.d., not detected. 
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(B) Proliferation curve over 5 days of Aclyf/f, PC9, PC9-ACLY-WT, and PC9-ACLY-H760A cells in 
acetate-free conditions (DMEM + 10% dFBS + 10 mM glucose); error bars indicate mean ± SEM 
of triplicate wells. 
(C) Image of ACLY-deficient PC9 cells cultured for 5 days in DMEM + 10% dFBS + 10 mM 
glucose, without (left) or with (right) 100 M sodium acetate. 
(D) Western blot of apoptotic markers cleaved poly(ADP-ribose) polymerase (PARP) and cleaved 
caspase-3 (CASP3) in Aclyf/f and PC9 cells cultured in acetate- free conditions (DMEM + 10% 
dFBS + 10 mM glucose) for 4 (D4) or 5 (D5) days. 
(E) Cell numbers following 5 days in culture in DMEM + 10% dFBS + 10 mM glucose alone 
(black) or supplemented with 100 M sodium acetate (red) in Aclyf/f, PC9, PC9-ACLY-WT, and 
PC9-ACLY-H760A cells; error bars indicate mean ± SEM of triplicates. ***p < 0.001. Dotted line 
represents cell number at plating. 
(F) Proliferation of PC9 cells over 5 days cultured in DMEM + 10% dFBS + 10 mM glucose, with 
100 M or 1 mM sodium acetate; error bars indicate mean ± SEM of triplicate wells. 
(G) Parental Aclyf/f MEFs and two clones of ACSS2-deficient Aclyf/f MEFs were administered Cre 
recombinase once (+) or twice (++) and proteins collected for western blot after 2 days (+) and 2 
weeks (++). See Figure S2.2D for corresponding images. 
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Figure 2.3 | Acetate Supports Lipid Synthesis in the Absence of ACLY 
(A) Measurements of glucose consumption and lactate production (left) and glutamine 
consumption and glutamate production (right), normalized to cell volume (cell number 3 mean cell 
volume); error bars indicate mean ± SEM of triplicate wells; **p < 0.01; ***p < 0.001. Experiment 
was performed in glucose-free DMEM + 10% dFBS + 10 mM glucose + 100 M sodium acetate. 
(B) Experimental design for heavy isotope labeling of fatty acids using [U-13C]glucose, with 
unlabeled acetate present (left) and [1,2-13C]acetate, with unlabeled glucose present (right). 
(C) Isotopologue distribution of palmitate after 48-hr labeling in 10 mM [U-13C]glucose in Aclyf/f, 
PC9, PC9-ACLY-WT, and PC9-ACLY-H760A MEFs (top). Expressed as percent enrichment of 
palmitate (bottom); error bars indicate mean ± SD of triplicates. **p < 0.01; ***p < 0.001. 
(D) Isotopologues of palmitate after 48-hr labeling in 100 M [1,2-13C]acetate in Aclyf/f, PC9, PC9-
ACLY-WT, PC9-Acly H760A MEFs (top). Expressed as percent enrichment of palmitate (bottom); 
error bars indicate mean ± SD of triplicates. ***p < 0.001; ns, not significant. 
(E) Isotopologues of HMG-CoA upon 6-hr labeling in 10 mM [U-13C]glucose (100 M unlabeled 
acetate present) in Aclyf/f and PC9 MEFs; error bars indicate mean ± SD of triplicates. 
(F) Isotopologues of HMG-CoA upon 6-hr labeling in 100 M [1,2-13C]acetate (10 mM unlabeled 
glucose present) in Aclyf/f and PC9 MEFs; error bars indicate mean ± SD of triplicates. 
(G) Total HMG-CoA quantitation in cells cultured in DMEM + 10% dFBS + 10 mM glucose + 100 
M sodium acetate (unlabeled); error bars indicate mean ± SEM of triplicates. n.s., not significant. 
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Figure 2.4 | ACLY Is Required for Sustaining Histone Acetylation Levels, 
despite ACSS2 Compensation 
(A) Western blot of acetylated histones extracted from Aclyf/f, PC9, PC9-ACLY-WT, and PC9-
ACLY-H760A MEFs cultured in complete medium (DMEM + 10% CS), dFBS medium (DMEM + 
10% dFBS), +100 M acetate medium (DMEM + 10% dFBS + 100 M sodium acetate), and +1 
mM acetate medium (DMEM + 10% dFBS + 1 mM sodium acetate) for 48 hr. 
(B–D) Fractions of histone H3-K14, -K18, and -K23 acetylation (m+2) derived from 10 mM [U-
13C]glucose, with unlabeled 100 M acetate present (B); 100 M [1,2-13C]acetate, with 10 mM 
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unlabeled glucose present (C); or 1 mM [1,2-13C]acetate, with 10 mM unlabeled glucose present 
(D); error bars indicate mean ± SEM of triplicate samples. Labeling was for 24 hr (see also Figure 
S2.3B for experimental design).  
(E–G) Overall percentage of H3K23 acetylated in each cell line (y axis), as well as the relative 
fraction of this acetylation incorporated from a labeled source (red): 10 mM [U-13C]glucose (E), 
100 M [1,2-13C]acetate (F), and 1 mM [1,2-13C]acetate (G) or unlabeled sources (black); error 
bars indicate mean ± SEM of triplicate samples. The same dataset is represented in parts (B–D) 
and (E–G). 
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Figure 2.5 | Acetyl-CoA Pools Are Sustained by Acetate in the Absence of 
ACLY 
(A) Relative whole-cell acetyl-CoA levels in Aclyf/f and PC9 MEFs cultured in glucose-free DMEM 
+ 10% dFBS + 10 mM glucose + 100 M sodium acetate for 6 hr, normalized to cellular volume; 
error bars indicate mean ± SD of triplicates. 
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(B) Schematic of acetyl-CoA production from glucose and acetate with (top) or without (bottom) 
ACLY. 
(C) Isotopologue distribution of citrate after 6-hr incubation with 10 mM [U-13C]glucose, with 100 
M unlabeled acetate present (black) or 100 M [1,2-13C]acetate with 10 mM unlabeled glucose 
present (red), in Aclyf/f (top) or PC9 (bottom) MEFs; error bars indicate mean ± SEM of triplicates. 
(D) Isotopologue distribution of malate in the same conditions as (C). 
(E–G) m+2 acetyl-CoA (E), malonyl-CoA (F), or succinyl-CoA (G) following 6-hr labeling in 10 mM 
[U-13C]glucose (with 100 M unlabeled acetate present) or 100 M [1,2-13C]acetate (with 10 mM 
unlabeled glucose present); error bars indicate mean ± SEM of triplicates. For (E–G), all 
statistical comparisons are to Aclyf/f using Holm-Sidak test. For all panels: *p < 0.05; **p < 0.01; 
***p < 0.001. 
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Figure 2.6 | ACSS2 Is Upregulated In Vivo upon Deletion of Acly from 
Adipocytes 
(A) Western blot of liver, SWAT, and VWAT from Aclyf/f and AclyFAT-/- mice. 
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(B) mRNA expression of Acly and Acss2 in SWAT (left) and VWAT (right) from Aclyf/f and 
AclyFAT-/- mice; error bars indicate mean ± SEM. 
(C) Representative SWAT and VWAT histology from male 16-week-old Aclyf/f and AclyFAT-/- mice. 
Scale bars, 100 m. 
(D) Body weight of male Aclyf/f (n = 9) and AclyFAT-/- (n = 8) mice; error bars indicate mean ± SD. 
(E) Expression of adipocyte genes in SWAT (left) and VWAT (right) from Aclyf/f (n = 8) and 
AclyFAT-/- (n = 7) mice; error bars indicate mean ± SEM. For all panels: *p < 0.05; **p < 0.01. 
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Figure 2.7 | ACLY-Deficient Adipose Tissue Exhibits Depot-Specific 
Alterations in DNL and Histone Acetylation 
(A) Acetyl-CoA abundance in SWAT, VWAT, and liver in 11-week-old Aclyf/f (n = 6) and AclyFAT-/- 
(n = 7) mice.           
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(B–D) Primary mature adipocytes were isolated from 12- to 16-week-old Aclyf/f (n = 5) and 
AclyFAT-/- (n = 3) mice and labeled with 100 M [1,2-13C]acetate (with 5 mM unlabeled glucose 
present). Acetyl-CoA (B), malonyl-CoA (C), and HMG-CoA (D) enrichment from acetate was 
analyzed; error bars indicate mean ± SEM.  
(E–G) Relative quantities of fatty acids synthesized de novo in SWAT (E), VWAT (F), and liver 
(G) of Aclyf/f (n = 6) and AclyFAT-/- (n = 8) mice; error bars indicate mean ± SEM. The # sign 
indicates not synthesized de novo. 
(H–J) Overall histone H3 acetylation levels in 11-week-old SWAT (H), VWAT (I), and liver (J) of 
Aclyf/f (n = 6) and AclyFAT-/- (n = 7) mice; error bars indicate mean ± SEM. 
For all panels: *p < 0.05; **p < 0.01. 
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Figure S2.1 | Deletion of Acly from mouse embryonic fibroblasts, related to 
Fig. 2.1. 
(A) Diagram of Acly locus in Aclyf/f mice, loxP sites flanking exon 9 are depicted. 
(B) Western blot of ACLY and ACSS2 expression in Aclyf/f MEFs, +/- Cre treatment at the time of 
initial deletion and one month later. 
(C) Proliferation curve of Aclyf/f MEFs with or without Cre treatment over 6 days, mean +/- SEM of 
triplicate wells. 
(D) Western blot of ACLY and ACSS2 expression in Aclyf/f MEFs and PC7 and PC9 knockout 
lines that have been reconstituted with wild type ACLY (+ACLY-WT) or catalytically dead ACLY 
(+ACLY-H760A). 
(E) Proliferation curve of Aclyf/f MEF and PC7 lines compared to PC7 with reconstituted ACLY-
WT or ACLY-H760A over 5 days, mean +/- SEM of triplicate wells, statistical significance 
compared to PC7. 
For all panels: **, p<0.01. 
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Figure S2.2 | Acetate sustains viability in the absence of ACLY, related to 
Fig. 2.2. 
(A) NMR spectrum of undiluted calf serum. 
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(B) Western blot verification of Acss2 knockout using CRISPR-Cas9 gene editing in Aclyf/f MEFs. 
(C) Proliferation curve over 5 days of three ACSS2-deficient clonal cell lines as compared to 
Aclyf/f MEFs, mean +/- SEM of triplicate wells. 
(D) Representative images of Aclyf/f MEFs and sgAcss2 6.2 Aclyf/f MEFs, treated twice with 
adenoviral Cre-recombinase at 4x zoom (left panels, bar represents 1000 µm) and 10x zoom 
(right panels, bar represents 400 µm). 
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Figure S2.3 | ACLY is required for sustaining histone acetylation levels, 
related to Fig. 2.4. 
(A) Histone acetylation in acid-extracted histones from Aclyf/f and PC9 MEFs cultured for 24 hours 
in glucose-free DMEM supplemented with 10% dFBS and the indicated glucose concentrations. 
(B) Experimental design of heavy isotope labeling of histone acetylation using 10 mM [U-
13C]glucose with 100 µM unlabeled acetate present (left), 100 µM [1,2-13C]acetate with 10 mM 
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unlabeled glucose present (center), and 1 mM [1,2-13C]acetate with 10 mM unlabeled glucose 
present (right). 
(C-E) Percent of total acetylation of H3K14 (left) and H3K18 (right) from labeled (red) and 
unlabeled (black) sources after labeling with 10 mM [U-13C]glucose (C), 100 µM [1,2-13C]acetate 
(D), or 1 mM [1,2-13C]acetate (E), mean +/- SEM of triplicate samples. 
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Figure S2.4 | Acetate regulates histone acetylation and gene expression in 
ACLY-deficient glioblastoma cells, related to Fig. 2.4. 
(A) Histone acetylation in acid-extracted histones from LN229 parental and ACLY KO clones 
cultured for 24 hours in glucose-free RPMI + 10% dFBS + 1 or 10 mM glucose + 2 mM glutamine 
+ 0, 0.1, or 1 mM acetate. 
(B) Relative expression of E2F2, MCM10, and SKP2 in LN229 parental and ACLY KO clones 
after 24 hours cultured in the same conditions as in panel A. 
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(C) Cell number after 48 hours of culture in indicated conditions. 
(D) Relative whole cell acetyl-CoA levels in LN229 parental and ACLY KO clones cultured in 
glucose-free RPMI + 10% dFBS + 10 mM glucose + 100 µM acetate + 2 mM glutamine for 6 
hours, normalized to cellular volume, mean +/- SEM of triplicate samples. 
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Figure S2.5 | Acetate contributes minimally to mitochondrial metabolism in 
the absence of ACLY, related to Figure 2.5. 
(A,B) Isotopologue distribution of citrate (A) and malate (B) upon 24 hours labeling in 10 mM [U-
13C]glucose or 100 µM [1,2-13C]acetate in Aclyf/f (top) and PC9 (bottom) MEFs, mean +/- SEM of 
triplicate samples. 
 
 109 
 
 
Figure S2.6 | Tissue fatty acid levels and enrichment after D2O labeling of 
Aclyf/f and AclyFAT-/- mice, related to Fig. 2.7. 
(A) Plasma D2O enrichment. 
(B-D) Abundance of fatty acids in SWAT (B), VWAT (C), and liver (D). 
(E-G) Fractions of fatty acids synthesized de novo present in SWAT (E), VWAT (F), and liver (G). 
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CHAPTER 3: Dietary fructose feeds hepatic lipogenesis via 
microbiome-derived acetate independent of citrate shuttling. 
Abstract 
 
Fructose consumption has risen dramatically in recent decades due to the use of sucrose 
and high fructose corn syrup in beverages and processed foods238, contributing to rising 
rates of obesity and non-alcoholic fatty liver disease (NAFLD)309–311. Fructose intake 
triggers hepatic de novo lipogenesis (DNL)229,311,312, a multistep process that utilizes 
acetyl-CoA as a substrate. ATP-citrate lyase (ACLY), the enzyme that cleaves cytosolic 
citrate to generate acetyl-CoA, is potently upregulated upon carbohydrate consumption250. 
Ongoing clinical trials are pursuing ACLY inhibition for treatment of metabolic diseases313. 
The route from dietary fructose to hepatic acetyl-CoA and lipids, however, remains 
unproven. Here we show that liver-specific Acly knockout (LAKO) mice are, unexpectedly, 
not protected from fructose-induced DNL or fatty liver. In vivo isotope tracer studies using 
13C-fructose gavage show that fructose-derived carbons are used for DNL even in the 
absence of ACLY. Dietary fructose is converted by the gut microbiome into acetate314, 
which supplies lipogenic acetyl-CoA independently of ACLY264. Depletion of the 
microbiome or silencing of hepatic ACSS2, which generates acetyl-CoA from acetate, 
potently suppresses fructose conversion into hepatic acetyl-CoA and fatty acids. Thus, 
bolus fructose feeds hepatic acetyl-CoA pools indirectly via acetate, bypassing ACLY. 
When fructose is consumed more gradually via drinking water to facilitate its absorption in 
the small intestine, both ACLY and microbial acetate production contribute to lipogenesis.  
The DNL transcriptional program, on the other hand, is induced in response to fructose 
consumption in a manner that is both ACLY- and microbiome-independent, consistent with 
a direct role for hepatic fructolysis in activating the carbohydrate-response element-
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binding protein (ChREBP). These data reveal a two-pronged mechanism regulating 
hepatic DNL, in which fructolysis within hepatocytes provides a signal to promote DNL, 
while fructose metabolism by the gut microbiota provides the substrate to feed DNL.   
Main Text  
 
Since ACLY links carbohydrate and lipid metabolism (Fig. 3.1a), we hypothesized that 
genetic deletion of Acly in hepatocytes would protect mice against fructose-induced lipid 
accumulation. While whole body Acly knockout is embryonic lethal5, liver-specific Acly 
knockout (LAKO) mice were grossly indistinguishable from wild-type (WT) littermate 
controls, with similar body weights and organ sizes between genotypes when fed either 
standard chow or a high-fructose (60%) diet (HFrD) (Extended Data Fig. 3.1a-b). Fructose 
consumption triggered mild hepatic lipid accumulation in both WT and LAKO mice (Fig. 
3.1b, Extended Data Fig. 3.1d). Neither fibrosis nor excess glycogen accumulation were 
observed (Extended Data Fig. 3.1c), consistent with prior observations315. ACLY protein 
was not detected within hepatocytes in LAKO livers (Extended Data Fig. 3.1e). 
Metabolomic and lipidomic analyses revealed striking diet-dependent changes, and 
relatively modest genotype-dependent differences (Extended Data Fig. 3.2a-b, 3.3a-c). 
Consistent with loss of ACLY activity, LAKO-specific accumulation of citrate and its 
downstream metabolite aconitate was observed (Extended Data Fig. 3.2c). Together, 
these data demonstrate that ACLY deficiency neither dramatically impacts global hepatic 
metabolite levels nor prevents fructose-induced accumulation of triglyceride.   
To more specifically investigate the role of hepatic ACLY in fructose-induced steatosis 
without altering the overall diet, we fed mice standard chow diets with either normal 
drinking water (H2O) or drinking water containing a 1:1 mixture of fructose and glucose 
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(15% each, Fruc:Gluc) (Extended Data Fig. 3.4a-c). Similar to HFrD, mice drinking 
Fruc:Gluc for 4 weeks developed mild hepatic steatosis regardless of ACLY expression 
(Extended Data Fig. 3.4d). Moreover, deuterated water (D2O) tracing revealed that 
Fruc:Gluc consumption increases hepatic DNL to a similar extent in WT and LAKO mice 
(Fig. 3.1c). Thus, deletion of Acly from liver does not prevent induction of DNL in response 
to fructose consumption. 
Given the unexpected result that hepatic ACLY is dispensable for fructose-induced DNL 
(Fig. 3.1c), we directly tested the impact of ACLY deficiency on fructose conversion into 
nascent fatty acids. WT and LAKO mice were gavaged with 1:1 fructose:glucose, with 
either glucose or fructose 13C-labeled (Fig. 3.1d). Strikingly, fructose carbons were 
incorporated into fatty acids in LAKO and WT mice to a similar extent, while glucose 
carbons were barely used (Fig. 3.1e, Extended Data Fig. 3.5a). These data indicate that, 
in contrast with existing models of fructose metabolism, the use of fructose carbons for 
hepatic DNL does not require ACLY.  
We next investigated the mechanisms of how fructose carbons are used for fatty acid 
synthesis in an ACLY-independent manner. It has been previously shown that the hepatic 
DNL program is activated in response to carbohydrate consumption by ChREBP316,317. 
Upon chronic high fructose consumption, livers of both WT and LAKO mice upregulated 
the highly active ChREBP- isoform285, along with lipogenic genes (Acaca and Fasn) and 
other ChREBP target genes, aldolase B (AldoB), and ketohexokinase (Khk)318 (Fig. 3.1f, 
Extended Data Fig. 3.6a). WT mice also exhibited upregulation of Acly on HFrD (Fig. 3.1f). 
The induction of the DNL program was also robust at the protein level (Fig. 3.1g, Extended 
Data Fig. 3.6b). Acyl-CoA synthetase short chain family member 2 (ACSS2), which 
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converts acetate into acetyl-CoA, was notably upregulated in fructose-consuming LAKO 
mice (Fig. 3.1g, Extended Data Fig. 3.6a-b). Moreover, the Acss2 genomic locus showed 
increased histone H3K27 acetylation, as well as ChREBP binding, after Fruc:Gluc 
drinking, concurrent with induction of DNL transcriptional program (Extended Data Fig. 
3.6c-e). We also confirmed ChREBP binding to the Acss2 locus in a published ChREBP 
ChIP-Seq study dataset319 (Extended Data Fig. 3.6f). Acss2 is also a known target of 
SREBP transcription factors, which are also activated in response to fructose 
consumption9,320,321.  These data suggest that Acss2 is component of the hepatic response 
to fructose consumption.  
Since acetate conversion to acetyl-CoA by ACSS2 can support de novo lipogenesis in the 
absence of ACLY264, we hypothesized that acetate might be an important source of acetyl-
CoA for hepatic DNL in the context of fructose feeding (Fig. 3.2a). Acetate can be 
generated within mammalian cells through several mechanisms, including acetyl-CoA 
hydrolysis, histone deacetylation, and pyruvate to acetate conversion322–324, prompting us 
to investigate whether fructose is converted to acetate in a cell autonomous manner in 
hepatocytes.  In primary hepatocytes, high concentrations of glucose induce the DNL gene 
program325. Incubation of wild-type murine hepatocytes with 25 mM 13C-fructose resulted 
in considerable labeling of fructolytic intermediates (Fig. 3.2b). Surprisingly, however, 13C-
fructose minimally labeled acetyl-CoA and malonyl-CoA, the core DNL substrates, in WT 
hepatocytes (Fig. 3.2c). In contrast, 13C-acetate, even at a much lower concentration, 
labeled acetyl-CoA and malonyl-CoA, as well as HMG-CoA, an intermediate in the 
mevalonate pathway downstream of acetyl-CoA (Fig. 3.2c). Therefore, even when ACLY 
is intact, fructose catabolism may be uncoupled from DNL in primary hepatocytes, while 
exogenous acetate can directly feed into lipogenic acetyl-CoA pools.  
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These findings suggested the possibility that fructose may be converted to acetate by a 
different cell type prior to reaching the liver, in order to feed hepatic DNL.  To test this 
possibility in vivo, we performed a 13C-fructose tracing time course in mice. Orally 
administered 13C-fructose quickly labeled fructose-1-phosphate (F1P) and pyruvate in the 
liver with peaks between 15-30 min, indicative of rapid hepatic fructolysis (Fig. 3.2d). 
Hepatic acetyl-CoA labeling was, however, much slower (peaking at 60-90 min) (Fig. 
3.2d). The slower kinetic of acetyl-CoA labeling was closely aligned with the appearance 
of labeled acetate in the portal circulation (Fig. 3.2d). Labeling of hepatic fatty acids follows 
that of acetyl-CoA (peaking at 120-180 min) (Fig. 3.2d). These data suggest that fructose 
may primarily feed hepatic acetyl-CoA and fatty acid production indirectly via acetate 
generated from fructose.  
We next sought to determine the source of fructose-derived acetate.  While fructose is 
mainly taken up by the small intestine, unabsorbed fructose reaches the colon where the 
microbiome converts fructose into short chain fatty acids (SCFAs), including acetate314. 
To test if the microbiome is important for hepatic DNL, we depleted it with an antibiotic 
cocktail (Extended Data Fig. 3.7a-c, 3.8b). Antibiotic treatment did not suppress the levels 
of labeled fructose and glucose in the portal vein following an oral administration of 13C-
fructose (Extended Data Fig. 3.7d-e), indicative of intact small intestine fructose 
absorption and metabolism. The induction of hepatic DNL genes following fructose 
consumption is thought to be dependent on fructolytic and/or glycolytic 
intermediates316,326, and silencing of hepatic Khk suppresses fructose-induced 
upregulation of DNL gene expression321. Consistent with normal passage of fructose from 
the intestine to the liver, DNL gene expression upon fructose consumption remained intact 
after antibiotic treatment (Extended Data Fig. 3.7f), as did labeling of F1P, pyruvate and 
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citrate in the liver (Fig. 3.3a). In contrast, microbiome depletion dramatically reduced the 
labeling of hepatic acetyl-CoA and palmitate, as well as fatty acids within circulating lipids, 
from 13C-fructose (Fig. 3.3a,b, Extended Data Fig. 3.8a). This reduction was well matched 
with depleted portal and cecal labeling of acetate, as well as other short-chain fatty acids 
(Fig. 3.3a, Extended Data Fig. 3.7g-h). Antibiotic treatment also reduced total hepatic 
triglycerides (Fig. 3.3c), which is consistent with prior observations240,327. Thus, depletion 
of the microbiome suppresses hepatic DNL from 13C-fructose, without impairing small 
intestine or hepatic fructose metabolism or induction of DNL gene expression.   
We next aimed to determine if acetate is a key microbial product supporting DNL.  To 
assess whether fructose intake led to an appreciable increase in portal acetate 
concentrations, we measured acetate in portal and systemic blood after gavage.  Portal 
vein acetate concentrations increased approximately twofold over baseline (to > 1 mM) at 
60-90 minutes after fructose gavage (Fig. 3.3d), corresponding with acetate labeling from 
fructose (Fig. 3.2d).  Strikingly, the rise in portal acetate was absent in antibiotic treated 
animals (Fig. 3.3d). Acetate concentrations in systemic circulation were lower than that in 
the portal vein and did not markedly fluctuate after fructose consumption, suggesting that 
fructose-derived acetate is primarily cleared by the liver (Fig. 3.3d). Next, to assess 
whether acetate supports DNL downstream of microbial metabolism, mice were gavaged 
with 13C-acetate, along with 1:1 fructose:glucose. This showed that DNL from 13C-acetate, 
in contrast to that from 13C-fructose, is not impacted by antibiotic treatment (Fig. 3.3e).  
Finally, to test if hepatic ACSS2 is required for fructose to feed DNL, ACSS2 in the liver 
was silenced using an adeno-associated viral hairpin targeting Acss2328 (Extended Data 
Fig. 3.8c-e). Depletion of hepatic ACSS2 strongly suppressed the labeling of circulating 
lipids from 13C-fructose (Fig. 3.3f). Altogether, these data point to a two-pronged 
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mechanism of fructose-dependent DNL, with cell autonomous effects of fructose and/or 
glucose in stimulating the hepatic DNL transcriptional program, but microbiome-
dependent acetate production serving as the major source of fructose-derived acetyl-CoA 
for lipogenesis, via hepatic ACSS2, after consumption of a fructose bolus (Extended Data 
Fig. 3.10a).   
Microbiome-dependent acetate production from fructose occurs when rate of ingestion 
exceeds small intestinal uptake capacity314. Thus, if fructose is consumed gradually, its 
contribution to DNL might occur to a greater extent via ACLY, and to a lesser extent via 
microbial acetate production. Still, upon providing Fruc:Gluc in the drinking water, DNL 
was comparably stimulated in the presence or absence of ACLY (Fig. 3.1c). To explore 
this further, mice were given 13C-labeled fructose or glucose in drinking water for 24 hours 
(Fig. 3.4a). Fructose-derived carbons provided a substantial contribution to hepatic lipid 
pools, with greater than 20% of total liver fatty acid carbons being labeled from 13C-
fructose after 24 hours of Fruc:Gluc drinking, while 13C-glucose contributed less (Fig. 
3.4b). In this context of more gradual fructose intake, ACLY deficiency suppressed 13C-
fructose and -glucose contribution to hepatic fatty acids (Fig. 3.4b). Nevertheless, total 
DNL as measured by D2O labeling was not different between WT and LAKO mice (Fig. 
3.4c), indicating sufficient availability of other two-carbon unit donors. One possibility is 
assimilation of acetate from other sources (e.g. fiber fermentation). To test utilization 
acetate for lipogenesis, we supplemented Fruc:Gluc drinking water with 13C-acetate upon 
initial exposure (naïve) as well as after 2 weeks of Fruc:Gluc water (conditioned) 
(Extended Data Fig. 3.9a). Fatty acid labeling from 13C-acetate was higher in LAKO mice 
at baseline (Fig. 3.4d).  After fructose conditioning, acetate contribution to DNL increased 
in WT animals, and this was further enhanced in LAKO mice (Fig. 3.4d), consistent with 
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increased hepatic ACSS2 expression in LAKO mice following fructose feeding, which 
preceded the onset of steatosis (Extended Data Fig. 3.9b-c). We next assessed the 
contribution of microbiome-derived acetate from all dietary sources in the context of 
sweetened water consumption. Antibiotic treatment suppressed total hepatic DNL in 
LAKO mice (Fig. 3.4e, Extended Data Fig. 3.9d). ChREBP and DNL gene expression 
were confirmed to be upregulated by Fruc:Gluc drinking  in all groups (Fig. 3.4f).  Finally, 
we examined DNL in Fruc:Gluc-drinking mice following silencing of hepatic ACSS2, 
finding that in the context of gradual fructose consumption via drinking water, loss of both 
ACLY and ACSS2 is necessary to suppress DNL (Fig. 3.4g).  These data indicate that 
when fructose is consumed gradually to reduce its passage into the colon, the rate of DNL 
is established by signaling mechanisms (i.e., sugar-driven ChREBP activation), and DNL 
is suppressed only when acetyl-CoA production by both ACLY and ACSS2 is inhibited 
(Extended Data Fig. 3.10b).  
In this study, we demonstrate that bolus fructose consumption triggers hepatic DNL 
independent of ACLY but dependent on fructose metabolism by gut microbiota. We found 
that fructose feeds hepatic fatty acid synthesis through its microbial metabolism to acetate, 
which reaches the liver via the portal vein. The induction of the DNL transcriptional 
program in the liver, on the other hand, appears to be independent of both ACLY and the 
microbiome, consistent with the notion that proximal fructolytic and/or glycolytic 
metabolites are important for ChREBP activation. When consumed more gradually, 
fructose can feed DNL in an ACLY-dependent manner.  However, acetate from other 
sources is also readily available to the liver, rendering ACLY dispensable for DNL even 
when fructose is gradually consumed. The data also suggest that diet and microbiome 
could potentially impact the efficacy of ACLY inhibitors, currently in clinical trials for 
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hypercholesterolemia329. Prior studies using RNAi to silence hepatic ACLY have reported 
that ACLY deficiency decreases hepatic lipid in db/db mice, but increases hepatic lipid in 
mice fed a high fat diet251,330.  In our own data, principal component analysis of hepatic 
triglycerides separated LAKO mice from WT mice on HFrD but not on chow (Extended 
Data Fig. 3.3c), supportive of the notion that ACLY may play distinct roles depending on 
diet. Thus, further study of the impact of ACLY deficiency in different nutritional contexts 
will be important to understand its physiological roles and to optimally leverage ACLY 
inhibitors for the treatment of metabolic diseases.   
Although hepatic fructose metabolism does not appear to directly supply substantial 
amounts of lipogenic acetyl-CoA, fructolysis and/or glycolysis in hepatocytes remain 
important for DNL induction at least in part to activate the DNL transcriptional program 
(Extended Data Fig. 7f).  This likely explains why KHK knockout mice are protected from 
fructose-induced fatty liver331,332.  Thus, we propose a revised model of fructose-
dependent DNL induction, in which hepatic fructose metabolism provides a signal to 
transcriptionally promote DNL while microbial fructose metabolism provides acetate to 
feed DNL (Extended Data Fig. 10a). These dual mechanisms may also explain higher 
lipogenic potential of fructose as compared to glucose333, at least in the context of high 
dose sugar consumption, in that the small intestine rapidly absorbs even large loads of 
glucose, whereas fructose spills over to the gut microbiome to generate acetate314. The 
data also indicate that fructose-dependent activation of the DNL transcriptional program 
can trigger enhanced DNL from other acetate sources (Extended Data Fig. 10b). Thus, it 
will be important in the future to define how fructose interacts with other dietary sources 
of acetate, such as ethanol and fermentable fibers. NAFLD currently afflicts ~30% of the 
United States population and can be a precursor to non-alcoholic steatohepatitis and 
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hepatocellular carcinoma334. Understanding the fundamental pathways involved in hepatic 
DNL is important for the development of new therapeutic interventions for metabolic 
diseases. The current data elucidate a previously unappreciated interplay between diet, 
the gut microbiome, and host organ metabolism that contributes to fructose-induced 
NAFLD. 
 
 
 
Methods 
 
Generation of Liver-specific ACLY Knockout (LAKO) mice: 
Generation of Aclyf/f mice on a C57Bl6/J background was previously described264. To 
generate hepatocyte-specific Acly knockouts, Aclyf/f mice were crossed to albumin-Cre 
transgenic mice (B6.Cg-Tg(Alb-Cre)21Mgn/J, Jackson Laboratory)335.  
Genoptying: 
Genotyping of the recombined Acly allele was confirmed as previously described264. 
Genotyping of the Albumin-Cre allele was confirmed with the following primer 
sequences: AlbCre-5’F (CCTGCCAGCATGGATATAA), AlbCre-3’R 
(GTTGTCCTTTGTGCTGCTGA), Alb-TSP3 (GAAGCAGAAGCTTAGGAAGATGG), and 
the following cycling conditions: 1 cycle - 94o x 5 min. 35 cycles - 94o x 45 sec., 58o x 45 
sec., 72o x 1 min. 1 cycle - 72o x 10 min, hold at 4oC. 
Animal studies: 
All animal protocols in this study were approved by the University of Pennsylvania's 
Institutional Animal Care and Use Committee (IACUC) and Princeton University's 
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IACUC. For diet studies, 4-week-old male mice were placed on either a regular chow 
diet (Lab Diet 5010) or a high-fructose chow diet (Teklad TD.89247) for indicated lengths 
of time. Weights of mice kept on each diet were taken weekly. For drinking water 
studies, mice were provided with regular tap water (filtered through a 0.22 µm filter) or a 
15% (w/v) fructose:15% (w/v) glucose (Sigma F3510, G8270) in tap water (filtered 
through a 0.22 µm filter). To deplete the gut microbiome, mice were given a daily 10 
µL/g body weight oral gavage consisting of 1 mg/mL ampicillin, 1 mg/mL gentamicin, 0.5 
mg/mL vancomycin, 1 mg/mL neomycin, 1 mg/ml metronidazole in a 0.9% NaCl solution 
for 7-10 days. Studies were controlled to mice given the same 0.9% NaCl solution 
without antibiotics. To knockdown Acss2, 6-8 week-old male mice were injected via tail 
vein with 2.0 x 1011 GC/mouse AAV8.U6.shAcss2.CMV.eGFP.SV40 (University of 
Pennsylvania Vector Core) or AAV8.CMV.PI.eGFP.WPRE.bGH (Addgene) as control; 
experiments were performed 1 week after injection. 
Histology: 
For H&E, Periodic Acid Shiff, Trichrome staining: tissues were fixed in formalin 
overnight, dehydrated by titrating in ethanol (50%, 75%, 95%), and submitted to the 
Molecular Pathology and Imaging Core at the University of Pennsylvania for paraffin 
embedding, sectioning, and staining. For Oil Red O staining: tissues were fixed in 
formalin overnight, dehydrated by titrating in sucrose (10%, 20%, 30%), and embedded 
in Richard-Allan Scientific NEG-50 frozen section medium (ThermoFisher Scientific 
6502) by freezing in 2-methylbutane that was cooled using dry ice. Tissues frozen in 
NEG-50 were submitted to the Molecular Pathology and Imaging Core at the University 
of Pennsylvania for cryosectioning and staining. Images were acquired on a Keyence 
BZ-X710 microscope. 
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Bacterial quantification: 
Cecal contents were collected, snap frozen, and weighed before storage in -80C until 
use. DNA was extracted from cecal contents using a Fecal DNA extraction kit (IBI 
scientific IB47821) according to manufacturer instructions. Samples were diluted 1:1000 
prior to use for RT-PCR. To establish a bacterial DNA standard, genomic DNA was 
extracted from Stbl3 E. coli cells. A standard curve was generated using a 1:4 serial 
dilution starting with 10 ng of E. coli DNA. RT-PCR was performed as described, using 
previously published universal 16s primers (Forward: TCCTACGGGAGGCAGCAGT, 
Reverse: GGACTACCAGGGTATCTAATCCTGTT)336. Relative bacterial load was 
calculated by normalizing DNA content to initial cecal content weight.  
Immunoblotting:  
Protein extraction from tissue was performed by re-suspending frozen tissue in 0.5 mL of 
RIPA buffer (1% NP-40, 0.5% Deoxycholate, 0.1% SDS, 150 mM NaCl, 50 mM Tris plus 
protease and phosphatase inhibitors), and lysed using a tissue lyser (Qiagen) twice for 
30 seconds at 20 Hz. Following lysis, samples were incubated on ice for 10 minutes, 
then spun down at 15,000 RCF for 5 minutes in 4oC. Supernatant was collected and 
stored in -80oC until immunoblotting. Antibodies used in this study: ATP-Citrate Lyase 
(Proteintech 15421-1-AP), Acyl-CoA Synthetase Family Member 2 (Cell Signaling 
Technology 3658S), Acetyl-CoA Carboxylase (Cell Signaling Technology 3676S), Fatty 
Acid Synthase (Cell Signaling Technology 3189S), Catalase (Cell Signaling Technology 
14097S), Ribosomal Protein S6 (Cell Signaling Technology 2217S), IRDye800CW Goat 
Anti-Rabbit (LI-COR 926-32211). Immunoblots were developed using a LI-COR 
Odyssey Clx.   
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Quantitative RT-PCR:  
RNA extraction from tissue was performed by re-suspending frozen tissue in 1 mL Trizol 
(Life Technologies), and lysed using a tissue lyser (Qiagen) for 60 seconds at 30 Hz, 
followed by manufacturer protocol for Trizol RNA extraction. cDNA was synthesized 
using high-capacity RNA-to-cDNA master mix (Applied Biosystems 4368814), as per the 
kit instructions. cDNA was diluted 1:20 and amplified using PowerUp SYBR Green 
Master Mix (Applied Biosystems A25778) on the ViiA-7 Real-Time PCR system. Fold 
change in expression was calculated using ΔCt, with 18S reference gene as an 
endogenous control. Primer sequences for RT-qPCR are: Aldob (Forward: 
GAAACCGCCTGCAAAGGATAA, Reverse: GAGGGTCTCGTGGAAAAGGAT), Khk 
(Forward: ATGTGGTGGACAAATACCCAGA, Reverse: 
CAAGCAAGGAAAGGACAGTGC), Acly (Forward: TTCGTCAAACAGCACTTCC, 
Reverse: ATTTGGCTTCTTGGAGGTG), Acss2 (Forward: 
GCTTCTTTCCCATTCTTCGGT, Reverse: CCCGGACTCATTCAGGATTG), Chrebpα 
(Forward: CGACACTCACCCACCTCTTC, Reverse: TTGTTCAGCCGGATCTTGTC), 
Chrebpβ (Forward: TCTGCAGATCGCGTGGAG, Reverse: 
CTTGTCCCGGCATAGCAAC), Fasn (Forward: ATTGGTGGTGTGGACATGGTC, 
Reverse: CCCAGCCTTCCATCTCCTG), Acc1 (Forward: 
ACAGTGGAGCTAGAATTGGAC, Reverse: ACTTCCCGACCAAGGACTTTG).  
Measurement of de novo lipogenesis using isotope tracers: 
To assess total lipogenesis, mice were provided with 50% (v/v) deuterated water (Sigma 
151882) mixed into 15% fructose:15% glucose drinking water for 24 hours. Systemic 
blood was collected by cardiac puncture, allowed to coagulate on ice for 10 minutes, and 
spun down at 15,000 x RCF for 10 minutes at 4oC to collect serum. To account for 
differences in drinking water consumption, calculated deuterium enrichment labeling in 
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serum water was used to normalize labeling into fatty acids. To assess lipogenesis from 
dietary carbohydrates, on day of experiment, mice were weighed and fasted from 10 
a.m. until 3 p.m., when they were given an oral gavage consisting of a 1:1 mixture of 
glucose and fructose in a 0.9% NaCl saline. Doses used in this study ranged from 
1.0g/kg of each sugar to 2.0g/kg of each hexose. [U-13C]-glucose (CLM-1396-1) or [U-
13C]-fructose (CLM-1553-1) were provided with the corresponding unlabeled hexose. Six 
hours following gavage, systemic blood was collected by tail bleeding the mice and 
incubating the blood on ice for 15 minutes before spinning down at 15,000 x RCF for 10 
minutes at 4oC to collect serum. Tissues were collected using a clamp pre-cooled with 
liquid nitrogen. The frozen liver samples were ground at liquid nitrogen temperature with 
a Cryomill (Retsch, Newtown, PA). Saponification of lipids and LC-MS analysis were 
performed as previously described337. Briefly, serum (20 µL) or tissue powder (10 mg) 
was incubated with 1 mL of 0.3 M KOH in 90% methanol at 80°C for 1 hour in a 2 mL 
glass vial. Formic acid (0.1 mL) was then added for neutralization. The saponified fatty 
acids were extracted by adding 0.5 mL of hexane, vortexing, and transferring the top 
hexane layer to a new glass vial. Samples were then dried under a stream of N2 and 
dissolved in 1 mL of isopropanol:methanol (1:1, v/v) solution for LC-MS analysis. 
Separation was performed by reversed-phase ion-pairing chromatography on a C8 
column coupled to negative-ion mode, full-scan LC-MS at 1-Hz scan time and 100,000 
resolving power (stand-alone orbitrap; Thermo Fischer Scientific). Data analysis with 
MAVEN software and natural isotope correction were performed as previously 
described338. 
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Primary Hepatocyte Isolation: 
Hepatocytes were isolated using a two-step collagenase/DNAse digestion protocol339 
and plated in M199 media containing 5 mM glucose, 10% FBS, 500 nM dexamethasone 
and 1 nM insulin. Following attachment, cells were changed to M199 media containing 5 
mM glucose, 500 nM dexamethasone and incubated overnight. Cells were switched to 
M199 containing 5 mM glucose, 10% FBS, 500 nM dexamethasone, 100 nM insulin and 
respective fructose and acetate supplementation for 6 hours on day of experiment.  
Acyl-CoA measurements in primary hepatocytes: 
Acyl-CoA measurements in primary hepatocytes were performed by liquid 
chromatograpy-mass spectrometry/high-resolution mass spectrometry (LC-MS/HRMS) 
as previously described292. Briefly, primary hepatocytes were isolated and cultured as 
described above in 6-well plates. At harvest, culture media was completely aspirated 
before harvesting cells in 0.5 mL ice-cold 10% trichloroacetic acid/well of a 6-well dish 
using a cell lifter. Samples were then sonicated for 10 x 0.5 second pulses to completely 
disrupt cellular membranes, and incubated on ice to precipitate proteins. Protein was 
pelleted at 16,000 x RCF for 10 minutes at 4oC. Supernatant was collected and purified 
by solid-phase extraction using Oasis HLB 1cc (30 mg) SPE columns (Waters). Eluate 
was evaporated to dryness under nitrogen gas and re-suspended in 50 µL of 5% 5-
sulfosalicylic acid (w/v) for injection. Samples were analyzed by an Ultimate 3000 
autosampler coupled to a Thermo Q-Exactive Plus instrument in positive electrospray 
ionization (ESI) mode. For isotopic tracer analysis, isotopic enrichment from [U-13C]-
fructose (Cambridge Isotope Laboratories, CLM-1553) or [U-13C]-acetate (Cambridge 
Isotope Laboratories, CLM-440-1) was calculated to compensate for the non-linearity of 
isotopic enrichment using the FluxFix calculator340. 
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Fructolyic measurements in primary hepatocytes: 
For fructolytic intermediate measurements in primary hepatocytes, culture media was 
completely aspirated before harvesting cells in 0.5 mL of cold 80:20 methanol:water/well 
of a 6-well dish using a cell lifter. Samples were then sonicated for 10 x 0.5 second 
pulses to completel disrupt cellular membranes, and incubated on ice. Samples were 
then spun down at 16,000 x RCF for 10 minutes at 4oC. Supernatant was collected and 
dried under nitrogen gas flow in preparation for water-soluble metabolomic analysis. 
Chromatin Immunoprecipitation (ChIP) – PCR: 
For H3K27ac-ChIP qPCR studies, male mice were provided with Fruc:Gluc drinking 
water for 24 hours, and orally gavaged with 2.0 g/kg fructose + 2.0 g/kg glucose 1 hour 
prior to sacrifice. For ChREBP-ChIP qPCR studies, female mice were provided with 
Fruc:Gluc drinking water for 24 hours, and orally gavaged with 3.0 g/kg fructose + 3.0 
g/kg glucose 1 hour prior to sacrifice. ChIP was performed as previously described341 
with adjustments to start from liver tissue.  Briefly, liver tissues were harvested from mice 
90 minutes following gavage, and 100 mg of tissue was weighed out. Tissues were 
homogenized by mincing briefly with razor blades followed by resuspension in 5 mL of 
ice-cold 1X PBS and several passages through a 16 gauge syringe needle into 15 mL 
conical tubes. Samples were crosslinked with 2% formaldehyde for 10 minutes at room 
temperature. The reactions were quenched with 0.25 M glycine. The cells were then 
washed with 1X PBS and resuspended in cell lysis buffer (10 mM Tris-HCl pH 8.1, 10 
mM NaCl, 1.5 mM MgCl2, 0.5% NP-40), supplemented with protease inhibitors (Roche). 
The cell pellet was resuspended in 0.5 mL of nuclear lysis buffer (50 mM Tris-HCl pH 
8.1, 5 mM EDTA, 1% SDS) supplemented with protease inhibitors. The chromatin was 
fragmented with a Diagenode Bioruptor Pico (12 cycles of 30 s on followed by 30 s off, 
at 4°C). Samples were incubated with protein G magnetic beads (Millipore-Sigma 16-
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662) and H3K27ac (Abcam ab4729), ChREBP (Novus Biologicals NB400-135), or 
Normal Rabbit IgG (Cell Signalling Technology 2729S) antibody overnight at 4°C. The 
next day, samples were washed 5 times with decreasingly stringent buffers. ChIP DNA 
was eluted off the beads by incubating beads in 125 µL elution buffer for 10 minutes at 
65°C. The combined supernatant was then incubated overnight at 65°C to reverse 
crosslinks and proteinase K treated for 1 hour the next morning. Samples were purified 
using Macherey-Nagel DNA purification kit, with NTB binding buffer. Samples were 
diluted 1:5 in nuclease-free water prior to RT-qPCR reactions, which were performed as 
described above with the following primers: Mlxipl p1 (Forward: 
CGCACCCGGTCTACAGTTT, Reverse: GTGCCTCCTTCTCTCCTTAGC), Mlxipl p2 
(Forward: GCCATCCACGTGCTAAGGA, Reverse: GGCTTTTAGACTGGGGTGTGG), 
Mlxipl igc (Forward: CCCAACAATCACCCAGCTTC, Reverse: 
GCGCCATCAGTACAAGCTCT), Pklr p1 (Forward: GGGAAGGATGCCCACTACAG, 
Reverse: TGGAAGCCTTGTACACTGGG), Pklr p2 (Forward: 
CCCAGTGTACAAGGCTTCCAT, Reverse: CTCTGCCTTTGTCAGTGGGA), Acss2 p1 
(Forward: ATTGGATGCCTAGAGCACGG, Reverse: CGCATCAAGTTCCGAACACC), 
Acss2 p2 (Forward: TCAGGACAGTTTAGGGTGCAA, Reverse: 
TTACAAAGACCTGCCTCTGCC). Acss2 p3 (Forward: GAGACTCTGGCCTACCACCA, 
Reverse: GGGCAGGATTTGTGGCTTGT), Acss2 igc (Forward: 
GGCGAAAGAAGTTTCTGTTTTGG, Reverse: TTGCCTTTTCAGTGAGGCTGTC).  
Triglyceride Measurements:  
Triglyceride measurements were performed using a Triglyceride Colorimetric Assay Kit 
(Cayman Chemical 10010303) as per manufacturer instructions.  
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Metabolomics: 
Water-soluble metabolite extraction was performed as previously described314. For 
serum samples, 100 μL -20°C 40:40:20 methanol:acetonitrile:water (extraction solvent) 
was added to 5 μL of serum sample and incubated on ice for 10 min, followed by 
vortexing and centrifugation at 16,000 x g for 10 min at 4°C. The supernatant (first 
extract) was transferred to a new tube. Then, 50 μL extraction solution was added to 
resuspend the pellet, followed by vortexing and centrifugation at 16,000 x g for 10 min at 
4°C. The supernatant (second extract) was combined with the first extract. Then, 3 μL of 
the 150 μL extract was loaded to LC-MS. For tissue samples, frozen tissue samples 
were ground at liquid nitrogen temperature with a Cryomill (Retsch, Newtown, PA). The 
resulting tissue powder was weighed (∼20 mg). The extraction was then done by adding 
-20°C extraction solvent to the powder and incubating in -20°C overnight, followed by 
vortexing and centrifugation at 16,000 x g for 10 min at 4°C. The volume of the 
extraction solution (μL) was 40 x the weight of tissue (mg) to make an extract of 25 mg 
tissue per mL solvent. Serum and tissue extracts were analyzed by LC-MS, using two 
different LC-MS methods chosen for optimal separation of glucose and fructose (in 
serum) and of hexose phosphate species (from tissues). Serum extracts were analyzed 
(without drying) using a quadrupole-orbitrap mass spectrometer (Q Exactive, Thermo 
Fisher Scientific, San Jose, CA) operating in negative ion mode, coupled to hydrophilic 
interaction chromatography via electrospray ionization and used to scan from m/z 70 to 
1000 at 1 Hz and 75,000 resolution. LC separation was on a XBridge BEH Amide 
column (2.1 mm x 150 mm, 2.5 μm particle size, 130 Å pore size) using a gradient of 
solvent A (20 mM ammonium acetate, 20 mM ammonium hydroxide in 95:5 water: 
acetonitrile, pH 9.45) and solvent B (acetonitrile). Flow rate was 150 μl/min. The LC 
gradient was: 0 min, 85% B; 2 min, 85% B; 3 min, 80% B; 5 min, 80% B; 6 min, 75% B; 
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7 min, 75% B; 8 min, 70% B; 9 min, 70% B; 10 min, 50% B; 12 min, 50% B; 13 min, 25% 
B; 16 min, 25% B; 18 min, 0% B; 23 min, 0% B; 24 min, 85% B; 30 min, 85% B. 
Autosampler temperature was 5°C, and injection volume was 3 μL. Tissue extracts were 
dried under nitrogen gas flow and re-dissolved in LC-MS grade water. Metabolites were 
analyzed via reverse-phase ion-pairing chromatography coupled to an Exactive Orbitrap 
mass spectrometer (Thermo Fisher Scientific, San Jose, CA). The mass spectrometer 
was operated in negative ion mode with resolving power of 100,000 at m/z 200 and scan 
range of m/z 75-1000. The LC method was modified from an earlier method (Lu et al., 
2010), using an Atlantis T3 column (150 mm × 2.1 mm, 3 μm particle size, 100 Å pore 
size), with a gradient of solvent A (97:3 water:methanol with 10 mM tributylamine and 15 
mM acetic acid) and solvent B (methanol). The LC gradient was 0 min, 0% B, 200 
μl/min; 2 min, 0% B, 200 μl/min; 4 min, 20% B, 200 μl/min; 13 min, 80% B, 200 μl/min; 
17 min, 100% B, 200 μl/min; 17.5 min, 100% B, 300 μl/min; 20 min, 100% B, 300 μl/min; 
20.5 min, 0% B, 300 μl/min; 24 min, 0% B, 300 μl/min; 25 min, 0% B, 200 μl/min. Other 
LC parameters, common to both methods, were column temperature 25°C, autosampler 
temperature 5°C, and injection volume 10 μL. Data analysis with MAVEN software and 
natural isotope correction were performed as previously described338. Volcano plot and 
principle component analysis of metabolomics data were generated using 
Metaboanalyst342. 
Acetate measurement: 
Acetate was derivatized and measured by LC-MS. The derivatizing reagent was 12 mM 
EDC, 15 mM 3-Nitrophenylhydrazine and pyridine (2% v/v) in methanol. Reaction was 
stopped with quenching reagent consisting of 0.5 mM beta-mercaptoethanol and 0.1% 
formic acid in water. Serum (5 µL) was mixed with derivatizing reagent (100 µL) and 
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incubated for 1 hour at 4°C. Then, the samples were centrifuged at 16,000 x g for 10 min 
at 4°C, and 20 µL of supernatant was mixed with 200 µL of the quenching reagent. After 
centrifugation at 16,000 x g for 10 min at 4°C, supernatants were collected for LC-MS 
analysis. A quadrupole-time of flight mass spectrometer (Q-TOF, Agilent, Santa Clara, 
CA) operating in negative ion mode was coupled to C18 chromatography via 
electrospray ionization and used to scan from m/z 100 to 300 at 1 Hz and 15,000 
resolution. LC separation was on an Acquity UPLC BEH C18 column (2.1 mm x 100 
mm, 1.7 5 µm particle size, 130 Å pore size; Waters, Milford, MA) using a gradient of 
solvent A (0.01% formic acid in water) and solvent B (0.01% formic acid in isopropanol). 
Flow rate was 400 µL/min, except that from 6 min to 8 min flow rate was increased to 
700 µL/min. The LC gradient was: 0 min, 10% B; 2 min, 15% B; 5 min, 25% B; 6 min, 
100% B; 8 min, 100% B; 8.6 min, 10% B; 10.5 min, 10% B. Autosampler temperature 
was 5°C, and injection volume was 10 µL. Ion masses for derivatized acetate was 194. 
Lipidomics: 
Lipidomics was performed as previously described343, with some modifications on an 
extraction step. Briefly, serum samples (10 μL) was dissolved in 100 μL of isopropanol. 
After centrifugation at 14,000 g at 4°C for 10 min, supernatant was transferred to a glass 
MS vial and injected into a 1290 Infinity UHPLC system coupled to Agilent 6550 iFunnel 
Q-TOF mass spectrometer. To cover both the positive charged and negative charged 
species, each sample was analyzed twice using the same LC gradient but with different 
mass spectrometer ionization modes. The LC separation was performed on an Agilent 
Poroshell 120 EC-C18 column (150 x 2.1 mm, 2.7 µm particle size) with a flow rate of 
150 µL/min. Solvent A was 1 mM ammonium acetate + 0.2% acetic acid in 
water/methanol (90:10). Solvent B was 1 mM ammonium acetate + 0.2% acetic acid in 
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methanol/2-propanol (2:98). The solvent gradient in volume ratios was as follows: 0-
2 min, 25% B; 2-4 min, 25 to 65% B; 4-16 min, 65 to 100% B; 16-20 min, 100% B; 20-
21 min, 100 to 25% B; 21-27 min, 25% B. Principle component analysis was generated 
using Metaboanalyst342 (https://www.metaboanalyst.ca) and heatmap of lipidomics data 
was generated using Morpheus (https://software.broadinstitute.org/morpheus).  
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Figures 
 
Figure 3.1 | Fructose-dependent fatty acid synthesis is ACLY-independent.  
a, Schematic of fructolysis and glycolysis feeding into de novo lipogenesis. F1P = fructose-1-
phosphate, F-1,6-BP = fructose-1,6-bisphosphate, GA = glyceraldehyde, DHAP = 
dihydroxyacetone phosphate, G3P = glyceraldehyde-3-phosphate.  
b, H&E and Oil Red O histological stains of livers from WT or LAKO mice on chow (CD) or high 
fructose diet (HFrD) for 4 or 18 weeks. Scale bars = 100 µm.  
c, Relative deuterium labeling in palmitic acid (16:0) and stearic acid (18:0) after 24-hour D2O 
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labeling of mice, normalized to percent plasma D2O labeling. D2O (n = 4/group) set to 1 and 
compared to D2O Fruc:Gluc (n = 6/group) within each genotype, data are mean ± SEM.  
d, Experimental design for data shown in e.  
e, % total labeled carbons in fatty acids from 13C-glucose or 13C-fructose.  
f, mRNA expression of ChREBP and its target genes in livers of WT or LAKO mice fed on CD or 
HFrD (n = 4 mice/group), statistical comparisons WT-CD vs. WT-HFrD: ***P<0.001, LAKO-CD vs. 
LAKO-HFrD: #P<0.05 as determined by Holm-Sidak test.  
g, Immunoblots of lipogenic enzymes in livers of WT or LAKO mice fed CD or HFrD for 4 weeks. 
For all panels, *P<0.05, **P<0.01, ***P<0.001. 
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Figure 3.2 | Lipogenic acetyl-CoA is preferentially produced from acetate in 
hepatocytes.  
a, Schematic of fructolysis, glycolysis, and acetate feeding into lipogenic acetyl-CoA and de novo 
lipogenesis.  
 134 
 
b, Total ion counts (TIC) of fructolytic intermediates in primary hepatocytes following 6 hours of 
incubation with 5mM glucose + 25mM fructose + 1mM acetate, 13C-labeled substrate indicated in 
bold, data are mean ± SD, n = 3.  
c, % labeling of acetyl-CoA, malonyl-CoA, or HMG-CoA from [U-13C]-fructose or [1,2-13C]-acetate, 
data are mean ± SD, n = 3.  
d, TIC of liver labeled F1P, pyruvate, and acetyl-CoA, concentrations (µM) of portal blood labeled 
acetate, and total % carbons labeled of liver 16:0 and 18:0 in WT mice gavaged with 2.0 g/kg [U-
13C]-fructose + 2.0 g/kg unlabeled glucose, data are mean ± SEM, n = 3/timepoint.  
 
 
 135 
 
 
Figure 3.3 | Microbiome metabolism of fructose to acetate feeds hepatic de 
novo lipogenesis. 
a, Area under curve (AUC 0-240 min) of labeled hepatic F1P, pyruvate, acetyl-CoA, palmitate and 
portal blood acetate in saline or antibiotic-treated WT mice following a gavage of 2.0 g/kg [U-13C]-
fructose + 2.0 g/kg glucose.  
b, % total labeled carbons in saponified serum fatty acids in saline or antibiotic-treated WT and 
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LAKO mice following a gavage of 2.0 g/kg [U-13C]-fructose + 2.0 g/kg glucose, *P<0.05, **P<0.01 
WT-saline vs. WT-antibiotics, #P<0.05 LAKO-saline vs. LAKO-antibiotics.  
c, Heat map of hepatic triglyceride abundance in livers of mice in b.  
d, Concentrations of portal and systemic blood acetate following gavage, each data point 
represents an individual mouse sacrificed at indicated time. *P<0.05, ***P<0.001.  
e, % total labeled carbons in saponified serum fatty acids from saline- or antibiotic-treated LAKO 
mice following a gavage of 2.0 g/kg fructose + 2.0 g/kg glucose + 0.5 g/kg acetate, 13C-labeled 
substrate indicated. **P<0.01, ***P<0.001 saline vs. antibiotics, #P<0.05, ##P<0.01 13C-fruc vs. 
13C-acet.  
f, % total labeled carbons in serum fatty acids from WT and LAKO mice 1 week after injection 
with AAV-GFP or AAV-shAcss2. **P<0.01 WT + GFP vs. WT + shAcss2, #P<0.05, ##P<0.01 
LAKO + GFP vs. LAKO + shACSS2.  
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Figure 3.4 | Gradual fructose consumption promotes hepatic lipogenesis 
from ACLY- and ACSS2-derived acetyl-CoA.  
a, Experimental design for gradual fructose consumption.  
b, % total labeled carbons from [U-13C]-fructose or glucose in hepatic 16:0 and 18:0, WT vs. 
LAKO: *, Fruc vs. Gluc: #.  
c, % total labeled hydrogens from D2O in hepatic 16:0 and 18:0.  
d, % total labeled carbons from [1,2-13C]-acetate supplemented Fruc:Gluc water in saponified 
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serum 16:0 and 18:0, see Extended Data Fig. 9a for experimental details, WT vs. LAKO: *, naïve 
vs. conditioned: #.  
e, total % labeled hydrogens from Fruc:Gluc D2O in hepatic 16:0 and 18:0 in WT and LAKO mice 
following 1 week of treatment with saline or antibiotics.  
f, mRNA expression of ChREBP and downstream lipogenic genes in livers of mice in (e), Abx = 
antibiotics.  
g, total % labeled hydrogens from Fruc:Gluc D2O in hepatic fatty acids in WT and LAKO mice 1 
week after injection with AAV-GFP or AAV-shAcss2. For all panels, */#P<0.05, **/##P<0.01, 
***/###P<0.001. 
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Extended Data Figure 3.1 | Hepatic ACLY deficiency minimally impacts the 
response to dietary fructose.  
a, Body weights of WT and LAKO mice on CD or HFrD for 18 weeks (n = WT-CD:13, LAKO-
CD:5, WT-HFrD:14, LAKO-HFrD:5).  
b, Weights of liver, subcutaneous (sWAT) and perigonadal (pgWAT) adipose tissues in WT and 
LAKO mice on CD or HFrD for 18 weeks.  
c, Representative images of Periodic Acid Schiff (PAS) stain for glycogen and Trichrome (TC) 
histological stain for fibrosis in livers from WT or LAKO mice on HFrD. Scale bars = 100 µm.  
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d, Triglyceride content in WT or LAKO mice on CD or HFrD for 18 weeks, n = (WT-CD: 4, LAKO-
CD: 3, WT-HFrD: 4, LAKO-HFrD: 3), **P<0.01 as determined by Welch's T test.  
e, Immunohistochemistry staining against ACLY in WT or LAKO mice on H2O or Fruc:Gluc water 
for 4 weeks. Yellow boxes approximate location of 20X panels. Scale bars = 100 µm for 10X, 50 
µm for 20X.  
For all panels, data are mean ± SD.  
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Extended Data Figure 3.2 | Hepatic ACLY deficiency results in only modest 
metabolic alterations on high fructose diet.  
a, Volcano plot of intrahepatic metabolites in WT and LAKO mice on CD or HFrD for 4 weeks, 
pink dots indicate significant hits as determined by a fold-change threshold of 2 and P-value 
threshold of 0.1, assuming equal variance.  
b, Principle component analysis of log-transformed data in Supplementary Table 1, each dot 
represents a unique sample, 95% CI shown in corresponding color. 
c, Relative metabolite abundance, normalized to WT-CD group, ***P<0.001, n = (WT-CD:5, 
LAKO CD: 3, WT-HFrD: 5, LAKO-HFrD: 4). 
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Extended Data Figure 3.3 | High fructose diet alters hepatic lipid 
metabolism.  
a, Hierarchical clustering of relative hepatic triglyceride abundance in WT or LAKO mice on CD or 
HFrD for 4 weeks, clustering performed using one minus pearson correlation and average 
linkage.  
b, Relative abundance of hepatic triglycerides composed of 16:0 to 18:1 fatty acids, subset of 
data in a.  
c, Principle component analysis of log-transformed data in Supplementary Table 2, each dot 
represents a unique sample, 95% CI shown in corresponding color.  
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Extended Data Figure 3.4 | Sweetened drinking water consumption induces 
steatosis independently of ACLY.  
a, Schematic of experimental set-up of drinking water study.  
b, Daily consumption of unsweetened (H2O) or 15% fructose + 15% glucose sweetened 
(Fruc:Gluc) water, ***P<0.001.  
c, Weight gain of WT or LAKO mice given H2O or Fruc:Gluc water for 4 weeks, **P<0.01 
comparing all H2O vs. Fruc:Gluc mice.  
d, H&E and Oil Red O histological stains of livers from WT or LAKO mice given H2O or 
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fructose:glucose sweetened drinking water for 4 weeks. Scale bars = 100 µm.  
For all panels, data are mean ± SD.   
 
Extended Data Figure 3.5 | Fructose carbons contribute substantially to 
newly synthesized fatty acids in the liver independently of ACLY.   
a, Isotopologue distribution of serum fatty acids from mice in Figure 1e, data are mean ± SD.  
 
 145 
 
 
Extended Figure Data 3.6 | Fructose signals the use of acetate for de novo 
lipogenesis.   
a, mRNA expression of lipogenic genes in livers of WT or LAKO mice given H2O or Fruc:Gluc 
water for 4 weeks (n = 4/group), statistical comparisons WT-H2O vs. WT-Fruc:Gluc: **P<0.01, 
***P<0.001, LAKO-H2O vs. LAKO-Fruc:Gluc:†P<0.05, ‡P<0.01, ¥P<0.001 as determined by 
Holm -Sidak test.  
b, Immunoblots of lipogenic enzymes in livers of WT or LAKO mice given H2O or Fruc:Gluc water 
for 4 weeks.  
c, mRNA expression of ChREBP and its target genes in livers of WT mice provided either water 
for 24 hours followed by an oral gavage of saline, or Fruc:Gluc water for 24 hours, followed by an 
oral gavage of 2.0 g/kg glucose and 2.0 g/kg fructose (n = 4 mice/group), livers harvested 90 
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minutes after gavage, *P<0.05, as determined by Holm-Sidak test.  
d, H3K27ac ChIP-qPCR under conditions used in panel c.  
e, ChREBP ChIP-qPCR under conditions used in panel c, igc = intergenic control.  
f, ChIP-seq tracks of Mlxipl, Pklr, Acss2 genomic loci319, red bars indicate genomic regions used 
to design ChIP-qPCR primers.  
For panels d-e, data are mean ± SEM.  
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Extended Data Figure 3.7 | Antibiotic depletion of microbiome blocks 
substrate contribution, but not signaling, of de novo lipogenesis following 
fructose consumption.  
a, Experimental set-up for antibiotic depletion of the microbiome followed by [U-13C]-fructose 
tracing into DNL.  
b, Representative images of cecums from a saline and antibiotic treated mouse.  
c, Heat map of microbial metabolite abundance in the portal blood, collected 1  hour after gavage. 
d-e, Abundance of portal blood [U-13C]-fructose (d), and % total labeled carbons in glucose (e), 
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statistical comparisons vs. Saline.  
f, mRNA expression of ChREBPβ, Acss2, and Fasn in liver, collected 1 hour after gavage, 
statistical comparisons vs. Saline  
g, Concentrations (µM) of portal blood labeled acetate, propionate, and butyrate, n = (WT-Saline: 
8, LAKO-Saline: 4, WT-Antibiotics: 8, LAKO-Antibiotics: 4). h, Abundance of cecal labeled 
acetate, propionate, and butyrate in WT mice, n = 3 mice/timepoint, except saline-180 n = 2 mice. 
For all panels, data are mean ± SD, *P<0.05, **P<0.01, as determined by Holm-Sidak test.  
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Extended Data Figure 3.8 | Bolus fructose-dependent DNL requires 
microbial acetate and hepatic ACSS2.   
a, Isotopologue distribution of serum fatty acids, collected 6 hours after gavage, data are mean ± 
SD, n = (WT-Saline: 8, LAKO-Saline: 4, WT-Antibiotics: 8, LAKO-Antibiotics: 4).  
b, Relative abundance of bacterial abundance in cecal contents from mice treated with saline or 
antibiotics as determined by 16s RT-qPCR to a reference standard of E. coli DNA. *P<0.05 as 
determined by Welch's t test.   
c, Western blot of liver lysates from WT and LAKO mice 1 week following tail-vein injection with 
AAV8-GFP or AAV8-shAcss2.  
d, Weight gain in WT and LAKO mice 1 week following tail-vein injection with AAV8-GFP or 
AAV8-shAcss2. *P<0.05 as determined by Holm-Sidak test.  
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e, Liver weight as % of body weight of WT and LAKO mice 1 week following tail-vein injection 
with AAV8-GFP or AAV8-shAcss2.  
  
 151 
 
 
Extended Data Figure 3.9 | Gradual fructose consumption promotes greater 
acetate usage in LAKO mice.  
a, Experimental set-up for [1,2-13C]-acetate tracing into DNL prior to and after gradual fructose 
administration.  
b, Western blot of ACLY, ACSS2, and S6 in liver lysates from WT and LAKO mice after 1 day or 
14 days of Fruc:Gluc water.  
c, Representative H&E stains of livers from WT and LAKO mice provided Fruc:Gluc water for 2 
weeks. Scale bars = 100 µm  
d, Relative abundance of acetate, propionate, and butyrate in the cecal contents of WT and 
LAKO mice treated with saline or antibiotics for 1 week. WT: *P<0.05, **P<0.01, LAKO: 
##P<0.01, ###P<0.001. 
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Extended Data Figure 3.10 | Fructose provides signal and substrate to 
promote hepatic de novo lipogenesis.  
a, Proposed model of bolus fructose-induced hepatic DNL. Fructose catabolism in hepatocytes 
acts as a signal to induce DNL genes including ACSS2, while fructose metabolism by the gut 
microbiome provides acetate as a substrate to feed DNL, mediated by ACSS2.  
b, Proposed model of gradual fructose-induced hepatic DNL. Like the bolus model, fructose 
catabolism in hepatocytes acts as a signal to induce DNL genes. Glucose and fructose 
catabolism provide citrate as a substrate to feed DNL, mediated by ACLY. Metabolism of fibers 
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and other dietary components by the gut microbiome provides also acetate as a substrate to feed 
DNL, mediated by ACSS2.  
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CHAPTER 4: Summary and Discussion 
 
Summary of Findings: 
Prior to this work, both ACLY and ACSS2 have been shown to contribute to nuclear-
cytosolic acetyl-CoA pools in proliferating cells. While both enzymes have been 
proposed as therapeutic targets in the treatment of cancer and other diseases70,313,344,345, 
their metabolic contributions to promoting disease have largely been investigated 
individually without taking the presence of the other into account. In this work, we 
studied how genetic deletion of ACLY affects ACSS2 and acetate contributions to acetyl-
CoA metabolism in the same system. By doing so, we identified a metabolic switch 
between ACLY and ACSS2 upon loss of ACLY function, but not vice versa, to meet 
cellular demands for acetyl-CoA production. This metabolic flexibility enables cells to 
synthesize acetyl-CoA from acetate in the absence of ACLY, and maintain processes 
such as DNL. Not only do we demonstrate this in proliferating cells, but also in intact 
liver tissue in response to high sugar consumption, a context relevant to current public 
health.  
Future Directions and Outstanding Questions: 
This body of work establishes that mammalian cells can compensate for the loss of 
ACLY function by upregulating ACSS2 and acetate metabolism in order to meet acetyl-
CoA demand. However, we also demonstrate that not all fates of acetyl-CoA, nor cellular 
functions, are sufficiently maintained in the absence of ACLY. These results raise further 
questions that warrant investigation. 
First, ACLY loss in immortalized MEFs and cancer cell lines results in impaired 
proliferation, consistent with previous observations173,276,279, but remain viable. This is 
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despite compensation for acetyl-CoA production from acetate via ACSS2, which is able 
to support lipid synthesis at physiological acetate concentrations. Although global 
histone acetylation is not maintained at comparable levels to WT cells in these 
conditions, supplementation of supraphysiological levels of acetate rescues global 
histone acetylation levels but not proliferation. One hypothesis for this is that ACLY has 
roles in other cellular functions that cannot be compensated for by ACSS2. Another 
hypothesis is that although global histone acetylation can be restored with acetate, 
ACLY and ACSS2 promote histone acetylation at unique sites of the genome. Indeed, 
evidence that ACLY promotes histone acetylation at double-stranded breaks in response 
to DNA damage to facilitate homologous recombination, and site-specific differences 
between glucose- and acetate-induced histone acetylation supports both of these 
theories346,347. However, the genome-wide locations of unique ACLY- and ACSS2-
dependent histone acetylation sites, and the functional consequences of these 
differences, are still under-characterized.  
Second, the molecular mechanism of ACSS2 upregulation following ACLY loss remains 
to be determined. Given our findings that both genetic and chemical depletion of ACLY 
activity promotes ACSS2 upregulation suggests that nuclear-cytosolic acetyl-CoA can be 
sensed by cells. However, whether acetyl-CoA itself, or another downstream product of 
acetyl-CoA is being sensed remains unknown. The transcription factor sterol regulatory 
element binding protein 2 (SREBP2) has been reported to regulate transcription of 
ACSS273. The SREBP family of proteins are activated in response to decreases in 
intracellular cholesterol by its regulatory proteins INSIG and SCAP, which cleaves the 
SREBP precursor to generate mature SREBP. Thus, one hypothesis is that loss of 
ACLY activity depletes intracellular cholesterol abundance, thereby activating SREBP 
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and upregulating ACSS2 expression. However, in conditions that ACSS2 is upregulated, 
HMG-CoA, the metabolic intermediate between acetyl-CoA and cholesterol synthesis, is 
being synthesized from acetate (Figure 2.3). This suggests that cholesterol can be made 
in the context of ACLY-deficiency, but fails to suppress SREBP. Another possibility is 
that HMG-CoA is being synthesized from ACSS2-derived acetyl-CoA, but is not being 
utilized for cholesterol synthesis. In addition to cholesterol, HMG-CoA is utilized to 
synthesized isoprenoids for protein prenylation, ubiquinone synthesis, and dolichol 
synthesis. Whether one of these fates of HMG-CoA, or an entirely different product of 
acetyl-CoA is being sensed remains an open question.  
Third, we identify that fructose-dependent lipogenesis depends, at least in part, on 
contributions from the gut microbiome. However, the exact specie(s) of bacteria involved 
is unclear. Moreover, how fructose consumption alters diversity of the gut microbiome is 
still an open question. One hypothesis is that continual fructose consumption causes a 
shift in microbial diversity to favor production of SCFAs and hepatic DNL. Fecal 
microbiome transplantation studies can be performed using germ-free mice to test if this 
is indeed the case. Furthermore, newborns acquire a significant proportion of their gut 
microbiomes from the mother348. In light of studies seeking to identify heritable risks for 
obesity349, whether constant maternal fructose consumption promotes shifts to microbial 
diversity that could be passed onto offspring is an important open question. Further 
studies should be done to investigate 1) How fructose consumption alters the diversity of 
the gut microbiome, and 2) If modulating the gut microbiome can influence hepatic DNL 
to yield beneficial outcomes for treatment of diseases such as NAFLD.  
Fourth, we show that DNL is largely maintained in liver, but not adipose tissue following 
ACLY deletion. This is despite elevated ACSS2 levels in ACLY-null adipose tissue, 
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suggesting that the extent or pattern of metabolic compensation may differ between 
tissues. How this occurs is currently unclear, but may involve nutrient availability in vivo. 
For instance, acetate availability to the liver from the portal vein is high relative to that 
available to adipose tissue in systemic circulation. Indeed, patterns of metabolite uptake 
and release between tissues is diverse350, and warrants further investigation to 
understand tissue-specific responses to loss of ACLY activity.  
Finally, loss of hepatic ACLY fails to suppress DNL in response to sugar consumption or 
protect against development of fatty liver disease due to compensation from acetate. 
Recent clinical evidence supports use of ETC-1002 to treat hypercholesterolemia in 
patients, but whether targeting ACLY will be effective in treating NAFLD or cancer 
remains unclear. A prediction of our findings is that targeting further downstream in the 
DNL pathway would be an effective therapeutic strategy. Indeed, inhibition of ACC 
prevents development of fatty liver, but promotes hypertriglyceridemia351,352. Thus, 
further investigation will be required to determine the utility of therapeutically targeting 
hepatic DNL for treatment of NAFLD. However, our findings that ACLY and ACSS2 can 
be simultaneously suppressed with minimal toxicity in liver, at least in the short term, 
provides preliminary evidence of a therapeutic window for targeting both enzymes in 
cancer. Coupled to our findings that ACLY inhibition can cause dependence on ACSS2 
and exogenous acetate, a therapeutic strategy using ACLY inhibitors to sensitize cancer 
cells to ACSS2 inhibitors could be envisioned.  
In conclusion, our data bridges current literature surrounding both ACLY and ACSS2, 
and provides a model in which substrate flexibility for acetyl-CoA may underlie disease 
phenotypes in the context of both cancer and metabolic diseases. This metabolic 
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flexibility should be acknowledged when considering therapeutic interventions targeting 
not only acetyl-CoA synthesis, but other metabolic pathways as well.  
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